159159

1,2-dimethoxyethane, diglyme, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; and water; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are alcohols.

Examples of the catalyst used for the debenzylation include palladium carbon, palladium hydroxide, Raney-Ni, platinum oxide, etc., among which palladium carbon is preferred.

The reaction temperature in the debenzylation is preferably about room temperature to 80°C, and the reaction temperature in the decarboxylation is preferably 10°C to 150°C.

The reaction time in the debenzylation is about 1 hour to 16 hours, preferably about 2 hours to 8 hours, and the reaction time in the decarboxylation is about 5 minutes to 4 hours, preferably about 10 minutes to 2 hours.

Step B-3'

In a similar manner to Step B-3 of Process B, a compound of the formula (23') can be prepared from a compound of the formula (22').

In accordance with the Steps 1-3, 1-4 and 1-5 of the process 1, the compounds of the present invention can be prepared from a compound of the formula (23) or (23') obtained in Step B-3 or B-3'.

Process C

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is

G00001



(wherein R^4 has the same meaning as defined above, R^{32} is $-CON(R^{11})(R^{12})$ in which R^{11} and R^{12} each has the same meaning as defined above, and 1' is 1).

Process C



In the above reaction scheme, R^4, R^{11} and R^{12} each has the same meaning as defined above, Me is methyl and t-Bu is tert-butyl.

Step C-1

An acid chloride can be prepared from a compound of the formula (24) in a similar manner to Step 1-1 of Process 1. The resulting acid chloride is reacted with a compound of the formula (25) in a similar manner to Step 1-3 of Process 1 to

give a compound of the formula (25).

Also, a compound of the formula (26) can be prepared by condensing a compound of the formula (24) with a compound of the formula (25) using a condensing agent (for example, WSC, HOBT). Alternatively, a compound of the formula (24) is converted into its mixed anhydride, followed by reaction with a compound of the formula (25) in the presence of a base, to give a compound of the formula (26).

Step C-2

In a similar manner to Step A-1 of Process A, a compound of the formula (28) can be prepared by reacting a compound of the formula (26) with a compound of the formula (27).

Step C-3

A compound of the formula (29) can be prepared by treating a compound of the formula (28) with an acid (trifluoroacetic acid, toluenesulfonic acid, methanesulfonic acid, etc.) in the presence or absence of a solvent under heating or at room temperature to convert the tert-butyl ester moiety into the carboxylic acid moiety, followed by decarboxylation.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and water; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are methylene chloride, chloroform or toluene.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C

The reaction time is about 1 hour to 24 hours, preferably about 2 hours to 12 hours.

Step C-4

In a similar manner to Step 1-2 of Process 1, a compound of the formula (30) can be prepared from a compound of the formula (29).

In accordance with the Steps 1-3, 1-4 and 1-5 of Process 1, the compounds of the present invention can be prepared from a compound of the formula (30) obtained in the above Step C-4.

Process D

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^4 has the same meaning as defined above, R^{33} is C_{1-6} alkoxy or C_{7-16} aralkyloxy, and l' is 1).

Process D



In the above reaction scheme, R^4, X_2, Me and Et each has the same meaning as defined above and R^{26} is C_{1-6} alkyl or C_{7-16} aralkyl.

Step D-1

A compound of the formula (32) can be prepared by reacting a compound of the formula (31) with a compound of the formula (16) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl

sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvents in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc., and alkali metal carbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, etc., among which sodium hydride is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C

The reaction time is about 2 hour to 48 hours, preferably about 6 hours to 24 hours.

Step D-2

A compound of the formula (33) can be prepared by hydrolyzing the ester moiety of a compound of the formula (32) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, etc.; and water, and they can be used solely or in combination thereof. Preferred solvents in the present reaction are tetrahydrofuran or a mixture of tetrahydrofuran and ethanol or methanol.

Examples of the bases used in the reaction include alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; aqueous solutions of alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc., among which sodium hydroxide is preferred.

The reaction temperature is about 0°C to 120°C, preferably

about room temperature to 80°C

The reaction time is about 1 hour to 24 hours, preferably about 2.5 hours to 12 hours.

Step D-3

In a similar manner to Step 1-1 of Process 1, a compound of the formula (34) can be prepared from a compound of the formula (33).

Step D-4

This process is a conversion reaction from acid chlorides to diazoketones. A compound of the formula (35) can be prepared by reacting a compound of the formula (34) with diazomethane in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc., and they can be used solely or in combination thereof. Preferred solvents in the present reaction are diethyl ether or tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -20°C to 50°C, preferably about 0°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step D-5

This process is one carbon homologation (Arndt-Eistert synthesis) by α-diazoketone rearrangement (Wolff rearrangement). A compound of the formula (35) is reacted by

use of a silver catalyst (for example, silver benzoate, silver oxide) in an alcohol in the presence of a base to give a compound of the formula (36).

The solvent (also served as the reaction reagents) used in the reaction includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc., and they can be used solely or in combination thereof. Preferred solvents (also served as the reaction reagents) in the present reaction are methanol or ethanol.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about room temperature to 120°C, preferably about 60°C to 120°C.

The reaction time is about 2 hours to 36 hours, preferably about 4 hours to 18 hours.

Step D-6

In a similar manner to Step 1-2 of Process 1, a compound of the formula (37) can be prepared from a compound of the formula (36).

In accordance with the Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (37) obtained in the above Step D-6. The resulting compound of the present invention is further subjected to the reactions of Step 2-2 of Process 2, whereby the substituent $-OR^{26}$ can be converted into -OH.

Process E

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^4 has the same meaning as defined above, R^{34} is $-N(R^{13})(R^{14})$ in which R^{13} and R^{14} each has the same meaning as defined above), and l' is 1).

Process E





In the above reaction scheme, R^4, R^{13}, R^{14}, Me and t-Bu each has the same meaning as defined above.

Step E-1

In a similar manner to Step A-1 of Process A, a compound of the formula (39) can be prepared by reacting a compound of the formula (38) with a compound of the formula (27).

Step E-2

In a similar manner to Step C-3 of Process C, a compound of the formula (40) can be prepared from a compound of the formula

(39).

Step E-3

A compound of the formula (42) can be prepared by reacting a compound of the formula (40) with a compound of the formula (41) without or in a solvent and in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine or a mixture of triethylamine and dimethylaminopyridine is preferred.

The reaction temperature is about 0°C to 120°C, preferably about room temperature to 100°C.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step E-4

In a similar manner to Step 1-2 of Process 1, a compound of the formula (43) can be prepared from a compound of the formula

(42).

In accordance with the Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (43) obtained in the above Step E-4.

Process F

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^4 has the same meaning as defined above and R^{35} is $-COO(R^{25})$ in which R^{25} is C_1-C_6 alkyl, and l' is 1).

Process F





In the above reaction scheme, R^4, R^{25} and Bn each has the same meaning as defined above.

Step F-1

In a similar manner to Step 1-1 of Process 1, a compound of the formula (45) can be prepared from a compound of the formula (44).

Step F-2

A compound of the formula (47) can be prepared by reacting a compound of the formula (45) with a compound of the formula (46) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -30°C to 80°C, preferably about -20°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step F-3

In a similar manner to Step A-1 of Process A, a compound of the formula (49) can be prepared by reacting a compound of the formula (47) with a compound of the formula (48).

Step F-4

A compound of the formula (49) was reacted in a similar manner to Step 1-2 of Process 1, followed by debenzylation and decarboxylation to give a compound of the formula (50).

In accordance with the alternative process described in Step 1-3 and Step 1-5 of Process 1, the compounds of the present invention can be prepared from a compound of the formula (50) obtained in the above Step F-4.

Process G

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^3 and R^4 each has the same meaning as defined above and l' is 1).

Process G



(51) (52) (53) (54) (55) (55')

In the above reaction scheme, R^3, R^4 and Et each has the same meaning as defined above.

Step G-1

In a similar manner to Step 1-1 of Process 1, a compound of the formula (52) can be prepared from a compound of the formula (51).

Step G-2

In a similar manner to Step D-4 of Process D, a compound of the formula (53) can be prepared from a compound of the formula (52).

Step G-3

In a similar manner to Step D-5 of Process D, a compound

of the formula (54) can be prepared from a compound of the formula (53).

Step G-4

In a similar manner to Step D-6 of Process D, a compound of the formula (55) can be prepared from a compound of the formula (54).

In accordance with Steps 1-3, 1-4 and 1-5 of the above Process 1, the compounds of the present invention can be prepared from a compound of the formula (55) obtained above in Step G-4.

Step G-5

In a similar manner to Step 1-4 of the above Process 1, a compound of the formula (55') can be prepared from a compound of the formula (54).

In accordance with Steps 1a-2, 1a-3 and 1a-4 of the above Process 1a, the compounds of the present invention can be prepared from a compound of the formula (55') obtained in the above Step G-5.

Process H

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^3 and R^4 each has the same meaning as defined above and l3 is 0).

Process H



In the above reaction scheme, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{23}, Alk^2, ring A, ring B, ring C, m and n each has the same meaning as defined above.

Step H-1

In a similar manner to Step 1-2 of Process 1, a compound of the formula (57) can be prepared from a compound of the formula (56).

Step H-2

In a similar manner to Step 1-3 of Process 1, a compound of the formula (58) can be prepared by reacting a compound of the formula (57) obtained in Step of H-1 (or commercially available product) with a compound of the formula (3).

Step H-3

In a similar manner to Step 1-4 of Process 1, a compound of the formula (59) can be prepared from a compound of the formula (58).

Step H-4

In a similar manner to Step 1-5 of Process 1, a compound of the formula (1-3) which is one of the objective compounds can be prepared by reacting a compound of the formula (59) with a compound of the formula (8).

Process I

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^3 and R^4 each has the same meaning as defined above and l4 is 1 to 3).

Process I



In the above reaction scheme, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, l4, m, n, ring A, ring C, Bn, Me, Alk^1, Alk^2 and X_2 each

has the same meaning as defined above.

Step I-1

In a similar manner to Step 1-3 of Process 1, a compound of the formula (61) can be prepared by reacting a compound of the formula (60) with a compound of the formula (3).

Step I-2

Under conditions similar to Step 1-2 of Process 1, with the proviso that palladium hydroxide is used as a catalyst, a compound of the formula (62) can be prepared from a compound of the formula (61).

Step I-3

A compound of the formula (64) can be prepared by reacting a compound of the formula (62) with a compound of the formula (63) in a solvent in the presence of a base. Alternatively, X_2-$(Alk^1)_{14}$-COOEt (in the formula, X_2, Alk^1, 14 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.;

alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; alkali metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; and alkali metal phosphates such as sodium phosphate, potassium phosphate, etc., among which potassium carbonate or sodium hydride is preferred.

The reaction temperature is about 0°C to 150°C, preferably about room temperature to 100°C.

The reaction time is about 1 hour to 48 hours, preferably about 2 hours to 24 hours.

Step I-4

In a similar manner to Step 1-4 of Process 1, a compound of the formula (65) can be prepared from a compound of the formula (64).

Step I-5

In a similar manner to Step 1-5 of Process 1, a compound of the formula (1-4) which is one of the objective compounds can be prepared by reacting a compound of the formula (65) with a compound of the formula (8).

Process J

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^3, R^4 and Alk^1 each has the same meaning as defied above and 14 is 1 to 3).

Process J



(66)

(67)



(68)

In the above reaction scheme, R^3, R^4, Me, Alk^1, 14 and X_2 each has the same meaning as defined above.

Step J-1

In a similar manner to Step I-3 of Process I, a compound of the formula (67) can be prepared by reacting a compound of the formula (66) with a compound of the formula (63). Alternatively, X_2-$(Alk^1)_{14}$-COOEt (in the formula X_2, Alk^1, 14 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

Step J-2

In accordance with the Step I-4 of Process I, a compound of the formula (68) can be prepared from a compound of the formula (67).

In a similar manner to Steps 1a-2, 1a-3 and 1a-4 of Process 1a, the compounds of the present invention can be prepared from a compound of the formula (68) obtained in the above Step J-2.

Process K

The following is an example of the process for preparing a compound of the formula (1) wherein ring B is



(wherein R^3, R^4, 14 and Alk^1 each has the same meaning as defined above).

Process K



(69) (70) (71)

In the above reaction scheme, R^3, R^4, Me, l4, Alk^1 and X_2 each has the same meaning as defined above.

Step K-1

In a similar manner to Step I-3 of Process I, a compound of the formula (70) can be prepared by reacting a compound of the formula (69) with a compound of the formula (63). Alternatively, X_2-$(Alk^1)_{l4}$-COOEt (in the formula X_2, Alk^1, l4 and Et each has the same meaning as defined above) may be used in place of a compound of the formula (63).

Step K-2

In a similar manner to Step I-4 of Process I, a compound of the formula (71) can be prepared from a compound of the formula (70).

In accordance with the Steps 1a-2, 1a-3 and 1a-4 of the above Process 1a, the compounds of the present invention can be prepared from a compound of the formula (71) obtained in the above Step K-2.

Process L

The following is an example of the process for preparing a compound of the formula (1) wherein R^3 of the ring B, and R^{10} of the X are taken together to form



(wherein R^4, l4 and Alk^1 each has the same meaning as defined above).

Process L



(1-5)

step L-1



(1-6)

In the above reaction scheme, R^1, R^2, R^4, R^5, R^6, R^7, R^8, R^9, l4, m, ring A, ring C, Alk^1 and Alk^2 each has the same meaning as defined above.

Step L-1

A compound of the formula (1-5) obtained by debenzylation of a compound (wherein R^{26} is benzyl) obtained in the Process 1 and the Process D is reacted with a phosgene equivalent reagent (for example, triphosgene or diphosgene, etc.) in a solvent in the presence of a base to give a compound of the formula (1-6).

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is chloroform.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -20°C to 100°C, preferably about 0°C to room temperature.

The reaction time is about 10 minutes to 4 hours, preferably about 30 minutes to 2 hours.

Process M

The following is an example of the process for preparing a compound of the formula (1) wherein R^{10} is other than hydrogen.

Process M



In the above reaction scheme, R^1, R^2, R^3, R^4, R^{23}, l, n, X_2, ring A, ring B, and Alk^1 each has the same meaning as defined above, and $R^{10'}$ is C_1-C_6 alkyl or C_3-C_7 cycloalkyl).

Step M-1

A compound of the formula (73) can be prepared by reacting

a compound of the formula (6) obtained in the Step 1-3 of Process 1 with a compound of the formula (72) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as acetone, N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is N,N-dimethylformamide.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; alkali metal carboxylates such as sodium acetate, potassium acetate, etc.; and alkali metal phosphates such as sodium phosphate, potassium phosphate, etc., among which sodium hydride is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C.

The reaction time is about 1 hour to 24 hours, preferably about 2 hours to 8 hours.

In accordance with the above Steps 1-4 and 1-5, the compounds of the present invention can be prepared from a compound of the formula (73) obtained in the above Step M-1.

Process N

The following is an example of the process for preparing a compound of the formula (1) wherein R^8 and R^9 are each -CONH($R^{19'}$)(wherein $R^{19'}$ is C_1-C_6 alkyl).

Process N



In the above reaction scheme, R^5, R^6, R^7, R^{25} and ring C each has the same meaning as defined above.

Step N-1

A compound of the formula (75) can be prepared by reacting a compound of the formula (74) with thionyl chloride or oxalyl chloride in a solvent.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they can be used solely or in combination thereof. A preferred

solvent used in the present reaction is toluene containing a catalytic amount of N,N-dimethylformamide.

The reaction temperature is about room temperature to 120°C, preferably about 50°C to 100°C.

The reaction time is about 10 minutes to 6 hours, preferably about 30 minutes to 3 hours.

Step N-2

A compound of the formula (77) can be prepared by reacting a compound of the formula (75) with a compound of the formula (76) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; and esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and they can be used solely or in combination thereof. Preferred solvents in the present reaction are methylene chloride or tetrahydrofuran.

Examples of the bases used in the reaction include organic bases such as triethylamine, pyridine, dimethylaminopyridine, N-methylmorpholine, etc., among which triethylamine is preferred.

The reaction temperature is about -40°C to 60°C, preferably about -30°C to room temperature.

The reaction time is about 2 hours to 48 hours, preferably about 6 hours to 24 hours.

Step N-3

A compound of the formula (78) can be prepared by reacting a compound of the formula (77) with paraformaldehyde or formalin without or in a solvent in the presence of a catalytic amount of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination thereof. A preferred solvent in the present reaction is tetrahydrofuran.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; and organic bases such as triethylamine, diethylamine, pyridine, etc., among which potassium t-butoxide, sodium ethoxide or potassium hydroxide is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C.

The reaction time is about 10 minutes to 24 hours,

preferably about 30 minutes to 12 hours.

In accordance with the above Processes 1, 1a and 2, the compounds of the present invention can be prepared using a compound of the formula (78) obtained in the above Step N-3 in place of a compound of the formula (8).

Process O

The following is an example of the process for preparing a compound of the formula (1) wherein R^8 and R^9 are each $-COOR^{25}$ (wherein R^{25} is C_1-C_6 alkyl).

Process O



(79) (80)

In the above reaction scheme, R^5, R^6, R^7, R^{25} and ring C each has the same meaning as defined above.

Step O-1

In a similar manner to Step N-3 of Process N, a compound of the formula (80) can be prepared from a compound of the formula (79).

In accordance with the above Processes 1, 1a and 2, the compounds of the present invention can be prepared using a compound of the formula (80) obtained in the above Step O-1 in place of a compound of the formula (8).

Process P

The following is an example of the process for preparing

a compound of the formula (1) wherein m is 2 or 3. In this process, tert-butyldimethylsilyl (TBS) may be used in place of benzyl (Bn).

Process P



In the above reaction scheme, R^5, R^6, R^7, R^8, R^9, X_2, m, Bn and ring C each has the same meaning as defined above.

Step P-1

A compound of the formula (83) can be prepared by reacting a compound of the formula (81) with a compound of the formula (82) in a solvent in the presence of a base.

The solvent used in the reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, dioxane, 1,2-dimethoxyethane, diglyme, etc.; hydrocarbons such as benzene, toluene, hexane, xylene, etc.; halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, etc.; alcohols such as methanol, ethanol, isopropyl alcohol, t-butanol, etc.; esters such as ethyl acetate, methyl acetate, butyl acetate, etc.; and polar solvents such as N,N-dimethylformamide, dimethyl sulfoxide, etc.; and they can be used solely or in combination

thereof. Preferred solvents in the present reaction are N,N-dimethylformamide or tetrahydrofuran.

Examples of the bases used in the reaction include alkali metal hydrides such as sodium hydride, potassium hydride, etc.; alkali metal alkoxides such as sodium ethoxide, sodium methoxide, potassium t-butoxide, etc.; alkali metal carbonates such as sodium carbonate, potassium carbonate, etc.; and organoalkali metals such as lithium diisopropylamide, etc., among which sodium hydride or lithium diisopropylamide is preferred.

The reaction temperature is about 0°C to 100°C, preferably about room temperature to 80°C

The reaction time is about 30 minutes to 48 hours, preferably about 2 hours to 24 hours.

Step P-2

In a similar manner to Step 2-2 of Process 2, a compound of the formula (84) can be prepared from a compound of the formula (83).

In accordance with the above Processes 1, 1a and 2, the compounds of the present invention can be prepared using a compound of the formula (84) obtained in the above Step P-2 in place of a compound of the formula (8).

Examples

The present invention is illustrated in more detail by Examples given below, but it goes without saying that the present invention is not limited thereto. In the Examples, Me is methyl, Et is ethyl, tBu is t-butyl and TBS is tert-butylmethylsilyl.

Example 1

4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenyl-acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester

a) phenylmalonic acid dichloride

Thionyl chloride (13.7 mL) was added dropwise to a mixture of phenylmalonic acid (11.31 g), dimethylformamide (230 μL) and toluene (27 mL) under ice-cooling. The mixture was stirred at 80°C for 70 minutes, and the solvent was removed off by evaporation. After azeotropic distillation with toluene, the residue was dried in vacuo to give the title compound (11.61 g).

b) Phenylmalonic acid diethylamide



To a mixed solution of ethylamine in tetrahydrofuran (2M, 45.5 mL), triethylamine (13.9 mL) and methylene chloride (80 mL) was dropwise added the phenylmalonic acid dichloride (8.99 g) obtained in Example 1-a) at -20°C. The mixture was stirred overnight while the temperature was raised to room temperature, and then diluted with ethyl acetate after addition of 3N hydrochloric acid. The organic layer was washed with saturated brine, saturated aqueous sodium bicarbonate and

saturated brine, dried over sodium sulfate and concentrated. The resulting solid was washed with ethyl acetate and hexane to give the title compound (4.85 g) as a white powder.

c) 2-Hydroxymethyl-2-phenylmalonic acid diethylamide



The phenylmalonic acid diethylamide (2.34 g) obtained in Example 1-b) and paraformamide (390 mg) were suspended in tetrahydrofuran (20 ml), and to this suspension was added potassium hydroxide (catalytic amount) at 60°C. The mixture was stirred for 5 hours and concentrated to remove the solvent. The residue was chromatographed on a column of silica gel with ethyl acetate:hexane=1:1 to give the title compound (2.31 g).

d) 4'-Trifluoromethylbiphenyl-2-carboxylic acid chloride



To a mixture of 4'-trifluoromethylbiphenyl-2-carboxylic acid (5.06 g), dimethylformamide (catalytic amount) and methylene chloride (30 mL) was added dropwise oxalyl chloride (2.43 mL) under ice-cooling. The mixture was stirred at room temperature for 100 minutes and the solvent was removed by evaporation. After azeotropic distillation with toluene, the residue was dried in vacuo to give the title compound (5.40 g).

e) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid ethyl ester



To a mixture of 4-aminophenylacetic acid ethyl ester (3.41 g), triethylamine (3.2 mL) and methylene chloride (30 mL) was added dropwise a solution of the 4'-trifluoromethylbiphenyl-2-carboxylic acid chloride (5.40 g) obtained in Example 1-d) in methylene chloride (10 mL) under ice-cooling, and the mixture was stirred at room temperature overnight. After addition of 1N hydrochloric acid, the reaction mixture was diluted with ethyl acetate, and the organic layer was washed with saturated brine, saturated aqueous sodium bicarbonate and saturated brine, dried over sodium sulfate, and then concentrated to give the title compound (8.12 g).

f) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid



The 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid ethyl ester (8.12 g) obtained in Example 1-e) was dissolved in 40 mL of tetrahydrofuran and 20 mL of ethanol. After addition of 4N sodium hydroxide (5 mL),

the solution was stirred at room temperature for 5 hours and concentrated. The powder formed upon addition of 1N hydrochloric acid was collected by filtration and dried in vacuo to give the title compound (7.48 g).

g) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



The 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid (519 mg) obtained in Example 1-f), the 2-hydroxymethyl-2-phenylmalonic aid diethylamide (317 mg) obtained in Example 1-c), dimethylaminopyridine (171 mg) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (WSC.HCl)(268 mg) were dissolved in methylene chloride (5 ml). The solution was stirred at room temperature for 6 hours and the solvent was removed off by evaporation. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:1 to 3:2 to give the title compound (725 mg)(see Table 1).

Example 1-2

2-Phenyl-2-{2-[4-(4'-trifluoromethylbiphenyl-2-carbonyloxy)phenyl]acetoxymethyl}malonic acid diethyl ester

a) 2-Hydroxymethyl-2-phenylmalonic acid diethyl ester

Paraformaldehyde (720 mg) was suspended in phenylmalonic acid diethyl ester (4.73 g), and a catalytic amount of potassium hydroxide was added thereto at 60°C. After stirring for 1.5 hours, the reaction mixture was purified by column chromatography on silica gel with ethyl acetate:hexane=1:5 to 1:2 to give the title compound (4.96 g).

b) 2-[2-(4-(Benzyloxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester



4-Benzyloxyphenylacetic acid (1.09 g) was suspended in methylene chloride (50 mL) and the suspension was dissolved by addition of dimethylaminopyridine (0.511 g). To the solution was added the 2-hydroxymethyl-2-phenylmalonic acid diethyl ester (1.20 g) obtained in Example 1-2 a), and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (0.864 g) was portionwise added thereto. The mixture was stirred at room temperature overnight and then

concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:4 to give the title compound (1.95 g) as a colorless oil.

c) 2-[2-(4-(Hydroxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester



The 2-[2-(4-(Benzyloxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (1.95 g) obtained in Example 1-2 b) was dissolved in methanol (2.5 mL). The solution was subjected to hydrogenation in the presence of 7.5% palladium-carbon (0.200 g) under normal pressure for 4 hours. The reaction solution was filtered through a Celite pad and concentrated to give the title compound (1.71 g) as a colorless oil.

d) 2-Phenyl-2-{2-[4-(4'-trifluoromethylbiphenyl-2-carbonyloxy)phenyl]acetoxymethyl}malonic acid diethyl ester



4'-Trifluoromethylbiphenyl-2-carboxylic acid (0.266 g) was suspended in methylene chloride (10 mL), and the suspension was dissolved by addition of 4-dimethylaminopyridine (0.122 g). To the solution was added the

2-[2-(4-(hydroxyphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (0.400 g) obtained in Example 1-2 c), and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (0.192 g) was portionwise added thereto. The mixture was stirred at room temperature overnight and then concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:3 to give the title compound (0.55 g) as an amorphous powder (see Table 1).

Example 1-3

2-(2-{3-Methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester

a) 2-(3-Methyl-4-nitrophenyl)malonic acid diethyl ester



Sodium hydride (60% mineral oil; 0.599 g) was suspended in dimethylformamide (10 mL), and a solution of malonic acid diethyl ester (2.00 g) in dimethylformamide (10 mL) was added dropwise thereto under ice-cooling. After foam generation is stopped, a solution of 4-fluoro-2-methylnitrobenzene (1.94 g) in dimethylformamide (5 mL) was added thereto, and the reaction temperature was raised to 100°C, followed by stirring for 6 hours. The reaction mixture was concentrated, acidified with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed successively with water and saturated brine,

dried over sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:5 to give the title compound (1.65 g) as a yellow oil.

b) (3-Methyl-4-nitrophenyl)acetic acid



Potassium hydroxide (0.168 g) was dissolved in 7 mL of methanol and 1 mL of water, and the 2-(3-methyl-4-nitrophenyl)malonic acid diethyl ester (0.250 g) obtained in Example 1-3 a) was dissolved in the solution. The solution was stirred at 100°C for 2 hours and concentrated. The residue was acidified with 2N hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine, dried over sodium sulfate and concentrated to give the title compound (0.143 g) as a yellow solid.

c) 2-[2-(3-Methyl-4-nitrophenyl)acetoxymethyl]-2-phenyl-malonic acid diethyl ester



The (3-Methyl-4-nitrophenyl)acetic acid (0.143 g) obtained in Example 1-3 b) was dissolved in methylene chloride (5 mL). To the solution were added 2-(3-methyl-4-nitrophenyl)malonic acid diethyl ester (0.195

g) obtained in Example 1-2 a), 4-dimethylaminopyridine (0.090 g) and 1-ethyl-3-(3'- dimethylaminopropyl)carbodiimide hydrochloride (0.141 g), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated and the residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:4 to give the title compound (0.219 g) as a yellow oil.

d) 2-[2-(4-Amino-3-methylphenyl)acetoxymethyl]-2-phenyl-malonic acid diethyl ester



The 2-[2-(3-Methyl-4-nitrophenyl}acetoxymethyl]-2-phenyl-malonic acid diethyl ester (0.219 g) obtained in Example 1-3 c) was dissolved in methanol (3 mL). The solution was subjected to hydrogenation in the presence of 7.5% palladium-carbon (0.030 g) under normal pressure to give the title compound (0.197 g) as a yellow oil.

e) 2-(2-{3-Methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester



In a similar manner to Example 1 d), 4'-trifluoromethyl-2-biphenylcarboxylic acid (0.124 g) was converted into its corresponding acid chloride. On the other hand, the title compound (0.215 g) was obtained as a colorless amorphous from the 2-[2-(4-amino-3-methylphenyl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (0.197 g) obtained in Example 1-3 d) in a similar manner to Example 1 e)(see Table 1).

Example 1-4

2-(2-{4-[Methyl-(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester

a) {4-[Methyl-(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid ethyl ester



Sodium hydride (51 mg) was dissolved in dimethylformamide (5 mL), and the solution was cooled to 0°C. To the solution was added the 4-[(4'-trifluoromethylbiphenyl-2-

carbonyl)amino]phenylacetic acid ethyl ester (500 mg) obtained in Example 1 e), and the mixture was stirred for one hour. After addition of iodomethane (183 mg), the mixture was stirred at room temperature for 3 hours and water was then added. The reaction solution was concentrated, diluted with ethyl acetate, and washed with water. The resulting solution was dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=4:1 to give the title compound (141 mg).

b) 2-(2-{4-[Methyl-(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester



The {4-[Methyl-(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid ethyl ester (141 mg) obtained in Example 1-4 a) was subjected to reactions similar to those in Examples 1 f) and 1 g) to give the title compound (56 mg)(see Table 1).

Example 1-5

{3-Ethyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester

a) 3-Ethyl-4-nitrophenylacetic acid ethyl ester



To a solution of 4-nitrophenylacetic acid ethyl ester (1.63 g) in tetrahydrofuran (100 mL) was dropwise added 2M ethyl magnesium chloride in tetrahydrofuran (3 mL) at -15°C under argon atmosphere, and the mixture was stirred at the same temperature for 30 minutes. After further dropwise addition of 2M ethyl magnesium chloride in tetrahydrofuran (3 mL), the mixture was stirred at -15°C for one hour, and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (3.0 g) was added thereto at the same temperature. The mixture was stirred overnight, and water (300 mL) was added thereto, followed by extraction with chloroform (150 mL x 3). The organic layers were combined, washed with saturated brine, dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=10:1 to give the title compound (1.09 g).

b) {3-Ethyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



The 3-ethyl-4-nitrophenylacetic acid ethyl ester (1.05 g) obtained in Example 1-5 a) was subjected to reactions similar to those in Example 1-3 d), Example 1 e), Example 1 f) and Example

1 g) to give the title compound (1.60 g)(see Table 1).

Examples 1-6 to 1-83

Compounds of Examples 1-6 to 1-85 were obtained in a similar manner to Examples 1 to 1-5. The compounds obtained were shown in Tables 2 to 17.

Table 1

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1	 m.p. 88.4-91.2	1.05(6H, t, J=7.3Hz), 3.18-3.29(4H, m), 3.53(2H, s), 4.83(2H, s), 6.95(1H, br-s), 7.02-7.23(8H, m), 7.27-7.36(3H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.77-7.84(1H, m)
1-2		1.19(6H, t, J=9.2Hz), 3.53(2H, s), 4.18(4H, q, J=9.2Hz), 4.82(2H, s), 6.79(2H, d, J=12Hz), 7.14(2H, d, J=12Hz), 7.29(5H, brs), 7.38-7.73(7H, m), 8.09(1H, dd, J=1.2Hz, J=7.5Hz).
1-3		1.21(6H, t, J=7.1Hz), 1.67(3H, s), 3.47(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.89((1H, brs), 6.92(1H, brs), 7.00(1H, d, J=10.6Hz), 7.30(5H, brs), 7.42-7.84(9H, m).
1-4		1.22(6H, t, J=7.2Hz), 3.23(3H, s), 3.40(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 6.10(2H, d, J=8.3Hz), 6.70(2H, d, J=8.3Hz), 7.07-7.61(13H, m)
1-5	 m.p. 105-109	0.93(3H, t, J=7.5Hz), 1.05(6H, t, J=7.3Hz), 1.94(2H, q, J=7.5Hz), 3.13-3.28(4H, m), 3.53(2H, s), 4.83(2H, s), 6.80-7.84(19H, m)

Table 2

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-6		3.56(2H, s), 3.65-3.78(2H, s), 4.55(2H, s), 5.49(1H, br), 7.01(1H, brs), 7.05-7.83(20H, m).
1-7		1.39(3H, d, J=7.2Hz), 3.48-3.68(2H, m), 3.70-3.89(2H, m), 4.44(1H, d, J=10.6Hz), 4.66(1H, d, J=10.6Hz), 5.46(1H, br), 6.96((1H, brs), 7.02-7.84(20H, m).
1-8		3.50(2H, s), 3.68-4.00(3H, m), 4.42(1H, dd, J=6.0, 11.0Hz), 4.62(1H, dd, J=7.9, 11.0Hz), 5.68(1H, t, J=6.8Hz), 6.95(1H, s), 7.03-7.17(4H, m), 7.17-7.36(5H, m), 7.44(1H, dd, J=1.5, 7.6Hz), 7.48-7.64(4H, m), 7.65-7.71(2H, m), 7.80(1H, dd, J=1.5, 7.6Hz)
1-9		1.20(6H, t, J=7.2Hz), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 6.92(1H, br-s), 7.04-7.18(4H, m), 7.24-7.35(5H, m), 7.44(1H, dd, J=1.5, 7.1Hz), 7.48-7.64(4H, m), 7.65-7.73(2H, m), 7.81(1H, dd, J=1.5, 7.1Hz)
1-10		1.47-1.76(6H, m), 1.90-2.03(2H, m), 3.60(2H, s), 3.71-3.85(2H, m), 4.10(2H, s), 6.94(1H, br-s), 7.12-7.20(4H, m), 7.44(1H, dd, J=1.2, 7.4Hz), 7.49-7.64(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.2, 7.4Hz)

Table 3

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
1-11		1.18(6H, d, J=6.4Hz), 1.20(6H, d, J=6.0Hz), 3.50(2H, s), 4.80(2H, s), 5.08(1H, sept, J=6.4Hz), 5.08(1H, sept, J=6.0Hz), 6.92(1H, s), 7.05-7.16(4H, m), 7.27-7.32(5H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.1Hz)
1-12		3.53(2H, s), 3.74-3.97(4H, m), 4.87(2H, s), 6.94(1H, s), 7.00-7.07(2H, m), 7.09-7.20(4H, m), 7.31-7.47(6H, m), 7.49-7.64(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz)
1-13		3.51(2H, s), 3.71(6H, s), 4.81(2H, s), 6.92(1H, br-s), 7.05-7.16(4H, m), 7.22-7.35(5H, m), 7.41-7.46(1H, m), 7.49-7.63(4H, m), 7.65-7.71(2H, m), 7.81(1H, dd, J=1.5, 7.2Hz)
1-14		1.20(6H, t, J=7.1Hz), 1.29-1.81(10H, br), 2.40-2.53(1H, m), 3.52(2H, s), 4.13(4H, q, J=7.1Hz), 4.48(2H, s), 6.93(1H, brs), 7.14(4H, brs), 7.39-7.83(8H, m).
1-15	 m.p. 108.8 - 112.4	1.27-1.44(5H, m), 1.46-1.61(3H, m), 1.79-1.90(2H, m), 3.57(2H, s), 3.72-3.87(2H, m), 4.07(2H, s), 5.71-5.81(1H, m), 6.94(1H, br-s), 7.10-7.21(4H, m), 7.40-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.77-7.83(1H, m)

Table 4

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-16	 m.p. 93-95	1.22(6H, t, J=7.2Hz), 3.57(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.20(1H, d, J=8.5Hz), 7.28-7.67(12H, m), 7.76(1H, d, J=7.4)
1-17	 m.p. 99-103	1.20(6H, t, J=7.1Hz), 3.53(2H, s), 4.19(4H, q, J=7.1Hz), 4.82(2H, s), 6.91(1H, d, J=8.3Hz), 7.11-7.56(16H, m), 8.33(1H, dd, J=7.8, 1.8Hz), 9.62(1H, br.s)
1-18		1.05(3H, m), 1.22(6H, t, J=7.2Hz), 1.58(2H, m), 1.99(2H, m), 3.57(2H, s), 4.21(6H, m), 4.85(2H, s), 7.04-7.60(12H, m), 8.30(1H, m), 10.07(1H, br.s)
1-19		1.22(6H, t, J=6.9Hz), 3.60(2H, s), 4.20(4H, q, J=6.9Hz), 4.85(2H, s), 7.12-7.37(9H, m), 7.63-7.73(2H, m), 7.79-7.86(1H, m), 7.90-8.00(1H, m).
1-20		1.18(6H, t, J=6.8Hz), 3.51(2H, s), 4.17(4H, q, J=6.8Hz), 4.80(2H, s), 6.70(2H, d, J=12Hz), 7.09(2H, d, J=12Hz), 7.27(5H, brs), 7.41-7.83(8H, m), 8.21(1H, d, J=10Hz).

Table 5

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-21		1.18(6H, t, J=7.2Hz), 3.49(2H, s), 4.15(4H, q, J=7.2Hz), 4.80(2H, s), 7.07(1H, d, J=8.6Hz), 7.27-7.54(17H, m), 7.88(1H, d, J=6.2Hz)
1-22		1.16-1.83(20H, m), 3.50(2H, s), 4.80-4.91(2H, m), 4.82(2H, s), 6.93(1H, br-s), 7.05-7.17(4H, m), 7.27-7.34(5H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.2Hz)
1-23		0.95-1.22(6H, m), 1.23-1.43(4H, m), 1.50-1.71(6H, m), 1.71-1.90(4H, m), 3.52(2H, s), 3.69-3.83(2H, m), 4.84(2H, s), 6.95(1H, br-s), 7.04-7.35(11H, m), 7.41-7.48(1H, m), 7.49-7.65(4H, m), 7.66-7.73(2H, m), 7.77-7.84(1H, m)
1-24		3.58(2H, s), 5.06(2H, s), 6.81(1H, br-s), 6.99-7.05(4H, m), 7.08-7.16(2H, m), 7.24-7.47(14H, m), 7.50-7.67(6H, m), 7.80(1H, dd, J=1.5, 7.5Hz), 9.08(2H, br-s)
1-25		1.04(6H, d, J=6.4Hz), 1.09(6H, d, J=6.8Hz), 3.52(2H, s), 3.95-4.09(2H, m), 4.83(2H, s), 6.92-7.03(3H, m), 7.03-7.10(2H, m), 7.11-7.23(4H, m), 7.27-7.36(3H, m), 7.41-7.47(1H, m), 7.49-7.64(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz)

Table 6

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-26		1.19(6H, t, J=7.1Hz), 3.24(2H, s), 3.59(2H, s), 4.15(4H, q, J=7.1Hz), 4.32(2H, s), 6.80-6.88(2H, m), 6.93(1H, brs), 7.11-7.28(7H, m), 7.39-7.83(8H, m)
1-27		1.21(6H, t, J=7.1Hz), 2.14(3H, s), 3.51(2H, s), 4.19(4H, q, J=7.1Hz), 4.80(2H, s), 6.87(1H, brs), 6.91-7.02(3H, m), 7.19-7.34(5H, m), 7.40-7.85(8H, m).
1-28		3.56(2H, s), 3.71-3.95(4H, m), 4.87(2H, s), 6.75-6.83(2H, m), 7.05-7.19(4H, m), 7.29-7.44(6H, m), 7.47-7.60(3H, m), 7.62-7.73(3H, m), 8.05-8.12(1H, m)
1-29		3.55(2H, s), 3.70-3.94(4H, m), 4.86(2H, s), 6.71-6.79(2H, m), 7.01-7.09(2H, m), 7.11-7.18(2H, m), 7.27-7.54(12H, m), 7.57-7.66(1H, m), 7.94-8.01(1H, m)
1-30		0.95(3H, t, J=7.4Hz), 1.45-1.60(2H, m), 1.76-1.88(2H, m), 3.62(2H, s), 3.79-3.97(4H, m), 4.08(2H, t, J=6.4Hz), 4.90(2H, s), 6.99-7.06(2H, m), 7.10-7.21(6H, m), 7.31-7.41(5H, m), 7.48-7.56(1H, m), 7.96(1H, dd, J=1.8, 8.0Hz)

Table 7

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
1-31		0.97-1.10(6H, m), 1.12(6H, t, J=6.8Hz), 1.54-1.78(4H, m), 2.05-2.17(1H, m), 3.54(2H, s), 4.13(4H, q, J=6.8Hz), 4.50(2H, s), 6.93(1H, brs), 7.14(4H, brs), 7.40-7.82(8H, m).
1-32		3.51(2H, s), 3.85(4H, m), 4.86(2H, s), 6.88(1H, s), 7.00-7.54(19H, m), 7.89(1H, m)
1-33		3.56(2H, s), 3.84(4H, m), 4.86(2H, s), 6.91(1H, d, J=8.3Hz), 7.07-7.55(18H, m), 8.32(1H, dd, J=7.9, 1.9Hz), 9.64(1H, s)
1-34		1.23(6H, t, J=7.1Hz), 3.70(2H,s), 4.22(4H, t, J=7.1Hz), 4.81(2H, s), 7.02(1H, brs), 7.13-7.97(16H, m).
1-35	 m.p. 100.5-104.0	0.85(6H, t, J=7.5Hz), 1.37-1.51(4H, m), 3.13-3.22(4H, m), 3.53(2H, s); 4.84(2H, s), 6.96(1H, br-s), 7.02-7.09(2H, m), 7.10-7.24(6H, m), 7.27-7.35(3H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.6, 8.0Hz)

Table 8

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-36		2.73(6H, d, J=4.9Hz), 3.53(2H, s), 4.81(2H, s), 6.94(1H, br-s), 7.01-7.09(4H, m), 7.11-7.21(4H, m), 7.27-7.35(3H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.66-7.72(2H, m), 7.81(1H, dd, J=1.5, 7.5Hz)
1-37		1.20(6H, t, J=7.0Hz), 3.50(2H, s), 4.21(4H, q, J=7.0Hz), 4.90(2H, s), 6.93(1H, br-s), 7.04-7.15(4H, m), 7.15-7.21(1H, m), 7.38-7.47(2H, m), 7.49-7.64(5H, m), 7.66-7.72(2H, m), 7.81(1H, dd, J=1.5, 7.5Hz), 8.46-8.51(1H, m)
1-38		1.22(6H, t, J=7.2Hz), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 6.98(1H, br-s), 7.03-7.17(4H, m), 7.22(1H, dd, J=5.0, 8.5Hz), 7.41-7.47(1H, m), 7.48-7.63(5H, m), 7.64-7.72(2H, m), 7.77-7.83(1H, m), 8.50-8.57(2H, m)
1-39		1.04(6H, t, J=7.4Hz), 3.16-3.29(4H, m), 3.55(2H, s), 4.84(2H, s), 6.75-6.83(2H, m), 7.04-7.14(4H, m), 7.17-7.22(2H, m), 7.27-7.35(3H, m), 7.41(1H, dd, J=1.1, 7.6Hz), 7.47-7.54(2H, m), 7.56(1H, dd, J=1.5, 7.6Hz), 7.61-7.72(3H, m), 8.08(1H, dd, J=1.1, 7.6Hz)
1-40		1.20(6H, t, J=7.1Hz), 3.55(2H, s), 4.21(4H, q, J=7.1Hz), 4.84(2H, s), 7.20-7.77(16H, m), 8.16(1H, br)

Table 9

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
1-41		1.01(3H, t, J=7.2Hz), 1.60(2H, m), 1.96(2H, m), 3.59(2H, s), 3.84(4H, m), 4.21(2H, t, J=6.5Hz), 4.89(2H, s), 7.00(1H, d, J=8.3Hz), 7.09-7.16(5H, m), 7.32-7.58(8H, m), 8.26(1H, dd, J=8.0, 1.9Hz), 10.07(1H, br.s)
1-42		0.88(6H, t, J=7.1Hz), 1.19-1.34(4H, m), 1.35-1.48(4H, m), 3.16-3.26(4H, m), 3.52(2H, s), 4.84(2H, s), 6.95(1H, br-s), 7.02-7.23(8H, m), 7.27-7.36(3H, m), 7.40-7.47(1H, m), 7.49-7.63(4H, m), 7.64-7.73(2H, m), 7.81(1H, dd, J=1.5, 7.5Hz)
1-43		1.22(6H, t, J=7.1Hz), 3.58(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 6.23(2H, d, J=8.5Hz), 7.30-7.73(10H, m), 7.87(2H, d, J=8.5Hz), 8.36(1H, dd, J=6.8, 2.3Hz), 12.3(1H, brs)
1-44		1.24(6H, t, J=7.1Hz), 3.58(2H, s), 4.23(4H, q, J=7.1Hz), 4.27(2H, s), 4.85(2H, s), 7.22(2H, d, J=8.5Hz), 7.27-7.98(13H, m), 7.61(2H, d, J=8.5Hz)
1-45	 m.p. 175-177	1.05(6H, t, J=7.3Hz), 1.69(3H, s), 3.14-3.30(4H, m), 3.49(2H,s), 4.83(2H, s), 6.77(1H, brs), 6.89(1H, brs), 6.92-7.85(17H, m).

Table 10

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-46		1.20(6H, t, J=7.1Hz), 2.38(3H, s), 3.49(2H, s), 4.19(4H, q, J=7.1Hz), 4.81(2H, s), 6.90(1H, brs), 7.05(4H, brs), 7.19-7.56(12H, m), 7.88(1H, d, J=7.1Hz).
1-47		1.20(6H, t, J=7.1Hz), 3.49(2H, s), 3.81(3H, s), 4.19(4H, q, J=7.1Hz), 4.81(2H, s), 6.87-7.56(17H, m), 7.86(1H, d, J=7.6Hz)
1-48		1.12(6H, t, J=7.2Hz), 2.49-2.58(2H, m), 3.30(4H, dq, J=5.6, 7.2Hz), 3.54(2H, s), 4.07-4.15(2H, m), 6.94(1H, br-s), 7.11-7.18(4H, m), 7.22-7.37(5H, m), 7.41-7.46(1H, m), 7.48-7.63(6H, m), 7.65-7.71(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz)
1-49		0.87(6H, t, J=7.2Hz), 1.51(4H, tq, J=7.2, 7.2Hz), 2.50-2.59(2H, m), 3.18-3.27(4H, m), 3.54(2H, s), 4.07-4.15(2H, m), 6.95(1H, br-s), 7.12-7.18(4H, m), 7.23-7.36(5H, m), 7.41-7.46(1H, m), 7.48-7.63(6H, m), 7.65-7.71(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz)
1-50		1.05(6H, t, J=7.1Hz), 3.17-3.28(4H, m), 3.51(2H, s), 4.82(2H, s), 6.87(1H, br-s), 6.97-7.22(8H, m), 7.27-7.35(3H, m), 7.39-7.59(8H, m), 7.90(1H, dd, J=1.5, 7.5Hz)

Table 11

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-51		1.03(6H, t, J=7.1Hz), 3.16-3.28(4H, m), 3.56(2H, s), 4.82(2H, s), 6.88-6.94(1H, m), 7.02-7.34(13H, m), 7.39-7.49(3H, m), 7.51-7.59(2H, m), 8.34(1H, dd, J=1.9, 7.9Hz), 9.63(1H, br-s)
1-52		1.05(3H, t, J=7.2Hz), 1.07(6H, t, J=7.2Hz), 1.54-1.68(2H, m), 1.92-2.05(2H, m), 3.19-3.31(4H, m), 3.58(2H, s), 4.23(2H, q, J=6.4Hz), 4.85(2H, s), 7.02(1H, d, J=8.3Hz), 7.06-7.38(10H, m), 7.44-7.53(1H, m), 7.57-7.65(2H, m), 8.30(1H, dd, J=1.9, 7.9Hz), 10.08(1H, br-s)
1-53		1.23(6H, t, J=7.1Hz), 3.53(2H, s), 4.23(4H, q, J=7.1Hz), 4.84(2H, s), 6.95(1H, brs), 7.10(2H, d, J=8.3Hz), 7.17(2H, d, J=8.3Hz), 7.32(5H, brs), 7.41-7.87(8H, m).
1-54		1.19(6H, t, J=7.1Hz), 3.50(2H, s), 4.16(2H, q, J=7.1Hz), 4.17(2H, q, J=7.1Hz), 4.80(2H, s), 6.89-7.90(17H, m)
1-55		1.05(6H, t, J=7.2Hz), 3.19-3.31(4H, m), 3.54(2H, s), 4.86(2H, s), 6.90(1H, d, J=8.3Hz), 7.02-7.11(3H, m), 7.16-7.23(2H, m), 7.25-7.36(4H, m), 7.41(1H, dd, J=1.2, 7.5Hz), 7.48-7.61(3H, m), 7.62-7.71(3H, m), 8.21(1H, dd, J=1.5, 7.5Hz)

Table 12

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-56		1.21(6H, t, J=7.1Hz), 3.51(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.99-7.57(16H, m), 7.84(1H, d, J=7.2Hz).
1-57		1.23(6H, t, J=7.2Hz), 3.57(2H, s), 4.22(4H, q, J=7.2Hz), 4.85(2H, s), 7.19-8.08(19H, m)
1-58		0.94(6H, d, J=6.8Hz), 1.22(6H, t, J=7.1Hz), 3.40(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 4.99(1H, m), 6.16(1H, br.s), 6.78(2H, d, J=8.6Hz), 7.08(1H, dd, J=8.6, 1.5Hz), 7.20-7.74(13H, m)
1-59		0.89(4H, m), 1.22(6H, t, J=7.1Hz), 1.28-1.78(6H, m), 3.40(2H, s), 4.20(4H, q, J=7.1Hz), 4.62(1H, m), 4.82(2H, s), 6.15(1H, br.s), 6.75(2H, m), 7.06-7.74(14H, m)
1-60		1.23(6H, t, J=6.9Hz), 1.28(6H, d, J=6.9Hz), 3.40(1H, sep, J=6.9Hz), 3.56(2H, s), 4.22(4H, q, J=6.9Hz), 4.84(2H, s), 7.12-7.61(14H, m)

Table 13

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-61		1.22(6H, t, J=7.1Hz), 3.53(2H, s), 4.22(4H, q, J=7.1Hz), 4.23(2H, s), 4.83(2H, s), 6.98-7.61(19H, m)
1-62		0.86(6H, t, J=7.3Hz), 1.50-1.69(4H, m), 3.50(2H, s), 4.10(4H, t, J=6.6Hz), 4.83(2H, s), 6.93(1H, brs), 7.08(2H, d, J=8.6Hz), 7.13(2H, d, J=8.6Hz), 7.29(5H, brs), 7.40-7.83(8H,m).
1-63		0.84(12H, d, J=6.6Hz), 1.80-1.97(2H, m), 3.50(2H, s), 3.92(4H, d, J=6.6Hz), 4.84(2H, s), 6.93(1H, brs), 7.08(2H, d, J=5.5Hz), 7.13(2H, d, J=5.5Hz), 7.29(5H, brs), 7.40-7.84(8H, m).
1-64		1.22(6H, t, J=7.1Hz), 3.57(2H, s), 4.21(4H, q, J=7.1Hz), 4.84(2H, s), 7.21(2H, d, J=8.5Hz), 7.23-7.60(8H, m), 7.57(2H, d, J=8.5Hz), 8.09(1H, dd, J=7.8, 1.8Hz), 8.26(1H, brs)
1-65		0.84(3H, t, J=7.3Hz), 1.23(6H, t, J=7.1Hz), 1.23-1.46(2H, m), 1.50-1.69(2H, m), 3.55(2H, s), 4.23(4H, q, J=7.1Hz), 4.25(2H, q, J=6.7Hz), 4.84(2H, s), 7.19(2H, d, J=8.4Hz), 7.21-7.37(5H, m), 7.44-7.64(3H, m), 7.56(2H, d, J=8.4Hz), 7.64(1H, brs), 7.95(1H, d, J=7.6Hz)

Table 14

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-66		0.84(12H, d, J=6.8Hz), 1.63-1.79(2H, m), 2.97-3.15(4H, m), 3.52(2H, s), 4.86(2H, s), 6.94(1H, br-s), 7.01-7.08(2H, m), 7.10-7.25(6H, m), 7.27-7.36(3H, m), 7.40-7.47(1H, m), 7.48-7.63(4H, m), 7.64-7.72(2H, m), 7.80(1H, dd, J=1.5, 8.0Hz)
1-67		0.87(12H, d, J=6.8Hz), 1.27-1.38(4H, m), 1.46-1.61(2H, m), 3.18-3.28(4H, m), 3.52(2H, s), 4.84(2H, s), 6.94(1H, br-s), 7.01-7.22(8H, m), 7.27-7.35(3H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.65-7.72(2H, m), 7.80(1H, dd, J=1.5, 7.5Hz)
1-68		1.07(3H, t, J=7.2Hz), 1.22(6H, t, J=7.1Hz), 3.40(2H, s), 3.72(2H, q, J=7.2Hz), 4.20(4H, q, J=7.1Hz), 4.83(2H, s), 6.14(2H, d, J=8.3Hz), 6.74(2H, d, J=8.3Hz), 7.07(1H, dd, J=9.1, 1.5Hz), 7.23-7.61(12H, m)
1-69		1.09(6H, t, J=7.1Hz), 1.26-1.50(6H, m), 1.81(4H, m), 2.99(1H, m), 3.26(4H, dq, J=7.1, 7.1Hz), 3.59(2H, s), 4.85(2H, s), 7.10-7.42(14H, m), 7.56(2H, d, J=8.3Hz)
1-70		1.05(6H, t, J=7.2Hz), 3.18-3.30(4H, m), 3.53(2H, s), 4.83(2H, s), 6.93(1H, br-s), 7.02-7.23(8H, m), 7.27-7.36(3H, m), 7.37-7.45(5H, m), 7.45-7.59(2H, m), 7.80(1H, dd, J=1.1, 7.5Hz)

Table 15

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-71		1.05(6H, t, J=7.2Hz), 3.18-3.30(4H, m), 3.54(2H, s), 4.84(2H, s), 7.02-7.14(5H, m), 7.17-7.35(8H, m), 7.37-7.62(5H, m), 7.74(1H, dd, J=1.5, 7.5Hz)
1-72	 m.p. 126.4-127.8	0.85(6H, t, J=7.5Hz), 1.44(4H, tq, J=7.5, 7.5Hz), 1.68(3H, s), 3.12-3.22(4H, m), 3.49(2H, s), 4.85(2H, s), 6.77(1H, br-s), 6.87-6.92(1H, m), 6.94-7.01(1H, m), 7.11-7.25(4H, m), 7.27-7.36(3H, m), 7.40-7.47(1H, m), 7.50-7.73(6H, m), 7.75-7.85(2H, m)
1-73		3.29(6H, s), 3.36-3.48(8H, m), 3.53(2H, s), 4.85(2H, s), 6.97(1H, br-s), 7.04-7.18(4H, m), 7.19-7.40(8H, m), 7.41-7.47(1H, m), 7.49-7.64(4H, m), 7.66-7.73(2H, m), 7.77-7.84(1H, m)
1-74		1.22(6H, t, J=7.1Hz), 2.78(3H, s), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.11(2H, d, J=8.5Hz), 7.19(2H, d, J=8.5Hz), 7.20-7.35(6H, m), 7.77(2H, d, J=8.3Hz), 7.86(2H, d, J=8.3Hz)
1-75		1.06(6H, t, J=7.3Hz), 2.78(3H, s), 3.20-3.29(4H, m), 3.55(2H, s), 4.84(2H, s), 6.98-7.34(12H, m), 7.77(2H, d, J=8.3Hz), 7.86(2H, d, J=8.3Hz)

Table 16

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-76		1.06(6H, t, J=7.3Hz), 3.19-3.28(4H, m), 3.54(2H, s), 4.83(2H, s), 6.99-7.48(13H, m), 7.71(2H, d, J=8.2Hz), 7.86(2H, d, J=8.2Hz), 8.05-8.13(1H, m), 8.75-8.84(1H, m)
1-77		1.06(6H, t, J=7.2Hz), 1.64(3H, s), 3.12-3.33(4H, m), 3.51(2H, s), 4.84(2H, s), 6.84(1H, brs), 6.91(1H, brs), 6.98-7.98(12H, m), 8.16(1H, d, J=8.1Hz), 8.84(1H, d, J=4.4Hz).
1-78		0.92(3H, t, J=7.5Hz), 1.20(6H, t, J=7.1Hz), 1.94(2H, q, J=7.5Hz), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.79-7.83(17H, m)
1-79		0.96(6H, d, J=6.6Hz), 1.05(6H, t, J=7.1Hz), 2.15(1H, sep, J=6.6Hz), 3.19-3.29(4H, m), 3.54(2H, s), 4.83(2H, s), 6.81-7.84(19H, m)
1-80	 m.p. 91.5-94.8	0.96(6H, d, J=6.8Hz), 1.20(6H, t, J=7.1Hz), 2.16(1H, sep, J=6.8Hz), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.79-7.82(17H, m)

Table 17

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
1-81	 m.p. 147-158	0.95(3H, t, J=7.7Hz), 1.13(6H, t, J=7.2Hz), 1.99(2H, q, J=7.7Hz), 2.54(2H, t, J=7.9Hz), 3.20-3.38(4H, m), 3.53(2H, s), 4.11(2H, t, J=7.9Hz), 6.79-7.84(19H, m)
1-82		0.72(6H, d, J=6.6Hz), 1.06(6H, t, J=7.2Hz), 1.26- 1.44(1H, m), 1.89(2H, d, J=7.3Hz), 3.20-3.27(4H, m), 3.52(2H, s), 4.83(2H, s), 6.82-7.88(19H, m)
1-83	 m.p. 80-86	0.71(6H, d, J=6.5Hz), 1.21(6H, t, J=7.1Hz), 1.26-1.43(1H, m), 1.88(2H, d, J=7.3Hz), 3.49(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 6.79-7.87(17H, m)
1-84		1.21(6H, t, J=7.2Hz), 3.48(2H, s), 4.22(4H, q, J=7.2Hz), 4.83(2H, s), 7.08(1H, d, J=8.7Hz), 7.12(1H, s), 7.25-7.67(13H, m), 7.84(1H, dd, J=1.5, 7.5Hz), 8.37(1H, d, J=8.7Hz)
1-85		1.21(6H, t, J=7.1Hz), 3.48(2H, s), 4.22(4H, q, J=7.1Hz), 4.83(2H, s), 7.13(1H, d, J=7.9Hz), 7.28-7.67(14H, m), 7.82(1H, dd, J=1.5, 7.5Hz), 8.35(1H, d, J=8.7Hz)

Example 2

{3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester

a) 5-Chloro-N,N-dimethyl-2-nitrobenzamide



The acid chloride obtained from 5-chloro-2-nitrobenzoic acid (5.0 g) in a similar manner to Example 1 d) was subjected to reactions similar to those in Example 1 e) to give the title compound (5.5 g).

b) 2-(3-Dimethylcarbamoyl-4-nitrophenyl)malonic acid tert-butyl ester methyl ester



Sodium hydride (350 mg) was dissolved in dimethylformamide (10 mL), and the solution was cooled to 0°C. After addition of tert-butyl methyl malonate (1.52 g), the mixture was stirred for one hour, and the 5-chloro-N,N-dimethyl-2-nitrobenzamide (1.0 g) obtained in Example 2 a) was added thereto. The mixture was stirred at 70°C for 4 .5 hours and water was added thereto. The resulting solution was concentrated, diluted with ethyl acetate and washed with water. The organic layer was dried over sodium sulfate and purified by column chromatography on silica gel with ethyl

acetate:hexane=1:1 to give the title compound (1.29 g).

c) (3-Dimethylcarbamoyl-4-nitrophenyl)acetic acid methyl ester



The 2-(3-dimethylcarbamoyl-4-nitrophenyl)malonic acid tert-butyl ester methyl ester (1.22 g) obtained in Example 2 b) was dissolved in dichloromethane (10 mL), and the solution was cooled to 0°C. After addition of trifluoroacetic acid (10 mL), the mixture was stirred at room temperature for 6 hours, and concentrated, followed by azeotropic distillation with toluene. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=3:1 to give the title compound (712 mg).

d) (4-Amino-3-dimethylcarbamoylphenyl)acetic acid methyl ester



The (3-dimethylcarbamoyl-4-nitrophenyl)acetic acid methyl ester (683 mg) obtained in Example 2 c) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (627 mg).

e) {3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid



The (4-amino-3-dimethylcarbamoylphenyl)acetic acid methyl ester (627 mg) obtained in Example 2 d) was subjected to reactions similar to those in Example 1 e) and Example 1 f) to give the title compound (1.07 g)(see Table 65).

f) {3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



The {3-Dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]phenyl}acetic acid (517 mg) obtained in Example 2 e) was subjected to reactions similar to those in Example 1 g) to give the title compound (387 mg)(see Table 18).

Examples 2-2 to 2-119

Compounds of Examples 2-2 to 2-119 were obtained in a similar manner to Example 2. The compounds thus obtained were shown in Tables 18 to 41. In addition, compound of Example 2-17 e) was obtained in a similar manner to Example 2 e) and the compounds thus obtained were shown in Table 65.

Table 18

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2		1.07(6H, t, J=7.2Hz), 2.85(3H, br.s), 2.95(3H, br.s), 3.26(4H, dq, J=7.2, 7.2Hz), 3.54(2H, s), 4.84(2H, s), 7.04-7.68(17H, m), 8.37(1H, d, J=8.3Hz), 9.16(1H, br.s)
2-2		0.86(6H, t, J=7.2Hz), 1.46(4H, tq, J=7.2, 7.2Hz), 2.85(3H, br.s), 2.95(3H, br.s), 3.19(4H, dt, J=7.2, 7.2Hz), 3.54(2H, s), 4.85(2H, s), 7.03-7.68(17H, m), 8.37(1H, d, J=8.7Hz), 9.17(1H, br.s)
2-3		1.07(6H, t, J=7.1Hz), 2.83(3H, d, J=4.5 Hz), 3.24(4H, dq, J=7.1, 7.1Hz), 3.59(2H, s), 4.80(2H, s), 7.10-7.76(18H, m), 8.53(1H, d, J=8.3Hz), 11.55(1H, br.s)
2-4  m.p. 128-129		1.12(6H, t, J=7.3Hz), 2.53(2H, t, J=7.7Hz), 2.86(3H, brs), 2.95(3H, brs), 3.20-3.40(4H, m), 3.54(2H, s), 4.12(2H, t, J=7.7Hz), 7.09(1H, brs), 7.17-7.75(14H, m), 8.36(1H, d, J=8.4Hz), 9.24(1H, brs).
2-5  m.p. 114-116		1.21(6H, t, J=7.1Hz), 2.81(3H, brs), 2.92(3H,brs), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.99(1H, brs), 7.17-7.71(14H, m), 8.33(1H, d, J=8.5Hz), 9.14(1H, brs).

Table 19

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-6		0.98(6H, t, J=7.3Hz), 3.12(4H, dq, J=7.3, 7.3Hz), 3.58(2H, s), 4.50(2H, d, J=5.9Hz), 4.79(2H, s), 7.01-7.59(16H, m), 7.72(1H, dd, J=7.0, 1.8Hz), 8.23(1H, m), 8.51(1H, d, J=8.5Hz), 11.49(1H, br.s)
2-7		1.07(6H, t, J=7.3Hz), 1.66(2H, m), 2.28(2H, m), 2.87(3H, br.s), 2.93(3H, br.s), 3.24(4H, dq, J=7.3, 7.3Hz), 3.57(2H, s), 4.11(2H, t, J=6.9Hz), 7.13-7.66(17H, m), 8.36(1H, d, J=8.4Hz), 9.08(1H, br.s)
2-8		1.08(6H, t, J=7.2Hz), 0.98-1.21(6H, brd), 3.26(4H, dq, J=7.2, 7.2Hz), 3.12-3.51(4H, brd), 3.56(2H, s), 4.84(2H, s), 7.06-7.63(17H, m), 8.21(1H, d, J=8.7Hz), 8.88(1H, s)
2-9	 m.p. 108-117	1.07(6H, t, J=7.1Hz), 0.93-1.59(6H, brd), 3.26(4H, dq, J=7.2, 7.2Hz), 3.56(2H, s), 3.41-3.95(2H, brd), 4.84(2H, s),7.01-7.62(17H, m), 8.08(1H, d, J=8.3Hz), 8.70(1H, br.s)
2-10		1.21(6H, t, J=7.1Hz), 0.95-1.27(6H, brd), 3.08-3.49(4H, brd), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s),7.06(1H, d, J=1.9Hz), 7.19(1H, dd, J=8.7, 1.9Hz), 7.31-7.63(13H, m), 8.19(1H, d, J=8.7Hz), 8.90(1H, br.s)

Table 20

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-11		1.21(6H, t, J=7.1Hz), 1.00-1.52(12H, brd), 3.52(2H, s), 3.49-3.92(2H, brd), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 7.02(1H, d, J=1.9Hz), 7.17(1H, dd, J=8.4, 1.9Hz), 7.31-7.64(13H, m), 8.06(1H, d, J=8.4Hz), 8.72(1H, br.s)
2-12		1.01-1.21(6H, m), 1.07(6H, t, J=7.3Hz), 2.78(3H, brs), 3.20-3.31(4H, m), 3.56(2H, s), 3.82-4.27(1H, m), 4.84(2H, s), 6.99-7.63(17H, m), 8.19(1H, d, J=8.4Hz), 8.98(1H, br.s)
2-13	 m.p.116.5-119.0	0.98-1.27(3H, br), 1.21(6H, t, J=7.1Hz), 2.73-2.96(3H, br), 3.05-3.49(2H, br), 3.51(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.00-7.08(1H, m), 7.19(1H, dd, J=1.9, 8.3Hz), 7.24-7.36(5H, m), 7.39(1H, dd, J=1.5, 7.9Hz), 7.43-7.70(7H, m), 8.28(1H, d, J=8.6Hz), 8.92-9.18(1H, br)
2-14		1.00-1.23(3H, br),1.08(6H, t, J=7.2Hz), 2.79-2.96(3H, br), 3.10-3.49(2H, br), 3.26(4H, dq, J=5.2, 7.2Hz), 3.55(2H, s), 4.84(2H, s), 7.04(1H, d, J=1.8Hz), 7.07-7.14(2H, m), 7.15-7.24(3H, m), 7.28-7.37(3H, m), 7.37-7.43(1H, m), 7.44-7.69(7H, m), 8.30(1H, d, J=8.3Hz), 8.88-9.17(1H, br)
2-15		1.02-1.24(3H, br), 1.12(6H, t, J=7.2Hz), 2.47-2.59(2H, m), 2.80-2.96(3H, br), 3.10-3.51(2H, br), 3.30(4H, dq, J=5.7, 7.2Hz), 3.55(2H, s), 4.07-4.18(2H, m), 7.09(1H, d, J=1.5Hz), 7.22-7.43(7H, m), 7.43-7.70(9H, m), 8.28(1H, d, J=8.3Hz), 8.85-9.14(1H, br)

Table 21

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-16		1.07(6H, t, J=7.2Hz), 1.32-1.71(5H, br), 3.10-3.79(8H, m), 3.54(2H, s), 4.84(2H, s), 7.03-7.79(15H, m), 8.28(1H, d, J=8.5Hz), 9.04(1H, brs).
2-17		1.07(6H, t, J=7.2Hz), 2.02-2.78(4H, br), 3.21-3.53(8H, m), 3.54(2H, m), 4.84(2H, s), 7.03-7.72(15H, m), 8.34(1H, d, J=7.2Hz), 9.83(1H, brs).
2-18	 m.p. 106.8-109.4	0.65-1.01(3H, br), 1.21(6H, t, J=7.2Hz), 1.43-1.66(2H, br), 2.75-2.98(3H, br), 3.05-3.41(2H, br), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 7.04(1H, br-s), 7.19(1H, dd, J=1.9, 8.6Hz), 7.24-7.35(5H, m), 7.39(1H, dd, J=1.5, 7.5Hz), 7.43-7.69(7H, m), 8.18-8.31(1H, br), 8.94-9.18(1H, br)
2-19		0.68-0.99(3H, br), 1.08(6H, t, J=7.1Hz), 1.42-1.69(2H, br), 2.79-2.98(3H, br), 3.06-3.42(2H, br), 3.26(4H, dq, J=5.6, 7.1Hz), 3.55(2H, s), 4.84(2H, s), 7.04(1H, d, J=1.8Hz), 7.11(2H, br-t, J=5.6Hz), 7.15-7.24(3H, m), 7.27-7.36(3H, m), 7.37-7.43(1H, m), 7.44-7.69(7H, m), 8.21-8.35(1H, br), 8.92-9.18(1H, br)
2-20		0.67-1.00(3H, br), 1.13(6H, t, J=7.1Hz), 1.43-1.67(2H, br), 2.48-2.59(2H, m), 2.82-2.98(3H, br), 3.06-3.42(2H, br), 3.30(4H, dq, J=5.6, 7.1Hz), 3.54(2H, s), 4.07-4.17(2H, m), 7.09(1H, d, J=2.2Hz), 7.22-7.42(7H, m), 7.43-7.69(9H, m), 8.20-8.34(1H, br), 8.89-9.14(1H, br)

Table 22

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-21		1.04(3H, t, J=7.2Hz), 2.84(3H, brs), 2.95(3H, brs), 3.16-3.29(2H, m), 3.50(2H, s), 3.64(1H, dd, J=7.7, 6.5Hz), 3.91(1H, dd, J=10.9, 6.5Hz), 4.64(1H, dd, J=10.9, 7.7Hz), 5.28-5.38(1H, m), 7.00-7.71(15H, m), 8.34(1H, d, J=8.5Hz), 9.15(1H, brs)
2-22	 m.p. 130-131	1.21(6H, t, J=7.1Hz), 1.73-2.00(4H, m), 3.22-3.53(4H, m), 3.51(2H, s), 4.20(4H, q, J=7.1Hz), 4.83(2H, s), 7.15-7.70(15H, m), 8.33(1H, d, J=8.9Hz), 9.84(1H, brs).
2-23	 m.p. 118-120	1.21(6H, t, J=7.1Hz), 1.35-1.70(6H, br), 3.00-3.76(4H, br), 3.51(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 7.03(1H, d, J=2.0Hz), 7.12-7.68(14H, m), 8.26(1H, d, J=8.5Hz), 9.06(1H, brs).
2-24		1.11(3H, t, J=7.6Hz), 2.19(2H, q, J=7.6Hz), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.28(1H, dd, J=11.3, 4.9Hz), 4.41(1H, dd, J=11.3, 7.0Hz), 5.25-5.33(1H, m), 5.87(1H, d, J=8.3Hz), 7.04-7.71(15H, m), 8.36(1H, d, J=8.5Hz), 9.14(1H, brs)
2-25	 m.p. 95-98	1.11(3H, t, J=7.5Hz), 2.19(2H, q, J=7.5Hz), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(1H, dd, J=11.3, 4.9Hz), 4.41(1H, dd, J=11.3, 7.0Hz), 5.26-5.33(1H, m), 5.86(1H, d, J=7.9Hz), 7.04-7.71(15H, m), 8.36(1H, d, J=8.7Hz), 9.14(1H, brs)

Table 23

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-26	 m.p. 152-155	2.53(4H, s), 2.89(3H, brs), 2.96(3H, brs), 3.55(2H, s), 4.66(1H, dd, J=10.9, 5.3Hz), 5.10(1H, t, J=10.9Hz), 5.37(1H, dd, J=10.9,5.3Hz), 7.07-7.69(15H, m), 8.35(1H, d, J=8.7Hz), 9.17(1H, brs)
2-27		1.19(3H, t, J=7.2Hz), 2.70-3.01(6H, br), 3.41(2H, dq, J=5.6, 7.2Hz), 3.60(2H, s), 5.32(2H, s), 6.18(1H, br-t, J=5.6Hz), 7.04(1H, d, J=1.9Hz), 7.21-7.29(1H, m), 7.30-7.56(7H, m), 7.56-7.66(4H, m), 7.69(1H, dd, J=1.5, 7.1Hz), 8.35(1H, d, J=8.7Hz), 9.09(1H, br-s)
2-28		1.04(3H, t, J=7.1Hz), 2.70-3.00(6H, br), 3.22(2H, dq, J=5.7, 7.1Hz), 3.53(2H, s), 3.57(2H, s), 5.13(2H, s), 5.43-5.54(1H, br), 7.08(1H, d, J=1.9Hz), 7.21-7.43(6H, m), 7.44-7.66(6H, m), 7.69(1H, dd, J=1.5, 7.2Hz), 8.34(1H, d, J=8.6Hz), 9.10(1H, br-s)
2-29		1.26-1.68(6H, m), 2.61-3.00(6H, m), 2.93-3.12(1H, m), 3.58-4.01(1H, m), 4.28-5.03(3H, m), 7.09-8.32(17H, m), 9.14(1H, brs), 9.40-10.24(2H, m)
2-30		1.10(6H, t, J=7.3Hz), 3.06(6H, brs), 3.21-3.42(4H, m), 3.61(2H, s), 4.86(2H, s), 7.06-7.77(13H, m), 8.37(1H, d, J=8.5Hz), 9.21(1H, brs)

Table 24

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-31	 m.p 106-110	1.23(6H, t, J=7.1Hz), 2.98(3H, brs) 3.05(3H, brs), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 7.11-7.75(11H, m), 8.35(1H, d, J=8.5Hz), 9.21(1H, brs)
2-32		1.24(6H, t, J=7.2Hz), 2.61(2H, t, J=7.1Hz), 2.86(3H, br.s), 2.94(3H, br.s), 3.46(2H, s), 4.07(2H, t, J=7.1Hz), 4.23(4H, q, J=7.2Hz), 7.08(1H, d, J=1.9Hz), 7.23-7.68(14H, m), 8.36(1H, d, J=8.6Hz), 9.15(1H, br.s)
2-33	 m.p. 125-128	1.22(6H, t, J=7.2Hz), 2.83(3H, br.s), 2.94(3H, br.s), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.00-7.51(14H, m), 7.68(1H, dd, J=7.6, 1.5Hz), 8.37(1H, d, J=8.3Hz), 8.93(1H, br.s)
2-34	 m.p. 124-128	1.22(6H, t, J=7.2Hz), 2.86(3H, br.s), 2.95(3H, br.s), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.01(1H, d, J=2.2Hz), 7.19-7.53(13H, m), 7.68(1H, dd, J=7.6, 1.5Hz), 8.40(1H, d, J=8.3Hz), 9.01(1H, br.s)
2-35		1.96(3H, s), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(1H, dd, J=11.6, 5.0Hz), 4.39(1H, dd, J=11.6, 7.1Hz), 5.23-5.33(1H, m), 5.90(1H, d, J=8.1Hz), 6.99-7.71(15H, m), 8.36(1H, d, J=8.5Hz), 9.14(1H, brs)

Table 25

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-36		0.92(3H, t, J=7.4Hz), 1.56-1.68(2H,m), 2.14(2H, t, J=7.5Hz), 2.84(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.29(1H, dd, J=11.4, 4.9Hz), 4.40(1H, dd, J=11.4, 7.1Hz), 5.23-5.33(1H, m), 5.90(1H, d, J=8.1Hz), 7.05(1H, d, J=2.0Hz), 7.15-7.72(14H, m), 8.36(1H, d, J=8.5Hz), 9.15(1H, brs)
2-37		1.07(3H, t, J=7.3Hz), 1.08(3H, t, J=7.3Hz), 2.97(3H, s), 3.10(3H, s), 3.18-3.31(4H, m), 3.59(2H, s), 4.87(2H, d, J=4.1Hz), 6.38(1H, d, J=8.2Hz), 6.92-7.64(18H, m), 7.83(1H, d, J=6.8Hz)
2-38		1.21(6H, t, J=7.1Hz), 2.96(3H, s), 3.07(3H, s), 3.55(2H, d, J=2.1Hz), 4.19(2H, q, J=7.1Hz), 4.20(2H, q, J=7.1Hz), 4.82and4.89(2H, each d, J=11.2Hz), 6.36(1H, d, J=8.2Hz), 6.93-7.59(16H, m), 7.83(1H, d, J=6.8Hz)
2-39	 m.p. 108.8-112.4	2.73-3.00(6H, br), 3.52(2H, s), 3.72(6H, s), 4.82(2H, s), 7.03(1H, d, J=1.9Hz), 7.16-7.36(6H, m), 7.40(1H, dd, J=1.5, 7.5Hz), 7.45-7.65(6H, m), 7.69(1H, dd, J=1.5, 7.2Hz), 8.35(1H, d, J=8.7Hz), 9.17(1H, br-s)
2-40	 m.p. 110-111	1.21(6H, t, J=7.1Hz), 1.31-1.60(6H, m), 1.67-1.82(2H, m), 2.40-2.57(1H, ,m), 2.88(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.14(4H, q, J=7.1Hz), 4.48(2H, s), 7.09(1H, d, J=1.8Hz), 7.21-7.72(9H, m), 8.37(1H, d, J=8.4Hz), 9.16(1H, brs).

Table 26

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-41	 m.p. 108-110	0.95-1.19(6H, m), 1.21(6H, t, J=9.5Hz), 1.60-1.80(4H, m), 2.00-2.18(1H, m), 2.88(3H, brs), 2.95(3H, brs), 3.52(2H, s), 4.14(4H, q, J=9.5Hz), 4.50(2H, s), 7.09(1H, d, J=2.7Hz), 7.19-7.73(9H, m), 8.38(1H, d, J=11.3Hz), 9.18(1H, brs).
2-42	 m.p. 121-124	1.22(6H, t, J=7.2Hz), 2.84(3H, br.s), 2.94(3H, br.s), 3.51(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.01(1H, d, J=1.9Hz), 7.20(1H, dd, J=8.7, 1.9Hz), 7.26-7.51(12H, m), 7.68(1H, dd, J=7.5, 1.5Hz), 8.40(1H, d, J=8.7Hz), 9.00(1H, br.s)
2-43		1.21(6H, t, J=7.2Hz), 2.57(3H, s), 2.75(3H, br.s), 2.94(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s), 7.00(1H, d, J=1.9Hz), 7.18(1H, dd, J=8.6, 1.9Hz), 7.26-7.59(11H, m), 7.70(1H, dd, J=7.6, 1.5Hz), 7.95(1H, d, J=8.3Hz), 8.35(1H, d, J=8.6Hz), 9.13(1H, br.s)
2-44		1.07(6H, t, J=7.3Hz), 2.76(3H, s), 2.86(3H, s), 3.21-3.30(4H, m), 3.57(2H, s), 4.83(2H, s), 6.82(1H, d, J=8.3Hz), 6.98-7.45(16H, m), 8.24(1H, dd, J=7.8, 1.8Hz), 8.44(1H, d, J=8.5Hz), 10.4(1H, brs)
2-45		1.22(6H, t, J=7.1Hz), 2.75(3H, s), 2.82(3H, s), 3.54(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 6.82(1H, d, J=7.6Hz), 7.05(1H, d, J=2.0Hz), 7.09-7.46(13H, m), 8.24(1H, dd, J=7.8, 1.8Hz), 8.42(1H, d, J=8.5Hz), 10.4(1H, brs)

Table 27

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-46		1.22(6H, t, J=7.2Hz), 2.90(3H, br.s), 2.97(3H, br.s), 3.52(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.05(1H, d, J=1.9Hz), 7.20(1H, dd, J=8.7, 1.9Hz), 7.29-7.73(13H, m), 8.33(1H, d, J=8.7Hz), 9.27(1H, br.s)
2-47		1.21(6H, t, J=7.2Hz), 2.44(3H, s), 2.77(3H, br.s), 2.91(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s), 7.01(1H, d, J=2.2Hz), 7.19(1H, dd, J=8.7, 2.2Hz), 7.30-7.59(12H, m), 8.35(1H, d, J=8.7Hz), 9.08(1H, br.s)
2-48	 m.p. 105-108	1.21(6H, t, J=7.1Hz), 2.44(3H, s), 2.80(3H, br.s), 2.94(3H, br.s), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 7.02(1H, d, J=2.2Hz), 7.16-7.30(8H, m), 7.56-7.63(5H, m), 8.35(1H, d, J=8.7Hz), 9.14(1H, br.s)
2-49		2.65(3H, s), 2.86(3H, brs), 2.95(3H, brs), 3.61(2H, s), 4.23-4.30(2H, m), 4.71-4.79(1H, m), 4.98((1H, d, J=7.1Hz), 7.09(1H, d, J=1.9Hz), 7.18-7.71(14H, m), 8.37(1H, d, J=8.7Hz), 9.16(1H, brs)
2-50		1.19(3H, t, J=7.1Hz), 2.86(3H, brs), 2.95(3H, brs), 3.52(2H, s), 3.89(1H, dd, J=9.1, 6.0Hz), 4.02-4.19(2H, m), 4.34(1H, dd, J=10.9, 6.0Hz), 4.58(1H, dd, J=10.9, 9.1Hz), 7.06(1H, d, J=2.3Hz), 7.18-7.71(14H, m), 8.36(1H, d, J=8.6Hz), 9.17(1H, brs)

Table 28

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-51		1.12-1.18(3H, m), 2.21-2.46(2H, m), 2.64-3.49(9H, m), 3.55-3.58(2H, m), 4.45-5.29(2H, m), 6.11-6.19(1H, m), 7.12-7.70(15H, m), 8.33-8.38(1H, m), 9.17(1H, brs) Conformer
2-52		1.24(6H, t, J=7.0Hz), 1.50-1.64(2H, m), 2.25-2.36(2H, m), 2.77-3.02(6H, br), 3.54(2H, s), 3.99-4.08(2H, m), 4.16-4.29(4H, m), 7.10(1H, d, J=1.9Hz), 7.24-7.43(7H, m), 7.44-7.57(2H, m), 7.59-7.64(4H, m), 7.68(1H, dd, J=1.5, 7.2Hz), 8.36(1H, d, J=8.7Hz), 9.16(1H, s)
2-53		1.21(6H, t, J=7.0Hz), 2.82(3H, br.s), 2.95(3H, br.s), 3.50(2H, s), 3.88(3H, s), 4.21(4H, q, J=7.0Hz), 4.82(2H, s), 6.87(1H, d, J=2.6Hz), 6.99(1H, dd,J=8.5, 2.6Hz), 7.03(1H, d, J=1.8Hz), 7.18(1H, dd, J=8.5, 1.8Hz), 7.29-7.69(10H, m), 8.35(1H, d, J=8.8Hz), 9.17(1H, br.s)
2-54		1.21(6H, t, J=7.0Hz), 2.81(3H, br.s), 2.94(3H, br.s), 3.51(2H, s), 4.20(4H, q, J=7.0Hz), 4.83(2H, s), 7.04(1H, d, J=2.2Hz), 7.19(1H, dd,J=8.4, 2.2Hz), 7.30-7.66(12H, m), 8.33(1H, d, J=8.5Hz), 9.29(1H, br.s)
2-55	 mp 102-105	1.20(6H, t, J=7.1Hz), 2.11(3H, s), 2.88(3H, brs), 3.04(3H, brs), 3.48(2H,s), 4.19(4H, q, J=7.1Hz), 4.81(2H, s), 7.04(1H, d, J=2.0Hz), 7.12(1H, dd, J=2.0Hz, J=8.5Hz), 7.24-7.50(10H, m), 7.60(2H, d, J=8.1Hz), 8.10(1H, d, J=8.5Hz), 9.06(1H, brs).

Table 29

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-56		2.81(3H, brs), 2.93(3H, brs), 3.52(2H,s), 4.45-4.60(4H, m), 4.88(2H, s), 7.02(1H, d, J=2.0Hz), 7.19(1H, dd, J=2.0Hz, J=8.7Hz), 7.23-7.64(12H, m), 7.68(1H, dd, J=2.0Hz, J=8.1Hz), 8.34(1H, d, J=8.1Hz), 9.10(1H, brs).
2-57	 mp 116.5-119.5	1.21(6H, t, J=7.1Hz), 2.95(3H, brs), 3.01(3H, brs), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 7.10(1H, s), 7.14-7.63(12H, m), 7.75((1H, d, J=6.6Hz), 8.22(1H, d, J=8.7Hz), 9.34(1H, brs).
2-58	 mp 119-121	1.23(6H, t, J=7.1Hz), 2.85(6H, br-s), 3.55(2H, s), 4.22(4H, q, J=7.1Hz), 4.83(2H, s), 7.03((1H, d, J=7.6Hz), 7.24-7.74(13H, m), 8.36(1H, d, J=12.2Hz), 9.45(1H, br-s).
2-59		1.22(6H, t, J=7.1Hz), 2.87(3H, s), 2.96(3H, s), 3.51(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 7.06(1H, brs), 7.25-7.68(14H, m), 7.77(1H, d, J=7.1Hz).
2-60		1.22(6H, t, J=7.1Hz), 2.86(3H, brs), 2.95(3H, s), 3.50(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 7.00(1H, d, J=1.5Hz), 7.20-7.66(13H, m), 7.73(1H, dd, J=1.5Hz, J=7.1Hz), 7.97(1H, brs).

Table 30

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-61	 mp 131-133	1.21(6H, t, J=7.2Hz), 2.88(3H, brs), 2.97(3H, brs), 3.52(2H, s), 4.20(4H, q, J=7.2Hz), 4.83(2H, s), 7.07(1H, d, J=2.2Hz), 7.18-7.72(13H, m), 8.33(1H, d, J=8.4Hz), 9.33(1H, brs).
2-62	 mp 120-125	1.21(6H, t, J=7.1Hz), 2.87(3H, brs), 2.96(3H, brs), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 7.07(1H, d, J=1.8Hz), 7.17-7.72(13H, m), 8.32(1H, d, J=8.4Hz), 9.32(1H, br-s).
2-63		1.22(6H, t, J=7.2Hz), 2.83(3H, brs), 2.94(3H, brs), 3.48(2H, s), 4.23(4H, q, J=7.21Hz), 4.94(2H, s), 6.98(1H, d, J=1.9Hz), 7.12-7.76(10H, m), 8.30(1H, d, J=8.3Hz), 8.38(1H, dd, J=2.6Hz, J=8.9Hz), 9.08(1H, brs), 9.22(1H, d, J=2.6Hz).
2-64		1.21(6H, t, J=7.2Hz), 2.83(3H, brs), 2.94(3H, brs), 3.48(2H, s), 3.49(1H, brs), 3.71(1H, brs), 4.20(4H, q, J=7.2Hz), 4.88(2H, s), 6.83(1H, dd, J=3.0Hz, J=8.3Hz), 7.03(1H, d, J=1.9Hz), 7.11-7.72(10H, m), 7.83(1H, d, J=3.1Hz), 8.25(1H, d, J=8.6Hz), 9.14(1H, brs).
2-65	 mp 149-155	1.21(6H, t, J=7.2Hz), 2.83(3H, brs), 2.93(3H, brs), 3.49(2H, s), 4.21(4H, q, J=7.2Hz), 4.93(2H, s), 7.03(1H, d, J=1.9Hz), 7.13-7.73(12H, m), 8.33(1H, d, J=8.6Hz), 8.47(1H, d, J=3.8Hz), 9.17(1H, brs).

Table 31

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-66		1.23(6H, t, J=7.2Hz), 2.88(3H, s), 2.97(3H, s), 3.61(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.03(1H, d, J=7.1Hz), 7.23-7.68(12H, m), 7.74(1H, dd, J=1.1Hz, J=7.5Hz). 7.84(1H, brs).
2-67		1,23(6H, t, J=7.2Hz), 2.88(3H, s), 2.96(3H, s), 3.62(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.09(1H, d, J=7.5Hz), 7.24-7.68(12H, m), 7.74-7.80(2H, m).
2-68		1.22(6H, t, J=7.2Hz), 2.26(3H, s), 2.84(3H, brs), 2.95(3H, brs), 3.48(2H, s), 4.10-4.61(4H, m), 4.88(2H, s), 6.99-7.73(14H, m), 8.43(1H, d, J=8.3Hz), 9.18(1H, brs).
2-69		1.21(6H, t, J=7.2Hz), 2.32(3H, s), 2.81(3H, brs), 2.93(3H, brs), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.01-7.74(14H, m), 8.36(1H, d, J=8.3Hz), 9.19(1H, br-s).
2-70		1.21(6H, t, J=7.2Hz), 2.33(3H, s), 2.82(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.01-7.74(14H, m), 8.35(1H, d, J=8.3Hz), 9.19(1H, brs).

Table 32

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-71		1.24(6H, t, J=7.2Hz), 2.84(3H, br-s), 2.95(3H, brs), 3.44(2H, s), 4.12-4.35(4H, ,m), 4.94(2H, s), 7.00(1H, d, J=2.2Hz), 7.05-7.73(13H, m), 8.31(1H, d, J=8.3Hz), 9.19(1H, brs).
2-72	 mp 122.2-125.0	1.22(6H, t, J=7.1Hz), 2.81(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.21(4H, q, J=7.1Hz), 4.80(2H, s), 7.03(1H, d, J=2.2Hz), 7.14-7.64(12H, m), 7.70(1H, dd, J=1.6Hz, J=7.2Hz), 8.36(1H, d, J=8.6Hz), 9.19(1H, brs).
2-73	 mp 132.0-134.4	1.21(6H, t, J=7.2Hz), 2.80(3H, brs), 2.94(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.80(2H, s), 7.02(1H, d, J=2.3Hz), 7.18-7.71(13H, m), 8.36(1H, d, J=8.3Hz), 9.18(1H, brs).
2-74		1.16(3H, t, J=7.0Hz), 1.18(3H, t,J=7.2Hz), 2.82(3H, brs), 2.93(3H,brs), 3.04(1H, d, J=16.5Hz), 3.20(H, d, J=16.5Hz), 3.46(2H, s), 4.04-4.20(4H, m), 4.75(1H,d,J=11.4Hz), 4.82(1H,d,J=11.4Hz), 6.98(1H, d, J=2.2Hz), 7.11-7.72(14H, m), 8.34(1H, d, J=8.8Hz), 9.17(1H, brs).
2-75	 mp 121.0-124.0	1.22(6H, t, J=7.1Hz), 2.84(3H, brs), 2.94(3H, brs), 3.44(2H, s), 3.74(3H, s), 4.22(4H, q, J=7.1Hz), 4.81(2H, s), 6.84-7.71(14H, m), 8.32(1H, d, J=8.7Hz), 9.18(1H, brs).

Table 33

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-76		1.21(6H, t, J=7.1Hz), 2.82(3H, brs), 2.94(3H, brs), 3.51(2H, s), 3.77(3H, s), 4.20(4H, q, J=7.1Hz), 4.81(2H, s), 6.83-6.91(3H, m), 7.04(1H, d, J=1.9Hz), 7.18-7.71(10H, m), 8.35(1H, d, J=8.3Hz), 9.19(1H, brs).
2-77		1.21(6H, t, J=7.1Hz), 2.80(3H, brs), 2.93(3H, brs), 3.51(2H, s), 3.79(3H, s), 4.20(4H, q, J=7.1Hz), 4.80(2H, s), 6.84(2H, dt, J=8.6Hz, J=3.4Hz), 7.03(1H, d, J=1.9Hz), 7.19-7.71(11H, m), 8.36(1H, d, J=8.7Hz), 9.18(1H, brs).
2-78	 m.p. 118-119	1.21(6H, t, J=7.2Hz), 2.82(3H, brs), 2.94(3H, brs), 3.52(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 7.05(1H, s), 7.19-7.30(6H, m), 7.61-7.84(7H, m), 8.34(1H, d, J=8.3Hz), 9.40(1H, brs)
2-79	 m.p. 135-138	1.20(6H, t, J=7.2Hz), 2.86(3H, brs), 3.06(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.2Hz), 4.82(2H, s), 7.06(1H, s), 7.15(1H, dd, J=2.1, 8.3Hz), 7.28-7.63(12H, m), 8.14(1H, d, J=8.3Hz), 9.25(1H, brs)
2-80	 m.p. 128-130	1.21(6H, t, J=7.0Hz), 2.83(3H, brs), 3.00(3H, brs), 3.51(2H, s), 4.21(4H, q, J=7.0Hz), 4.82(2H, s), 7.05(1H, d, J=2.2Hz), 7.19(1H, dd, J=2.2, 8.4Hz), 7.25-7.65(12H, m), 8.27(1H, d, J=8.4Hz), 9.28(1H, brs)

Table 34

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-81		1.24(6H, t, J=7.2Hz), 2.44(3H, s), 2.61(3H, t, J=7.1Hz), 2.86(3H, brs), 2.95(3H, brs), 3.46(2H, s), 4.07(2H, t, J=7.1Hz), 4.23(4H, q, J=7.2Hz), 4.82(2H, s), 7.07-7.63(14H, m), 8.37(1H, d, J=8.7Hz), 9.12(1H, brs)
2-82		1.21(6H, t, J=7.1Hz), 1.45(3H, t, J=7.2Hz), 2.81(3H, brs), 2.95(3H, brs), 3.50(2H, s), 4.11(2H, q, J=7.2Hz), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 6.86(1H, d, J=2.6Hz), 6.97(1H, dd, J=2.6, 8.7Hz), 7.03(1H, d, J=1.9Hz), 7.18(1H, dd, J=1.9, 8.7Hz), 7.28-7.30(5H, m), 7.56-7.67(5H, m), 8.36(1H, d, J=8.7Hz), 9.17(1H, brs)
2-83		1.21(6H, t, J=7.2Hz), 1.28(6H, d, J=6.0Hz), 2.81(3H, brs), 2.95(3H, brs), 4.21(4H, q, J=7.2Hz), 4.64(1H, sept, J=6.0Hz), 4.82(2H, s), 6.85(1H, d, J=2.2Hz), 6.96(1H, dd, J=2.6, 8.7Hz), 7.03(1H, d, J=2.2Hz), 7.18(1H, dd, J=8.7, 1.9Hz), 7.28-7.30(5H, m), 7.56-7.66(5H, m), 8.36(1H, d, J=8.3Hz), 9.16(1H, brs)
2-84		1.24(6H, t, J=7.2Hz), 2.61(2H, t, J=7.1Hz), 2.89(3H, brs), 2.94(3H, brs), 3.47(2H, s), 4.08(2H, t, J=7.1Hz), 4.24(4H, q, J=7.2Hz), 7.11-7.39(7H, m), 7.61-7.83(7H, m), 8.34(1H, d, J=8.7Hz), 9.36(1H, brs)
2-85	 m.p. 107-109	1.20(6H, t, J=7.2Hz), 2.81(3H, brs), 3.02(3H, brs), 3.49(2H, s), 3.78(3H, s), 4.20(4H, q, J=7.2Hz), 4.81(2H, s), 7.02(1H, d, J=1.9Hz), 7.07(1H, d, J=8.3Hz), 7.15(1H, dd, J=2.3, 8.7Hz), 7.24-7.30(6H, m), 7.41-7.60(5H, m), 8.22(1H, d, J=8.7Hz), 9.05(1H, brs)

Table 35

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-86	 m.p. 125-129	1.21(6H, t, J=7.2Hz), 2.48(3H, s), 2.69(3H, brs), 2.91(3H, brs), 3.50(2H, s), 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 6.99(1H, d, J=2.2Hz), 7.20(1H, dd, J=1.5, 8.3Hz), 7.28-7.41(8H, m), 7.57-7.64(4H, m), 8.18(1H, d, J=8.6Hz), 8.81(1H, brs)
2-87		1.23(6H, t, J=7.2Hz), 3.00(3H, brs), 3.03(3H, brs), 3.58(2H, s), 4.22(4H, q, J=7.2Hz), 4.85(2H, s), 7.18(1H, d, J=1.9Hz), 7.28-7.33(6H, m), 7.79(1H, d, J=7.9Hz), 7.92(1H, d, J=7.9Hz), 7.99(1H, s), 8.35(1H, d, J=8.3Hz), 9.46(1H, s)
2-88	 m.p. 129-131	1.21(6H, t, J=7.2Hz), 2.33(3H, s), 2.76(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.21(4H, q, J=7.2Hz), 4.82(2H, s), 6.99(1H, d, J=1.2Hz), 7.14-7.51(13H, m), 7.65(1H, d, J=7.6Hz), 8.34(1H, d, J=8.6Hz), 8.78(1H, brs)
2-89	 m.p. 81-82	1.24(6H, t, J=7.2Hz), 1.29(3H, t, J=7.6Hz), 2.92(2H, q, J=7.6Hz), 3.03(6H, brs), 3.57(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.18(1H, d, J=2.3Hz), 7.27-7.33(6H, m), 7.51-7.60(3H, m), 8.40(1H, d, J=8.2Hz), 9.51(1H, brs)
2-90	 m.p. 110-112	1.21(6H, t, J=7.1Hz), 1.22(3H, t, J=6.9Hz), 2.64(H, q, J=6.9Hz), 2.75(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 6.99(1H, d, J=1.8Hz), 7.17-7.66(14H, m), 8.30(1H, d, J=8.3Hz), 8.76(1H, brs)

Table 36

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-91		1.21(6H, t, J=7.1Hz), 2.13(3H, s), 2.71(3H, brs), 2.89(3H, brs), 3.49(2H, s), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 5.10(1H, s), 5.43(1H, s), 6.98(1H, d, J=2.2Hz), 7.19(1H, dd, J=1.9, 8.3Hz), 7.28-7.53(12H, m), 7.67(1H, d, J=7.6Hz), 8.39(1H, d, J=8.6Hz), 8.87(1H, brs)
2-92	 m.p. 107-110	1.21(6H, t, J=7.1Hz), 1.21(6H, t, J=7.1Hz), 2.76(3H, brs), 2.89(1H, sept, J=7.1Hz), 2.94(3H, brs), 3.50(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.01(1H, d, J=1.9Hz), 7.14-7.51(13H, m), 7.62(1H, d, J=6.4Hz), 8.21(1H, d, J=8.3Hz), 8.70(1H, brs)
2-93		1.23(6H, t, J=7.2Hz), 2.12(3H, s), 2.99(3H, brs), 3.04(3H, brs), 3.56(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 5.15(1H, s), 5.23(1H, s), 7.15(1H, d, J=1.8Hz), 7.25-7.31(6H, m), 7.55(1H, s), 7.61(1H, d, J=7.9Hz), 7.73(1H, d, J=7.9Hz), 8.36(1H, d, J=8.3Hz), 9.35(1H, m)
2-94		1.24(6H, t, J=7.2Hz), 1.29(6H, t, J=6.8Hz), 3.03(6H, brs), 3.44(1H, sept, J=6.8Hz), 3.57(2H, s), 4.23(4H, q, J=7.2Hz), 4.85(2H, s), 7.18(1H, d, J=1.9Hz), 7.26-7.33(6H, m), 7.52(2H, s), 7.63(1H, s), 8.41(1H, d, J=8.3Hz), 9.44(1H, brs)
2-95		1.23(6H, t, J=7.1Hz), 3.01(3H, brs), 3.10(3H, brs), 3.57(2H, s), 4.23(4H, q, J=7.1Hz), 4.85(2H, s), 6.91-6.96(1H, m), 7.20-7.41(12H, m), 7.46(1H, s), 7.66(1H, d, J=7.7Hz), 8.29(1H, d, J=8.3Hz), 9.78(1H, s), 10.17(1H, brs)

Table 37

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-96		1.21(6H, t, J=7.1Hz), 2.75(3H, brs), 3.02(3H, brs), 3.55(2H, s), 4.20(4H, q, J=7.1Hz), 4.84(2H, s),6.92(1H, d, J=8.3Hz), 7.15-7.68(14H, m), 8.07(1H, dd, J=1.3, 7.7Hz)
2-97		1.22(6H, t, J=7.1Hz), 2.83(3H, brs), 2.86(3H, brs), 3.53(2H, s), 4.21(4H, q,, J=7.1Hz), 4.83(2H, s), 6.85(1H, d, J=7.7Hz), 7.07(1H, d, J=2.0Hz), 7.20-7.52(12H, m), 8.25(1H, dd, J=1.8, 7.9Hz), 8.41(1H, d, J=8.5Hz), 10.48(1H, brs)
2-98		0.65(6H, t, J=7.4Hz), 1.69(4H, q, J=7.4Hz), 2.81(3H, brs), 2.94(3H, brs), 3.50(2H, s), 4.30(2H, s), 7.02(1H, d, J=1.8Hz), 7.18-7.62(13H, m), 7.70(1H, d, J=7.3Hz), 8.35(1H, d, J=8.5Hz), 9.15(1H, brs)
2-99		1.21(6H, t, J=7.1Hz), 2.87(6H, brs), 3.53(2H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 6.92(1H, d, J=7.6Hz), 7.08(1H, d, J=2.1Hz), 7.20-7.48(10H, m), 7.63(2H, d, J=8.7Hz), 8.23(1H, dd, J=1.7, 7.9Hz), 8.35(1H, d, J=8.5Hz), 10.38(1H, brs)
2-100		0.85-0.93(4H, m), 2.78(3H, brs), 2.93(3H, brs), 3.52(2H, s), 4.16(2H, s), 7.04(1H, d, J=2.1Hz), 7.17-7.61(13H, m), 7.70(1H, dd, J=1.5, 7.2Hz), 8.35(1H, d, J=9.0Hz), 9.15(1H, brs)

Table 38

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-101		2.79(3H, brs), 2.94(3H, brs), 3.45(2H, s), 4.31(1H, t, J=7.6Hz), 4.62(2H, d, J=7.6Hz), 6.96(1H, d, J=2.0Hz), 7.15-7.69(19H, m), 8.30(1H, d, J=8.5Hz), 9.15(1H, brs)
2-102	 mp. 103.0-109.0	1.62-1.76(4H, m), 1.82-1.99(4H, m), 2.78(3H, brs), 2.93(3H, brs), 3.44(2H, s), 4.08(2H, s), 6.97(1H, d, J=2.0Hz), 7.09-7.26(6H, m), 7.35-7.72(8H, m), 8.34(1H, d, J=8.5Hz), 9.15(1H, brs)
2-103		2.40(1H, t, J=5.7Hz), 2.42(1H, t, J=6.3Hz), 3.53(2H, s), 2.80(3H, brs), 2.93(3H, brs), 3.82(2H, dd, J=6.3, 11.4Hz), 3.96(2H, dd, J=5.7, 11.4Hz), 4.58(2H, s), 7.01(1H, d, J=1.8Hz), 7.14-7.71(14H, m), 8.29(1H, d, J=8.4Hz), 9.05(1H, brs)
2-104		1.98(6H, s), 2.83(3H, brs), 2.93(3H, brs), 3.49(2H, s), 4.40(4H, s), 4.44(2H, s), 7.00(1H, d, J=2.2Hz), 7.15(1H, dd, J=2.2, 8.4Hz), 7.22-7.65(12H, m), 7.70(1H, dd, J=1.9, 7.0Hz), 8.32(1H, d, J=8.4Hz), 9.13(1H, brs)
2-105	 mp. 98.8-103.3	1.23(6H, t, J=7.1Hz), 2.83(3H, brs), 2.94(3H, brs), 3.51(2H, s), 4.22(4H, q,, J=7.1Hz),4.82(2H, s), 6.94-7.04(3H, m), 7.16-7.71(10H, m), 8.34(1H, d, J=8.5Hz), 9.17(1H, brs)

Table 39

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-106	 mp.116.1-121.6	1.22(6H, t, J=7.1Hz), 2.81(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.20(4H, q, J=7.1Hz), 4.79(2H, s), 7.01-7.04(2H, m), 7.25-7.71(11H, m), 8.35(1H, d, J=8.5Hz), 9.17(1H, brs)
2-107		1.25(6H, t, J=7.1Hz), 2.75(3H, brs), 2.92(3H, brs), 3.78(2H, s), 4.22(4H, q, J=7.1Hz), 4.85(2H, s), 6.98(1H, s), 7.28-7.72(13H, m), 8.71(1H, s), 9.52(1H, brs)
2-108		1.22(6H, t, J=7.2Hz), 2.13(3H, s), 2.85(3H, brs), 2.93(3H, brs), 3.50(2H, s), 4.16-4.26(4H, m), 4.80(2H, s), 6.78(1H, d, J=5.1Hz), 7.05(1H, d, J=2.2Hz), 7.15(1H, d, J=5.2Hz), 7.16-7.64(8H, m), 7.69(1H, dd, J=1.5, 7.3Hz), 8.33(1H, d, J=8.5Hz), 9.16(1H, brs)
2-109	 mp.104.6-108.3	1.22(6H, t, J=7.2Hz), 2.44(3H, s), 2.84(3H, brs), 2.94(3H, brs), 3.52(2H, s), 4.20(4H, q, J=7.2Hz), 4.78(2H, s), 6.58(1H, dd, J=1.2, 3.5Hz), 6.76(1H, d, J=3.5Hz), 7.04(1H, d, J=2.0Hz), 7.20(1H, dd, J=2.1, 8.6Hz), 7.37-7.62(7H, m), 7.68(1H, dd, J=1.4, 7.6Hz), 8.33(1H, d, J=8.4Hz), 9.17(1H, brs)
2-110	 mp.121.5-124.7	1.22(6H, t, J=7.1Hz), 2.85(3H, brs), 2.94(3H, brs), 3.46(2H, s), 4.23(4H, q, J=7.1Hz), 4.97(2H, s), 7.00(1H, d, J=2.2Hz), 7.13-7.16(1H, m), 7.36(1H, d, J=3.3Hz), 7.38-7.71(8H, m), 7.75(1H, d, J=3.3Hz), 8.31(1H, d, J=8.5Hz), 9.16(1H, brs)

Table 40

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
2-111	 mp 96-98	0.97(6H, d, J=7.2Hz), 1.21(6H, t, J=7.2Hz), 2.45(1H, sep. J=7.2Hz), 2.88(3H, brs), 2.94(2H, brs), 3.52(2H, s), 4.15(4H, q, J=7.2Hz), 4.50(2H, s), 7.09(1H, d, J=2.3Hz), 7.20-7.72(9H, m), 8.34(1H, d, J=8.3Hz), 9.15(1H, brs).
2-112	 mp 100-104.5	0.90(3H, t, J=7.2Hz), 0.92(3H, t, J=6.5Hz), 0.95-1.10(1H, m), 1,21(3H, t, J=7.2Hz), 1.48-1.62(1H, m), 2.05-2.16(1H, m), 2.88(3H, brs), 2.94(3H, brs), 3.52(2H, s), 4.14(4H, q, J=7.2Hz), 4.51(2H, s), 7.09(1H, d, J=1.9Hz), 7.21-7.72(9H, m), 8.36(1H, d, J=8.3Hz), 9.16(1H, brs).
2-113	 mp 106-109.5	0.83(6H, d, J=6.4Hz), 1.21(6H, t, J=7.2Hz), 1.51-1.65(1H, m), 1.88(2H, d, J=6.4Hz), 2.88(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.15(4H, q, J=7.2Hz), 4.52(2H, s), 7.08(1H, d, J-2.3Hz), 7.22-7,71(9H, m), 8.37(1H, d, J=8.3Hz), 9.16(1H, brs).
2-114	 mp 98-99.5	0.88(3H, t, J=7.2Hz), 1.09-1.31(2H, m), 1.21(6H, t, J=7.2Hz), 1.79-1.93(2H, m), 2.89(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.15(4H, q, J=7.2Hz), 4.49(2H, s), 7.09(1H, brs), 7.21-7.74(9H, m), 8.37(1H, d, J=8.3Hz), 9.15(1H, brs).
2-115	 mp 86.5-90.0	0.83(3H, t, J=7.5Hz), 1.21(6H, t, J=7.2Hz), 1.96(2H, q, J=7.5Hz), 2.88(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.16(4H, q, J=7.2Hz), 4.50(2H, s), 7.08(1H, d, J=1.9Hz), 7.21-7.74(9H, m), 8.36(1H, d, J=8.7Hz), 9.15(1H, brs).

Table 41

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
2-116	 mp 97.5-98.0	0.86(3H, t, J=7.2Hz), 1.06-1.36(4H, m), 1.21(6H, t, J=7.2Hz), 1.84-1.94(2H, m), 2.88(3H, brs), 2.94(3H, brs), 3.53(2H, s), 4.15(4H, q, J=7.2Hz), 4.49(2H, s), 7.08(1H, d, J=2.3Hz), 7.21-7.71(9H, m), 8.37(1H, d, J=8.6Hz), 9.16(1H, brs).
2-117	 mp.76.9-82.0	1.21(6H, t, J=7.1Hz), 2.67(2H, d, J=7.4Hz), 2.87(3H, brs), 2.95(3H, brs), 3.54(2H, s), 4.10-4.20(4H, m), 4.47(2H, s), 5.00-5.10(2H, m), 5.56-5.67(1H, m), 7.09(1H, d, J=2.1Hz), 7.24(1H, d, J=2.0Hz), 7.38-7.68(7H, m), 7.70(1H, d, J=1.4Hz), 8.37(1H, d, J=8.4Hz), 9.14(1H, brs)
2-118		1.25(9H, t, J=7.2Hz), 2.89(3H, brs), 2.95(3H, brs), 3.56(2H, s), 4.23(6H, q, J=7.2Hz), 4.70(2H, s), 7.11(1H, d, J=1.8Hz), 7.24(1H, d, J=2.2Hz), 7.28-7.70(8H, m), 8.36(1H, d, J=8.8Hz), 9.16(1H, brs)
2-119	 mp.72.3-78.6	0.87(3H, t, J=7.2Hz), 0.92(3H, t, J=6.8Hz), 1.00-1.16(2H, m), 1.20(6H, t, J=7.1Hz), 1.38-1.53(2H, m), 2.18-2.23(1H, m), 2.88(3H, brs), 2.95(3H, brs), 3.52(2H, s), 4.08-4.18(4H, m), 4.50(2H, d, J=2.1Hz), 7.08(1H, d, J=1.9Hz), 7.22-7.69(9H, m), 8.35(1H, d, J=8.6Hz), 9.15(1H, brs)

Example 3

2-(2-{3-Ethoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester

a) 3-Ethoxy-4-nitrobenzoic acid methyl ester



To a suspension of sodium hydride (60% mineral oil: 1.20g) in dimethylformamide (50 mL) was added 3-hydroxy-4-nitrobenzoic acid methyl ester (4.93 g) under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. After addition of ethyl iodide (4.4 g), the solution was stirred at 60°C overnight, cooled down to room temperature, poured into saturated aqueous ammonium chloride, and extracted with ethyl acetate-tetrahydrofuran. The organic layer was washed with saturated aqueous ammonium chloride and saturated brine, dried over sodium sulfate and concentrated to give a solid, which was washed with ethyl acetate-hexane to afford 3-ethoxy-4-nitrobenzoic acid methyl ester (3.30 g) as a pale yellow solid.

b) 3-Ethoxy-4-nitrobenzoic acid chloride



3-Ethoxy-4-nitrobenzoic acid chloride was obtained in a similar manner to Example 1 f) and Example 1 d) from the 3-ethoxy-4-nitrobenzoic acid methyl ester obtained in Example 3 a).

c) 2'-Diazo-3-ethoxy-4-nitroacetophenone



A solution of the 3-ethoxy-4-nitrobenzoic acid chloride (2.06 g) obtained in Example 3 b) in diethyl ether (30 mL) was added dropwise to a mixture of diazomethane in diethyl ether (0.35M, 64 mL) and triethylamine (3.12 mL) under ice-cooling. The mixture was stirred for 2 hours under ice-cooling and the temperature was raised to room temperature, followed by stirring overnight. After addition of acetic acid (1 mL), the mixture was stirred at room temperature for one hour and evaporated to remove the solvent. The residue was purified by column chromatography on silica gel with hexane:ethyl acetate=5:2 to give the title compound (1.80 g) as a yellow solid.

d) 3-Ethoxy-4-nitrophenylacetic acid ethyl ester



A solution of silver benzoate (270 mg) in triethylamine

(2.7 ml) was added dropwise in 10 divided doses to a solution of the 2'-diazo-3-ethoxy-4-nitroacetophenone (1.80 g) obtained in Example 3 c) in ethanol (25 mL) under reflux. The mixture was refluxed for 9 hours and the reaction solution was filtered through a Celite pad. The filtrate was concentrated, and the concentrate was diluted with diethyl ether and washed with 10% aqueous sodium carbonate, water and saturated brine. The organic layer was dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=4:1 to give the title compound (1.27 g) as a yellow solid.

e) 4-Amino-3-ethoxyphenylacetic acid ethyl ester

The 3-ethoxy-4-nitroacetic acid methyl ester (1.27 g) obtained in Example 3 d) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (1.12 g) as a brown oil.

f) 2-(2-{3-Ethoxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester



The 4-amino-3-ethoxyphenylacetic acid ethyl ester obtained in Example 3 e) and the 2-hydroxymethyl-2-

phenylmalonic acid diethyl ester obtained in Example 1-2 a) were subjected to reactions similar to those in Examples 1 e), 1 f) and 1 g) to give the title compound (0.159 g) (see Table 42).

Example 3-2

{3-Hydroxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



{3-Benzyloxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester (300 mg) obtained in a similar manner to Example 3, except that reduction of the nitro group was carried out with iron dust, was subjected to reactions in a similar manner to Example 1-2 c) to give the title compound (244 mg)(See Table 42).

Examples 3-3 to 3-16

Compounds of Examples 3-3 to 3-16 were obtained in a

similar manner to Examples 3 to 3-2. The compounds thus obtained were shown in Tables 42 to 45.

Table 42

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
3		1.19(6H, t, J=7.1Hz), 1.20(3H, t, J=7.1Hz), 3.49(2H, s), 3.77(2H, q, J=7.1Hz), 4.18(4H, q, J=7.1Hz), 4.83(2H, s), 6.59(1H, d, J=1.5Hz), 6.75(1H, dd, J=1.5, 8.2Hz), 7.25-7.33(5H, m), 7.44(1H, dd, J=1.5, 7.2Hz), 7.49-7.66(6H, m), 7.70-7.76(1H, m), 7.80(1H, dd, J=1.5, 7.2Hz), 8.35(1H, d, J=8.0Hz)
3-2		1.05(6H, t, J=7.2Hz), 3.23(4H, dq, J=7.2, 7.2Hz), 3.48(2H, s), 4.83(2H, s), 6.48(1H, d, J=7.9Hz), 6.55(1H, dd, J=7.9, 1.9Hz), 6.77(1H, d, J=1.5Hz), 7.17-7.86(15H, m) ,8.58(1H,s)
3-3 m.p. 112-114		1.05(6H, t, J=7.2Hz), 3.23(4H, dq, J=7.2, 7.2Hz), 3.53(2H, s), 3.55(3H, s), 4.83(2H, s), 6.60(1H, s), 6.73(1H, d, J=7.9Hz), 7.10-7.66(15H, m), 7.85(1H, dd, J=7.5, 1.5Hz), 8.33(1H, d, J=7.9Hz)
3-4		1.19(6H, t, J=6.9Hz), 3.50(5H, s), 4.17(4H, q, J=6.9Hz), 4.83(2H, s), 6.58(1H, s), 6.75(1H, d, J=6.9Hz), 7.26-7.65(13H, m), 7.85(1H, d, J=7.3Hz), 8.31(1H, d, J=8.1Hz)
3-5		0.84(6H, t, J=7.2Hz), 1.43(4H, tq, J=7.2, 7.2Hz), 3.16(4H, m), 3.52(2H, s), 3.55(3H, s), 4.83(2H, s), 6.60(1H, br.s), 6.72(1H, dd, J=8.3, 1.5Hz), 7.12-7.66(15H, m), 7.84(1H, dd, J=7.9, 1.9Hz), 8.33(1H, d, J=7.9Hz)

Table 43

Example	Structure	NMR (δ, 300MHz, $CDCl_3$)
3-6		1.13(6H, t, J=7.2Hz), 2.55(2H, t, J=8.0Hz), 3.30(4H, dq, J=7.2, 7.2Hz), 3.53(2H, s), 3.57(3H, s), 4.12(2H, t, J=8.0Hz), 6.67(1H, br.s), 6.82(1H, dd, J=8.3, 1.9Hz), 7.26-7.66(15H, m), 7.84(1H, dd, J=7.9, 1.9Hz), 8.33(1H, d, J=7.9Hz)
3-7		1.05(6H, t, J=7.2Hz), 1.24(3H, t, J=7.1Hz), 3.17-3.29(4H, m), 3.52(2H, s), 3.83(2H, q, J=7.1Hz), 4.82(2H, s), 6.60(1H, d, J=1.5Hz), 6.69-6.76(1H, m), 7.04-7.14(2H, m), 7.15-7.22(2H, m), 7.25-7.34(3H, m), 7.41-7.47(1H, m), 7.49-7.66(6H, m), 7.73(1H, br-s), 7.77-7.83(1H, m), 8.37(1H, d, J=8.3Hz)
3-8		1.13(6H, t, J=7.2Hz), 1.24(3H, t, J=7.1Hz), 2.49-2.59(2H, m), 3.31(4H, dq, J=5.3, 7.2Hz), 3.52(2H, s), 3.87(2H, q, J=7.1Hz), 4.07-4.17(2H, m), 6.68(1H, d, J=1.5Hz), 6.78-6.84(1H, m), 7.23-7.37(5H, m), 7.41-7.47(1H, m), 7.48-7.66(8H, m), 7.73(1H, s), 7.76-7.82(1H, m), 8.37(1H, d, J=8.3Hz)
3-9		1.10(6H, d, J=6.0Hz), 1.19(6H, t, J=7.2Hz), 3.48(2H, s), 4.19(4H, q, J=7.2Hz), 4.36(1H, sept, J=6.0Hz), 4.82(2H, s), 6.62(1H, d, J=1.5Hz), 6.70-6.77(1H, m), 7.27-7.32(5H, m), 7.41-7.46(1H, m), 7.49-7.67(6H, m), 7.72-7.82(2H, m), 8.39(1H, d, J=8.2Hz)
3-10		1.05(6H, t, J=7.2Hz), 1.13(6H, d, J=6.1Hz), 3.23(4H, dq, J=5.6, 7.2Hz), 3.52(2H, s), 4.40(1H, sept, J=6.1Hz), 4.82(2H, s), 6.62(1H, d, J=1.5Hz), 6.67-6.75(1H, m), 7.10(2H, br-t, J=5.6Hz), 7.16-7.23(2H, m), 7.24-7.35(3H, m), 7.44(1H, dd, J=1.5, 7.6Hz), 7.50-7.70(6H, m), 7.71-7.82(2H, m), 8.40(1H, d, J=8.3Hz)

Table 44

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
3-11		1.13(6H, t, J=7.2Hz), 1.13(6H, d, J=6.1Hz), 2.48-2.60(2H, m), 3.31(4H, dq, J=5.7, 7.2Hz), 3.52(2H, s), 4.07-4.17(2H, m), 4.43(1H, sept, J=6.1Hz), 6.69(1H, d, J=1.5Hz), 6.79(1H, dd, J=1.5, 8.3Hz), 7.23-7.37(5H, m), 7.41-7.46(1H, m), 7.48-7.68(8H, m), 7.72-7.82(2H, m), 8.40(1H, d, J=8.3Hz)
3-12		0.90(3H, t, J=7.4Hz), 1.05(6H, t, J=7.3Hz), 1.53-1.69(2H, m), 3.16-3.30(4H, m), 3.53(2H, s), 3.75(2H, t, J=6.7Hz), 4.82(2H, s), 6.58-6.74(2H, m), 7.02-7.78(16H, m), 8.36(1H, d, J=8.2Hz)
3-13		1.04(6H, t, J=7.2Hz), 3.23(4H, dq, J=7.2, 7.2Hz), 3.52(2H, s), 4.82-4.86(4H, m), 6.70-7.79(16H, m), 7.71(1H, br.s), 7.78(1H, dd, J=7.1, 1.9Hz), 8.40(1H, d, J=8.3Hz)
3-14		1.19(6H, t, J=7.1Hz), 3.49(2H, s), 4.17(4H, q, J=7.1Hz), 4.78(2H, s), 4.83(2H, s), 6.70(1H, d, J=1.9Hz), 6.78(1H, dd, J=8.3, 1.5Hz), 7.21-7.57(12H, m), 7.70(1H, br.s), 7.77(1H, dd, J=7.2, 1.9Hz), 8.38(1H, d, J=8.3Hz)
3-15		1.20(6H, t, J=7.2Hz), 3.47(2H, s), 4.19(4H, q, J=7.2Hz), 4.82(2H, s), 6.29(1H, d, J=7.9Hz), 6.57(1H, dd, J=7.9, 1.9Hz), 6.79(1H, d, J=1.9Hz), 7.18(1H, br.s), 7.28-7.74(11H, m), 7.86(1H, dd, J=7.9, 1.5Hz), 8.39(1H, s)

Table 45

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
3-16		1.17(6H, t, J=7.1Hz), 3.54(2H, s), 3.72(3H, s), 4.16(4H, q, J=7.1Hz), 4.83(2H, s), 6.72-6.80(3H, m), 7.29-7.66(12H, m), 8.14(1H, dd, J=1.3, 7.7Hz)

Example 4

2-{3-Dimethylamino-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester

a) 2-(3-Bromo-4-nitrophenyl)malonic acid tert-butyl ester methyl ester



Sodium hydride (60%, mineral oil; 0.985 g) was suspended in dimethylformamide (20 mL), and a solution of tert-butyl methyl malonate (4.29 g) in dimethylformamide (5 mL) was added dropwise thereto under ice-cooling. After foam generation is stopped, a solution of 2-bromo-4-fluoro-1-nitrobenzene (2.71 g) in dimethylformamide (5 mL) was added dropwise thereto at the same temperature, and the mixture was further stirred at

60°C for 3 hours, and then concentrated. The residue was neutralized with 1N hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine, dried over sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:4 to 1:5 to give the title compound (7.54 g) as an oil.

b) (3-Bromo-4-nitrophenyl)acetic acid methyl ester



The 2-(3-bromo-4-nitrophenyl)malonic acid tert-butyl ester methyl ester (1.18 g) obtained in Example 4 a) was dissolved in chloroform (10 mL), trifluoroacetic acid (10 g) was added thereto under ice-cooling, and the mixture was stirred at room temperature for 5 hours. The reaction mixture was poured gradually into ice and saturated aqueous sodium bicarbonate, and extracted with ethyl acetate. The extract was washed with water and saturated brine, dried over sodium sulfate and concentrated to give the title compound (0.820 g) as a pale yellow oil.

c) (3-Dimethylamino-4-nitrophenyl)acetic acid methyl ester



The (3-bromo-4-nitrophenyl)acetic acid methyl ester (0.320 g) obtained in Example 4 b) was dissolved in

tetrahydrofuran (10 mL). To this solution were added triethylamine (0.237 g) and dimethylamine (2M tetrahydrofuran ; 0.58 mL), and stirred overnight while heating. The reaction mixture was concentrated and purified by column chromatography on silica gel with ethyl acetate:hexane=1:4 to give the title compound (0.145 g) as an orange oil.

d) (4-Amino-3-dimethylaminophenyl)acetic acid methyl ester



The (3-dimethylamino-4-nitrophenyl)acetic acid methyl ester (0.245 g) obtained in Example 4 c) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (0.188 g) as a red oil.

e) 2-{3-Dimethylamino-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



The (4-amino-3-dimethylaminophenyl)acetic acid methyl ester (0.188 g) obtained in Example 4 d) was subjected to reactions similar to those in Example 1 e), 1 f) and 1 g) to give the title compound (0.058 g) (See Table 46).

Examples 4-2 to 4-8

Compounds of Examples 4-2 to 4-8 were obtained in a similar manner to Example 4. The compounds thus obtained were shown in Tables 46 to 47.

Table 46

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
4		1.04(6H, t, J=7.2Hz), 2.26(6H, s), 3.23(4H, m), 3.51(2H, s), 4.83(2H, s), 6.86-7.80(15H, m), 8.40(1H, d, J=8.7Hz), 8.45(1H, brs).
4-2		1.05(6H, t, J=7.3Hz), 1.49(6H, br.s), 2.48(4H, br.s), 3.24(4H, dq, J=7.3, 7.3Hz), 3.53(2H, s), 4.84(2H, s), 6.93(2H, m), 7.20-7.70(15H, m), 8.40(1H, d, J=9.2Hz), 8.54(1H, br.s)
4-3		1.04(6H, t, J=7.3Hz), 1.76(4H, m), 2.59(4H, t, J=6.2Hz), 3.23(4H, dq, J=7.3, 7.3Hz), 3.51(2H, s), 4.83(2H, s), 4.82(2H, m), 7.12-7.63(14H, m), 7.74(1H, dd, J=7.3, 1.4Hz), 8.18(1H, br.s), 8.30(1H, d, J=8.1Hz)
4-4		1.20(6H, t, J=7.1Hz), 1.48(6H, br.s), 2.47(4H, br.s), 3.49(2H, s), 4.19(4H, q, J=7.1Hz), 4.83(2H, s), 6.92-7.72(15H, m), 8.39(1H, d, J=8.3Hz), 8.56(1H, br.s)
4-5		1.20(6H, t, J=7.2Hz), 1.74(4H, m), 2.57(4H, m), 3.48(2H, s), 4.19(4H, q, J=7.2Hz), 4.82(2H, s), 6.90(2H, m), 7.30-7.63(12H, m), 7.74(1H, dd, J=7.2, 1.5Hz), 8.20(1H, br.s), 8.29(1H, d, J=8.7Hz)

Table 47

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
4-6		1.20(6H, t, J=7.1Hz), 2.24(6H, s), 3.48(2H, s), 4.19(4H, q, J=7.1Hz), 4.82(2H, s), 6.88-6.98(2H, m), 7.29(5H, brs),7.43(1H, d, J=7.2Hz), 7.48-7.60(2H, ,m), 7.62(4H, s), 7.77(1H, d, J=7.5Hz), 8.39(1H, d, J=8.3Hz), 8.47(1H, brs).
4-7		1.21(6H, t, J=7.0Hz), 2.38-2.47(4H, m), 3.51(2H, s), 3.53-3.60(4H, m), 4.20(4H, q, J=7.0Hz), 4.84(2H, s), 6.93(1H, s), 7.00(1H, dd, J=1.5, 7.4Hz), 7.29-7.35(5H, m), 7.47-7.68(7H, m), 7.73(1H, dd, J=1.8, 7.4Hz), 8.42-8.51(2H, m)
4-8		0.67(6H, t, J=7.0Hz), 1.21(6H, t, J=7.2Hz), 2.64(4H, q, J=7.0Hz), 3.49(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 6.90-7.01(2H, m), 7.28-7.35(5H, m), 7.42-7.65(7H, m), 7.69(1H, dd, J=1.5, 7.2Hz), 8.41(1H, d, J=8.3Hz), 8.85(1H, br-s)

Example 5

2-[2-(2-{2-methyl-3-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxy)ethyl]-2-phenylmalonic acid diethyl ester

a) 2'-Diazo-3-nitro-2-methylacetophenone



2-Methyl-3-nitrobenzoic acid (500 mg) was subjected to reactions similar to those in Example 3 b) and 3 c) to give the title compound (377 mg).

b) 2-Methyl-3-nitrophenylacetic acid ethyl ester

The 2'-diazo-3-nitro-2-methylacetophenone (377 mg) obtained in Example 5 a) was subjected to reactions similar to those in Example 3 d) to give the title compound (363 mg).

c) 2-Methyl-3-nitrophenylacetic acid



The 2-methyl-3-nitrophenylacetic acid ethyl ester (352 mg) obtained in Example 5 b) was subjected to reactions similar to those in Example 1 f) to give the title compound (307 mg).

d) 2-(2-Benzyloxyethyl)-2-phenylmalonic acid diethyl ester



Sodium hydride (406 mg) was dissolved in dimethylformamide (20 mL) and the solution was cooled to 0°C. To this solution was added phenylmalonic acid diethyl ester (2.0 g), and the mixture was stirred at room temperature for 30 minutes. Bromoethyl benzyl ether (2.0 g) was further added thereto, stirred at 60°C for 4 hours, and water was added thereto. The reaction mixture was concentrated, diluted with ethyl acetate, washed with water, dried over sodium sulfate and purified by column chromatography on silica gel with ethyl acetate:hexane=1:9 to give the title compound (1.2 g).

e) 2-(2-Hydroxyethyl)-2-phenylmalonic acid diethyl ester



The 2-(2-benzyloxyethyl)-2-phenylmalonic acid diethyl ester (1.2 g, not purified) obtained in Example 5 d) was subjected to reactions similar to those in Example 1-2 c) to give the title compound (726 mg).

f) 2-{2-[2-(2-Methyl-3-nitrophenyl)acetoxy]ethyl}-2-phenylmalonic acid diethyl ester



The 2-methyl-3-nitrophenylacetic acid (307 mg) obtained in Example 5 c), 4-dimethylaminopyridine (217 mg) and the 2-(2-hydroxyethyl)-2-phenylmalonic acid diethyl ester (250 mg) obtained in Example 5 e) were subjected to reactions similar to those in Example 1-3 c) to give the title compound (366 mg).

g) 2-[2-(2-{2-methyl-3-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxy)ethyl]-2-phenylmalonic acid diethyl ester



The 2-{2-[2-(2-methyl-3-nitrophenyl)acetoxy]ethyl}-2-phenylmalonic acid diethyl ester (345 mg) obtained in Example 5 f) was subjected to reactions similar to those in Example 1-3 d) and 1-3 e) to give the title compound (318 mg)(See Table 48).

Examples 5-2 to 5-18

Compounds of Examples 5-2 to 5-18 were obtained in a similar manner to Example 5. The compounds thus obtained were shown in Tables 48 to 51.

Table 48

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
5		1.23(6H, t, J=7.0Hz), 1.70(3H, s), 2.61(2H, t, J=7.0Hz), 3.50(2H, s), 4.07(2H, t, J=7.0Hz), 4.21(4H, q, J=7.0Hz), 6.84(1H, br.s), 6.98(1H, d, J=7.7Hz), 7.13-7.71(15H, m), 7.80(1H, d, J=7.0Hz)
5-2		1.17(6H, t, J=7.1Hz), 3.50(2H, s), 4.14(4H, q, J=7.1Hz), 4.83(2H, s), 6.83(1H, s), 6.91(1H, d, J=7.5Hz), 6.99(1H, br.s), 7.16-7.81(15H, m)
5-3	 m.p. 88-91	1.23(6H, t, J=7.2Hz), 2.62(2H, t, J=7.2Hz), 3.41(2H, s), 4.13(2H, t, J=7.2Hz), 4.20(4H, q, J=7.2Hz), 7.05-7.79(18H, m)
5-4		1.10(6H, t, J=7.2Hz), 2.53-2.61(2H, m), 3.28(4H, dq, J=5.3, 7.2Hz), 3.54(2H, s), 4.07-4.17(2H, m), 6.95-7.10(3H, m), 7.14-7.36(7H, m), 7.40-7.46(1H, m), 7.46-7.62(6H, m), 7.64-7.71(2H, m), 7.77(1H, dd, J=1.5, 7.5Hz)
5-5		0.85(6H, t, J=7.2Hz), 1.49(4H, tq, J=7.2, 7.2Hz), 2.54-2.63(2H, m), 3.16-3.25(4H, m), 3.53(2H, s), 4.08-4.17(2H, m), 6.96-7.01(1H, m), 7.03-7.10(2H, m), 7.15-7.36(7H, m), 7.40-7.46(1H, m), 7.47-7.62(6H, m), 7.65-7.71(2H, m), 7.77(1H, dd, J=1.5, 7.5Hz)

Table 49

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
5-6		1.24(6H, t, J=7.4Hz), 1.68(3H, s), 2.65(2H, t, J=7.3Hz), 3.50(2H, s), 4.09(2H, t, J=7.3Hz), 4.22(4H, q, J=7.4Hz), 6.81(1H, br.s), 6.92-7.83(16H, m)
5-7		1.23(6H, t, J=7.4Hz), 2.20(3H, s), 2.63(2H, t, J=7.0Hz), 3.47(2H, s), 4.08(2H, t, J=7.0Hz), 4.21(4H, q, J=7.4Hz), 6.94(1H, s), 7.07-7.81(16H, m)
5-8		1.11(6H, d, J=6.4Hz), 1.13(6H, d, J=6.8Hz), 2.49-2.58(2H, m), 3.53(2H, s), 3.98-4.15(4H, m), 6.96-7.01(1H, m), 7.03-7.16(3H, m), 7.17-7.37(8H, m), 7.40-7.61(5H, m), 7.64-7.71(2H, m),7.77(1H, dd, J=1.5, 7.6Hz)
5-9		1.11(6H, t, J=7.0Hz), 1.72(3H, s), 2.52(2H, t, J=7.9Hz), 3.29(4H, dq, J=7.0, 7.0Hz), 3.57(2H, s), 4.08(2H, t, J=7.9Hz), 6.85(1H, br.s), 6.99-7.81(18H, m)
5-10		0.98(6H, t, J=7.1Hz), 1.53(2H, m), 1.79(3H, s), 1.95(2H, m), 3.09(4H, dq, J=7.1, 7.1Hz), 3.64(2H, s), 4.06(2H, t, J=5.7Hz), 7.03-7.62(18H, m), 8.02(1H, br.s)

Table 50

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
5-11		0.86(6H, t, J=7.1Hz), 1.50(4H, tq, J=7.1, 7.1Hz), 2.53(2H, t, J=7.9Hz), 3.21(4H, m), 3.57(2H, s), 4.08(2H, t, J=7.9Hz), 6.85(1H, br.s), 7.00(1H, d, J=7.5Hz), 7.14-7.80(17H, m)
5-12		1.11(6H, t, J=7.2Hz), 2.53(2H, t, J=7.9Hz), 3.22(3H, d), 3.29(4H, dq, J=7.2, 7.2Hz), 3.55(2H, s), 4.09(2H, t, J=7.9Hz), 6.95(1H, dd, J=7.5, 1.5Hz), 7.04-7.64(16H, m), 7.74(1H, dd, J=7.5, 1.5Hz), 8.34(1H, dd, J=8.3, 1.1Hz)
5-13	 m.p. 78-81	1.23(6H, t, J=7.1Hz), 2.61(2H, t, J=7.2Hz), 3.22(3H, s), 3.49(2H s), 4.08(2H, t, J=7.2Hz), 4.21(4H, q, J=7.1Hz), 6.93(1H, dd, J=7.6, 1.5Hz), 7.28-7.75(14H, m), 7.73(1H, dd, J=7.6, 1.5Hz), 8.33(1H, dd, J=8.3, 1.5Hz)
5-14		1.11(6H, t, J=7.4Hz), 1.15(3H, t, J=7.2Hz), 2.52(2H, t, J=7.5Hz), 3.29(6H, m), 3.54(2H, s), 4.09(2H, t, J=7.5Hz), 6.95(1H, dd, J=7.9, 1.1Hz), 7.10(1H, dd, J=7.9, 7.9Hz), 7.24-7.73(16H, m), 8.36(1H, d, J=8.3Hz)
5-15		1.15(3H, t, J=7.2Hz), 1.23(6H, t, J=7.2Hz), 2.61(2H, t, J=7.2Hz), 3.29(2H, q, J=7.2Hz), 3.49(2H s), 4.07(2H, t, J=7.2Hz), 4.21(4H, q, J=7.2Hz), 6.94(1H, dd, J=7.5, 1.5Hz), 7.08(1H, dd, J=7.9, 7.9Hz), 7.30-7.73(14H, m), 8.34(1H, dd, J=7.9, 1.5Hz)

Table 51

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
5-16		1.05(6H, d, J=6.4Hz), 1.23(6H, t, J=7.2Hz), 2.62(2H, t, J=7.2Hz), 3.51(2H s), 3.85(1H, sep, J=6.4Hz), 4.10(2H, t, J=7.2Hz), 4.20(4H, q, J=7.2Hz), 6.95(1H, dd, J=7.9, 1.5Hz), 7.07(1H, dd, J=7.9, 7.9Hz), 7.30-7.61(12H, m), 7.68(1H, dd, J=7.9, 1.5Hz), 7.75(1H, br.s), 8.28(1H, dd, J=7.9, 1.5Hz)
5-17		1.23(6H, t, J=7.1Hz), 2.61(2H, t, J=7.1Hz), 3.71(3H, s), 3.75(2H, s), 4.07(2H, t, J=7.1Hz), 4.22(4H, q, J=7.1Hz), 6.94(1H, d, J=7.6Hz), 7.29-7.62(13H, m), 7.72(1H, dd, J=1.4, 7.6Hz), 8.47(1H, d, J=8.3Hz), 10.25(1H, brs)
5-18		1.13(3H, t, J=7.2Hz), 1.23(6H, t, J=7.1Hz), 2.30(3H, s), 2.61(2H, t, J=7.1Hz), 3.25(2H, q, J=7.2Hz), 3.44(2H, s), 4.07(2H, t, J=7.1Hz), 4.21(4H, q, J=7.1Hz), 6.75(1H, s), 7.30-7.69(14H, m), 8.19(1H, brs)

Example 6

4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester

a) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid ethyl ester



4-Aminobenzoic acid ethyl ester (0.568 g) and triethylamine (0.570 g) were dissolved in methylene chloride (20 mL), and to this solution was dropwise added a solution of 4'-trifluoromethylbiphenyl-2-carboxylic acid chloride, which is prepared from 4'-trifluoromethylbiphenyl-2-carboxylic acid (1.00 g) in a similar manner to Example 1 d), in methylene chloride under ice-cooling. The solution was stirred at room temperature for 2 hours, followed by addition of methylene chloride (100 mL). The reaction mixture was washed with 2N hydrochloric acid and saturated brine, dried over sodium sulfate and concentrated to give the title compound (1.43 g).

b) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid



The 4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid ethyl ester (0.700 g) obtained in Example 6 a) was subjected to reactions similar to Example 1 f) to give the title compound (0.680 g) as a white solid.

c) 9-[2-(Tert-butyldimethylsilanyloxy)ethyl]-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide



9H-Fluorene-9-carboxylic acid (2,2,2-trifluoroethyl)amide (3.00 g) was dissolved in tetrahydrofuran (100 mL), and to this solution was added dropwise a 1.5M solution (13.7 mL) of lithium diisopropylamide under ice-cooling. The mixture was stirred for one hour under ice-cooling, and to this was added a solution of tert-butyldimethylsilanyloxyethyl bromide (2.46 g) in tetrahydrofuran (5 mL). The temperature was gradually raised from under ice-cooling to room temperature, and the mixture was stirred overnight. Saturated aqueous ammonium chloride was added to the reaction mixture under ice-cooling and then extracted with ethyl acetate (50 mL × 2). The extract was washed with saturated brine, dried over sodium sulfate and purified by column chromatography on silica gel with ethyl acetate:hexane=1:2.5 to give the title compound (6.00 g).

d) 9-(2-Hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide



The 9-[2-(Tert-butyldimethylsilanyloxy)ethyl]-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide (6.00 g) obtained in Example 6 c) was dissolved in tetrahydrofuran (13 mL) - acetic acid (39 mL) - water (13 mL). The solution was stirred at room temperature for 20 hours and concentrated in vacuo. The residue was purified by column chromatography on silica gel with ethyl acetate:hexane=1:1 to give the title compound (3.80 g).

e) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid 2-[9-(2,2,2-trifluoromethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester



The 4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]benzoic acid (0.345 g) obtained in Example 6 b) and the 9-(2-hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide (0.300 g) obtained in Example 6 d) were subjected to reactions similar to those in Example 1 g) to give the title compound (0.390 g) as a colorless solid (see Table 52).

Examples 6-2 to 6-22

Compounds of Examples 6-2 to 6-22 were obtained in a similar manner to Examples 6, 1-2 b), 1-2 c) and 1-2 d). The compounds thus obtained were shown in Tables 52 to 56.

Table 52

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
6		2.98(2H, t, J=6.8Hz), 3.63-3.71(2H, m), 3.81(2H, t, J=6.8Hz), 5.27(1H, br), 7.00(1H, brs), 7.12(2H, m), 7.30-7.84(18H, m).
6-2		2.45-2.58(2H, m), 4.10-4.18(1H, m), 4.21(2H, t, J=7.5Hz), 7.02(1H, brs), 7.14-7.88(20H, m).
6-3		3.01(2H, t, J=6.6Hz), 3.60-3.74(2H, m), 3.86(2H, t, J=6.6Hz), 5.27(18H, m), 7.20-7.61(18H, m), 7.75(2H, d, J=6.6Hz), 7.97(1H, brs), 8.52(1H, d, J=8.4Hz).
6-4		3.56(2H, t, J=5.2Hz), 4.06(2H, t, J=5.2Hz), 5.52(1H, br), 7.08(1H, brs), 7.15-7.98(21H, m).
6-5		3.42-3.54(2H, m), 3.55(2H, s), 4.26(2H, t, J=6.6Hz), 5.52(1H, br), 7.06(1H, brs), 7.18-7.88(21H, m).

Table 53

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
6-6		2.31-2,42(1H, m), 2.80-2.93(1H, m), 3.73-3.89(2H, m), 4.16-4.26(1H, m), 4.32-4.43(2H, m), 5.62(1H, br), 7.09((1H, brs), 7.26-8.01(19H, m).
6-7		2.15-2.29(2H, m), 3.34(2H, t, J=7.9Hz), 4.01-4.18(2H, m), 4.40(2H, t, J=6.2Hz), 6.15(1H, br), 7.08(1H, brs), 7.18-7.98(17H, m), 7.92(1H, d, J=8.4Hz).
6-8		2.88(2H, t, J=8.3Hz), 3.83-3.93(2H, m), 4.23(2H, t, J=8.3Hz), 5.90(1H, t, J=6.4Hz), 7.01(1H, brs), 7.16-7.86(22H, m).
6-9		2.12-2.29(1H, m), 2.56-2.68(1H, m), 3.70-3.80(3H, m), 4.09-4.29(2H, m), 5.41(1H, br), 7.05(1H, brs), 7.12-7.78(20H, m), 7.86(1H, d, J=7.5Hz).
6-10		2.16-2.30(2H, m), 2.62-2.72(2H, m), 3.61(1H, t, J=7.5Hz), 3.71-3.99(4H, m), 4.12-4.37(4H, m), 5.67(1H, br), 7.05(1H, brs), 7.15-7.91(17H, m).

Table 54

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
6-11		3.49(2H, t, J=6.9Hz), 4.09-4.29(2H, m), 4.56(2H, t, J=6.9Hz), 6.34(1H, br). 7.08(1H, brs), 7.12-8.00(18H, m).
6-12		2.39-2.50(1H, m), 2.93-3.05(1H, m), 3.78-4.06(2H, m), 4.20-4.41(2H, m), 4.77(1H, d, J=6.4Hz, J=9.6Hz), 5.42(1H, 1H, t, J=6.4Hz), 7.07(1H, brs), 7.19-7.88(15H, m).
6-13		2.19-2.30(1H, m), 2.62-2.73(1H, m), 3.79-3.82(2H, m), 4.20-4.40(3H, m), 5.80(1H, t, J=6.4Hz), 7.06(1H, brs), 7.16-7.92(16H, m).
6-14		1.22(6H, t, J=7.1Hz), 2.77(2H, t, J=6.9Hz), 4.21(4H, q, J=7.1Hz), 4.30(2H, t, J=6.9Hz), 7.06(1H, brs), 7.19-7.88(17H, m)
6-15		1.23(6H, t, J=7.1Hz), 1.64(3H, s), 2.77(2H, t, J=6.9Hz), 4.21(4H, q, J=7.1Hz), 4.29(2H, t, J=6.9Hz), 6.93(1H, brs), 7.20-8.24(16H, m)

Table 55

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
6-16		1.22(3H, t, J=7.1Hz), 1.23(3H, t, J=7.1Hz), 2.76(2H, t, J=6.9Hz), 4.20(2H, q, J=7.1Hz), 4.21(2H, q, J=7.1Hz), 4.29(2H, t, J=6.9Hz), 6.95-7.91(17H, m)
6-17		1.22(6H, t, J=7.1Hz), 2.77(2H, t, J=6.9Hz), 4.20(4H, q, J=7.1Hz), 4.31(2H, t, J=6.9Hz), 6.93(2H, d, J=8.8Hz), 7.26-8.13(13H, m), 7.92(2H, d, J=8.8Hz)
6-18		1.22(6H, t, J=7.1Hz), 2.76(2H, t, J=6.9Hz), 4.20(4H, q, J=7.1Hz), 4.30(2H, t, J=6.9Hz), 6.85(2H, d, J=8.8Hz), 7.21-7.81(13H, m), 7.88(2H, d, J=8.8Hz), 8.21(1H, dd, J=7.6, 1.3)
6-19		1.14(6H, t, J=7.2Hz), 2.63-2.71(2H, m), 3.31(4H, dq, J=5.6, 7.2Hz), 4.29-4.38(2H, m), 7.15-7.20(1H, m), 7.23-7.38(7H, m), 7.41-7.47(1H, m), 7.49-7.63(4H, m), 7.64-7.75(4H, m), 7.81(1H, dd, J=1.5, 7.5Hz), 7.86-7.93(2H, m)
6-20		1.14(6H, t, J=7.1Hz), 2.65-2.74(2H, m), 3.31(4H, dq, J=5.7, 7.1Hz), 4.33-4.43(2H, m), 7.08(1H, d, J=8.3Hz), 7.27-7.44(6H, m), 7.47-7.61(5H, m), 7.63-7.72(3H, m), 7.90(1H, dd, J=1.9, 8.6Hz), 8.07(1H, d, J=1.9Hz), 8.23(1H, dd, J=1.5, 7.9Hz)

Table 56

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
6-21		1.14(6H, t, J=7.2Hz), 2.64-2.73(2H, m), 3.32(4H, dq, J=5.6, 7.2Hz), 4.31-4.41(2H, m), 6.91-6.98(2H, m), 7.26-7.36(5H, m), 7.41(1H, dd, J=1.1, 7.5Hz), 7.47-7.59(3H, m), 7.60-7.71(5H, m), 7.94-8.01(2H, m), 8.11(1H, dd, J=1.1, 7.5Hz)
6-22		1.13(6H, t, J=7.2Hz), 2.66-2.75(2H, m), 3.32(4H, dq, J=5.3, 7.2Hz), 4.36-4.45(2H, m), 7.27-7.46(8H, m), 7.48-7.54(2H, m), 7.55-7.73(4H, m), 7.99(2H, s), 8.32(1H, dd, J=1.1, 7.9Hz)

Example 7

Trans-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester

a) 4-[(4'-Trifluoromethylbiphenyl-2-carbonyl)amino]cyclohexanecarboxylic acid



4-Amino-cyclohexanecarboxylic acid (0.538 g) was dissolved in 4N sodium hydroxide (0.933 mL), and to this solution were dropwise added simultaneously a solution of the acid chloride which is obtained from 4'-trifluoromethylbiphenyl-2-carboxylic acid (1.0 g) in a similar manner to Example 1 d) in tetrahydrofuran (5 mL) and 4N aqueous sodium hydroxide (0.933 mL) under ice-cooling. The mixture was stirred at room temperature for one hour, acidified with 2N hydrochloric acid and extracted with ethyl acetate. The extract was washed with saturated brine and dried over sodium sulfate to give the title compound (1.20 g) as a colorless powdery solid.

b) Trans-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoroethylcarbamoyl)-9H-fluoren-9-yl]ethyl ester



The 4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]cyclohexanecarboxylic acid (0.570 g) obtained in Example 7 a) and 9-(2-hydroxyethyl)-9H-fluoren-9-carboxylic acid (2,2,2-trifluoroethyl)amide (0.500 g) obtained in Example 6 d) were treated in a similar manner to Example 1 g) to give the title compound (0.534 g) as a colorless solid (see Table 57).

Examples 7-2 to 7-5

Compounds of Examples of 7-2 to 7-5 were obtained in a similar manner to Example 7. The compounds thus obtained were shown in Table 57.

Table 57

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
7	 m.p. 156.3-158.0	1.08-1.20(4H, m), 1.28-1.42(4H, m), 1.87-1.94(1H, m), 2.80(2H, t, J=7.1Hz), 3.52(2H, t, J=7.1Hz), 3.65(1H, m), 3.89(1H, br), 5.18(1H, d, J=8.3Hz), 5.25(1H, t, J=6.4Hz), 7.29-7.79(16H, m).
7-2		0.60-0.71(2H, m), 1.05-1.27(2H, m), 1.53-1.86(4H, m), 2.82(2H, t, 6.9Hz), 3.54(2H, t, J=6.9Hz), 3.56-3.73(2H, m), 4.96(1H, d, J=8.3Hz), 5.27(1H, t, J=7.7Hz), 7.30-7.80(16H, m).
7-3		1.33-1.73(8H, m), 2.00-2.13(1H, m), 2.22-2.37(1H, m), 2.45-2.60(1H, m), 3.52(1H, t, J=7.0Hz), 3.66-4.11(4H, m), 5.30(1H, d, J=11.3Hz), 5.72(1H, t, J=8.2Hz), 7.20-7.33(13H, m).
7-4		1.09-1.20(2H, m), 1.24(6H, t, J=7.2Hz), 1.36-1.53(6H, m), 2.27-2.38(1H, m), 3.82-3.95(1H, m), 4.22(4H, q, J=7.2Hz), 4.80(2H, s), 5.21(1H, br-d, J=7.9Hz), 7.22-7.39(6H, m), 7.42-7.57(4H, m), 7.60-7.70(3H, m)
7-5		1.12-2.27(9H, m), 1.24(6H, t, J=7.2Hz), 2.60(2H, t, J=7.2Hz), 3.59-3.78and3.90-4.15(1H, m), 4.02(2H, t, J=7.2Hz), 4.22(4H, q, J=7.2Hz), 4.98and5.30(1H, each d, J=8.4Hz), 7.18-7.22(13H, m) cis,trans mixture

Example 8

2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]piperidin-1-yl}acetoxymethyl)malonic acid diethyl ester

a) 1-Benzyl-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidine



4'-Trifluoromethyl-biphenyl-carboxylic acid (5.0 g) was dissolved in dimethylformamide (50 mL), and to this solution were added at room temperature 4-amino-1-benzylpiperidine (3.55 g), 1-hydroxybenzotriazole hydrate (3.0 g) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (3.58 g). The mixture was stirred at room temperature overnight, and the reaction solution was concentrated in vacuo to precipitate crystals. The crystals were washed successively with saturated aqueous sodium bicarbonate and water, and dried in vacuo to give the title compound (7.42 g).

b) 4-(4'-Trifluoromethylbiphenyl-2-carbonylamino)piperidine



To a solution of the 1-benzyl-4-(4'-

trifluoromethylbiphenyl-2-carbonylamino)piperidine (1.47 g) obtained in Example 8 a) in tetrahydrofuran-methanol (1:1; 50 mL) was added palladium hydroxide (300 mg) in a stream of argon under ice-cooling. The mixture was stirred for one day at normal pressure under hydrogen atmosphere, and further stirred for one day at normal pressure under hydrogen atmosphere after further addition of palladium hydroxide (300 mg). The reaction mixture was filtered through a Celite pad and washed with methanol. The filtrate and the washings were combined, concentrated in vacuo and purified by column chromatography on silica gel with chloroform:methanol:aqueous ammonia=100:10:1 to give the title compound (1.03 g).

c) [4-(4'-Trifluoromethylbiphenyl-2-carbonyl-amino)piperidin-1-yl]acetic acid ethyl ester



To a solution of 4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidine (1.03 g) obtained in Example 8 b) in dimethylformamide (5 mL) were added potassium carbonate (276 mg) and bromoacetic acid ethyl ester (223 μL). The mixture was stirred overnight at ambient temperature of 90°C, and then concentrated in vacuo. The residue was distributed with water and chloroform, and the aqueous layer was further extracted with chloroform. The organic layers were combined, washed with

saturated brine, dried over sodium sulfate, concentrated in vacuo and purified by column chromatography on silica gel with chloroform:methanol=30:1 to give the title compound (598 mg).

d) [4-(4'-Trifluoromethylbiphenyl-2-carbonyl-amino)piperidin-1-yl]acetic acid



To a solution of [4-(4'-trifluoromethylbiphenyl-2-carbonylamino)piperidin-1-yl]acetic acid ethyl ester (595 mg) obtained in Example 8 c) in tetrahydrofuran-methanol (1:2; 10.2 mL) was added 1M aqueous lithium hydroxide (6.8 mL), and the mixture was stirred at room temperature for 6 hours. The reaction solution was concentrated in vacuo and 2N hydrochloric acid was added to the residue to adjust the pH to about 3, thereby crystals were precipitated. The crystals were collected by filtration, washed with cold water and dried in vacuo to give the title compound (411 mg).

e) 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]piperidin-1-yl}acetoxymethyl)malonic acid diethyl ester



The [4-(4'-trifluoromethylbiphenyl-2-carbonyl-amino)piperidin-1-yl]acetic acid obtained in Example 8 d) and the 2-hydroxymethyl-2-phenylmalonic acid diethyl ester obtained in Example 1-2 a) were subjected to reactions similar to those in Example 1 g) to give the title compound (90 mg) (see Table 58).

Table 58

Example	structure	NMR(δ,300MHz, $CDCl_3$)
8		1.07-1.19(2H, m), 1.25(6H, t, J=7.0Hz), 1.54-1.68(2H, m), 2.10-2.22(2H, m), 2.52-2.62(2H, m), 3.08(2H, s), 3.70-3.85(1H, m), 4.24(4H, q, J=7.0Hz), 4.85(2H, s), 5.07-5.16(1H, m), 7.28-7.39(6H, m), 7.42-7.57(4H, m), 7.61-7.71(3H, m)

Example 9

2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]indol-1-yl}acetoxymethyl)malonic acid diethyl ester

a) (4-Nitroindol-1-yl)acetic acid ethyl ester



Sodium hydride (60% /mineral oil:81 mg) was dissolved in dimethylformamide (5 mL), and the solution was cooled to 0°C. After addition of 4-nitroindole (300 mg), the mixture was stirred for one hour, and bromoacetic acid ethyl ester (340 mg) was added thereto, followed by stirring at 0°C for 4 hours. Water was added thereto and the mixture was concentrated, diluted with ethyl acetate, washed with water, dried over sodium sulfate, then concentrated to give the title compound (367 mg).

b) (4-Nitroindol-1-yl)acetic acid

The (4-nitroindol-1-yl)acetic acid ethyl ester obtained in Example 9 a) was subjected to reactions similar to those in Example 1 f) to give the title compound (243 mg).

c) 2-[2-(3-Nitroindol-1-yl)acetoxymethyl]-2-phenylmalonic acid diethyl ester



The (4-nitroindol-1-yl)acetic acid (229 mg) obtained in Example 9 b), 4-dimethylaminopyridine (143 mg) and the

2-hydroxymethyl-2-phenylmalonic acid diethyl ester (240 mg) obtained in Example 1-2 a) were subjected to reactions similar to those in Example 1-3 c) to give the title compound (301 mg).

d) 2-[2-(4-Aminoindol-1-yl)acetoxymethyl]-2-phenylmalonic acid diethyl ester



The 2-[2-(3-Nitroindol-1-yl)acetoxymethyl]-2-phenylmalonic acid diethyl ester (100 mg) obtained in Example 9 c) was dissolved in tetrahydrofuran (2 mL), ethanol (4 mL) and water (1 mL), and to the solution were added ammonium chloride (57 mg) and reduced iron (60 mg). The mixture was stirred at 100°C for 2 hours, cooled, and filtered through a Celite pad. The filtrate was concentrated and diluted with ethyl acetate. The extract was washed successively with saturated aqueous sodium bicarbonate, water and saturated brine, dried over sodium sulfate, and concentrated to give the title compound (93 mg).

e) 2-Phenyl-2-(2-{4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]indol-1-yl}acetoxymethyl)malonic acid diethyl ester



The 2-[2-(4-aminoindol-1-yl)acetoxymethyl]-2-

phenylmalonic acid diethyl ester obtained in Example 9 d) was treated in a similar manner to Example 1 e) to give the title compound (119 mg)(see Table 59).

Example 9-2

2-(2-{2-methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl}amino]benzimidazol-1-yl}acetoxymethyl)-2-phenyl-malonic acid diethyl ester

a) 2-Methyl-4-nitro-1H-benzimidazole



3-Nitrobenzene-1,2-diamine (1.0 g) was dissolved in ethanol (90 mL) and 5N hydrochloric acid (24 mL), and to this solution was added 2,4-pentanedione (1.3 g). The mixture was heated for 3 hours under reflux, cooled down to room temperature and concentrated. To this concentrate was added ethyl acetate, and the mixture was washed successively with saturated aqueous sodium bicarbonate and water, and dried over sodium sulfate to give the title compound (1.1 g).

b) (2-Methyl-4-nitrobenzimidazol-1-yl)acetic acid ethyl ester



The 2-methyl-4-nitro-1H-benzimidazole (1.1 g) obtained in Example 9-2 a) was subjected to reactions similar to those in Example 9 a) to give the title compound (1.44 g).

c) 2-(2-{2-Methyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]benzimidazol-1-yl}acetoxymethyl)-2-phenylmalonic acid diethyl ester



The (2-Methyl-4-nitrobenzimidazol-1-yl)acetic acid ethyl ester (500 mg) obtained in Example 9-2 b) was subjected to reactions similar to those in Examples 9 d), 1 d), 1 e), 1 f) and 1 g) to give the title compound (152 mg)(see Table 59).

Example 9-3

[2-Oxo-3-(4'-trifluoromethylbiphenyl-2-carbonyl)-2,3-dihydrobenzoxazol-6-yl]acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester



The {3-Hydroxy-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetic acid 2,2-bisethylcarbamoyl-2-phenylethyl ester (195 mg) obtained in Example 3-2 was dissolved in chloroform (5 mL), and to this solution was added triethylamine (72 mg). The solution was cooled to 0°C and triphosgene (35 mg) was added thereto. After stirring for one hour, the reaction solution was washed with water, dried over sodium sulfate and purified by column chromatography on silica gel with hexane:ethyl acetate=1:1 to give the title compound (173 mg)(see Table 59).

Example 9-4

2-(2-{3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester

a) 5-Chloro-2-nitrobenzoic acid chloride

5-Chloro-2-nitrobenzoic acid was subjected to reactions similar to those in Example 1 d) to give the title compound.

b) 5-Chloro-2-nitrobenzoic acid ethyl ester



To a mixture of ethanol (1.23 mL), triethylamine (3.05 mL) and tetrahydrofuran (35 mL) was dropwise added a solution of 5-chloro-2-nitrobenzoic acid chloride (4.44 g) obtained in Example 9-4 a) in tetrahydrofuran (10 mL) under ice-cooling. The mixture was stirred at room temperature overnight, and water was then added. The solution was diluted with ethyl acetate, and the organic layer was washed successively with saturated aqueous sodium bicarbonate and saturated brine, dried over sodium sulfate and concentrated to give the title compound (4.43 g) as a pale brown solid.

c) 3-Ethoxycarbonyl-4-nitrophenylmalonic acid dibenzyl ester



The 5-chloro-2-nitrobenzoic acid ethyl ester (4.40 g) obtained in Example 9-4 b) and malonic acid dibenzyl ester were subjected to reactions similar to those in Example 1-3 a) to give the title compound (4.61 g).

d) 4-Amino-3-ethoxycarbonylphenylacetic acid



The 3-ethoxycarbonyl-4-nitrophenylmalonic acid

dibenzyl ester (1.51 g) obtained in Example 9-4 c) was subjected to reactions similar to those in Example 1-3 d) to give the title compound (4.59 g).

e) 3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid



The 4-amino-3-ethoxycarbonylphenylacetic acid (1.51 g) obtained in Example 9-4 d) and 4'-trifluoromethylbiphenyl-2-carboxylic acid chloride (1.99 g) were subjected to reactions similar to those in Example 7 a) with the proviso that sodium bicarbonate was used as a base, thereby the title compound (1.87 g) was given as a pale yellow amorphous powder.

f) 2-(2-{3-Ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetoxymethyl)-2-phenylmalonic acid diethyl ester



The 3-ethoxycarbonyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)amino]phenylacetic acid (0.532 g) obtained in Example 9-4 e) and the 2-hydroxymethyl-2-phenylmalonic acid diethyl ester (1.04 g) obtained in Example 1-2 a) were treated in a similar manner to Example 1 g) to give the title compound (0.524 g)(see Table 59).

Example 9-5

2-(3-{3-Dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester

a) 5-Methyl-2-nitrobenzoic acid chloride

5-Methyl-2-nitrobenzoic acid was treated in a similar manner to Example 1 d) to give the title compound.

b) 5, N, N-Trimethyl-2-nitrobenzamide



The 5-methyl-2-nitrobenzoic acid chloride obtained in Example 9-5 a) was treated in a similar manner to Example 1 e) to give the title compound.

c) 5-Bromomethyl-N,N-dimethyl-2-nitrobenzamide



The 5, N, N-Trimethyl-2-nitrobenzamide (4.16 g) obtained in Example 9-5 b), N-bromosuccinimide (3.56 g) and 2,2'-azobisisobutyronitrile (328 mg) were suspended in carbon tetrachloride (80 mL). The suspension was stirred at 90°C for 2 hours, filtered through a Celite pad and purified by column chromatography on silica gel with hexane:ethyl acetate=5:4 to give the title compound (602 mg).

d) 3-(3-Dimethylcarbamoyl-4-nitrophenyl)-2-methoxycarbonylpropionic acid benzyl ester



The 5-bromomethyl-N,N-dimethyl-2-nitrobenzamide (0.597 g) obtained in Example 9-5 c) and malonic acid benzyl ester methyl ester were subjected to reactions similar to those in Example 9-4 c) to give the title compound (0.491 g).

e) 3-(4-Amino-3-dimethylcarbamoylphenyl)-2-methoxycarbonyl-propionic acid



The 3-(3-dimethylcarbamoyl-4-nitrophenyl)-2-methoxycarbonyl-propionic acid benzyl ester (0.490 g) obtained in Example 9-5 d) was subjected to reactions similar to those in Example 1-2 c) to give the title compound (0.353 g).

f) 3-(4-Amino-3-dimethylcarbamoylphenyl)propionic acid methyl ester



The 3-(4-amino-3-dimethylcarbamoylphenyl)-2-methoxycarbonylpropionic acid (347 mg) obtained in Example 9-5 e) was stirred at 150°C for 40 minutes, cooled down to room temperature, and purified by column chromatography on silica gel with hexane:ethyl acetate (1:1 to 0:1) to give the title compound (180 mg).

g) 2-(3-{3-Dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]phenyl}propionyloxymethyl)-2-phenylmalonic acid diethyl ester



The 3-(4-amino-3-dimethylcarbamoylphenyl)propionic acid methyl ester (0.138 g) obtained in Example 9-5 f) was subjected to reactions similar to those in Examples 1 e), 1 f) and 1 g) to give the title compound (0.158 g)(see Table 59).

Examples 9-6 to 9-29

Compounds of Examples 9-6 to 9-29 were obtained in a similar manner to Examples 9 to 9-5. The compounds thus obtained were shown in Tables 59 to 64.

Table 59

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9		1.18(6H, t, J=7.2Hz),4.15(4H, q, J=7.2Hz), 4.73(2H, s), 4.85(2H, s), 5.56(1H, d, J=3.0Hz), 6.85(1H, d, J=3.4Hz), 6.91 (1H, d, J=8.3Hz), 7.16-7.78(16H, m), 7.92(1H, d, J=6.8Hz)
9-2		1.17(6H, t, J=7.1Hz), 2.38(3H, s), 4.13(4H, q, J=7.1Hz), 4.70(2H, s), 4.87(2H, s), 6.84(1H, d, J=7.9Hz), 7.12-7.63(13H, m), 7.80(1H, dd, J=7.5, 1.5Hz), 8.18(1H, d, J=7.9Hz), 8.41(1H, s)
9-3		1.08(6H, t, J=7.2Hz), 3.27(4H, dq, J=7.2, 7.2Hz), 3.61(2H, s), 4.88(2H, s), 6.93(1H, d, J=1.1Hz), 7.04(1H, dd, J=8.3, 1.5Hz), 7.11-7.70(15H, m), 7.79(1H, d, J=8.3Hz)
9-4		1.21(6H, t, J=7.1Hz), 1.35(3H, t, J=7.1Hz), 3.55(2H, s), 4.15-4.30(6H, m), 4.83(2H, s), 7.24-7.38(6H, m), 7.41-7.47(1H, m), 7.48-7.62(6H, m), 7.76(1H, dd, J=1.5, 7.5Hz), 7.81(1H, d, J=1.9Hz), 8.68(1H, d, J=8.7Hz), 11.23(1H, br-s)
9-5		1.24(6H, t, J=7.0Hz), 2.53(2H, t, J=7.3Hz), 2.76-3.00(6H, br), 2.81(2H, t, J=7.3Hz), 4.24(4H, q, J=7.0Hz), 4.81(2H, s), 6.96(1H, d, J=2.3Hz), 7.17(1H, dd, J=1.2, 8.4Hz), 7.29-7.37(5H, m), 7.37-7.42(1H, m), 7.44-7.57(2H, m), 7.60-7.64(4H, m), 7.68(1H, dd, J=1.5, 7.4Hz), 8.28(1H, d, J=8.4Hz), 9.05(1H, br-s)

Table 60

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9-6		1.12(6H, t, J=7.2Hz), 3.30(4H, dq, J=5.7, 7.2Hz), 4.39(2H, d, J=6.0Hz), 5.08(2H, s), 5.59(1H, br-t, J=6.0Hz), 6.97-7.03(2H, m), 7.28-7.42(8H, m), 7.43-7.55(4H, m), 7.56-7.61(2H, m), 7.66-7.71(1H, m), 7.76-7.83(2H, m)
9-7		1.08(3H, t, J=7.2Hz), 2.64-2.82(2H, m), 2.86-2.97(2H, m), 3.13-3.36(2H, m), 5.87-5.98(1H, br), 6.03(1H, s), 7.00(1H, s), 7.04-7.15(4H, m), 7.30-7.40(5H, m), 7.43(1H, dd, J=1.1, 7.5Hz), 7.48-7.63(4H, m), 7.63-7.71(2H, m), 7.78(1H, dd, J=1.5, 7.5Hz)
9-8		1.04(6H, t, J=7.2Hz), 3.23(4H, dq, J=5.7, 7.2Hz), 3.55(2H, s), 4.85(2H, s), 5.23(2H, s), 7.08(2H, br-t, J=5.7Hz), 7.14-7.22(2H, m), 7.23-7.47(10H, m), 7.48-7.64(6H, m), 7.76(1H, dd, J=1.5, 7.1Hz), 7.81(1H, d, J=2.2Hz), 8.69(1H, d, J=8.7Hz), 11.17(1H, br-s)
9-9		1.05(6H, t, J=7.2Hz), 3.25(4H, dq, J=5.6, 7.2Hz), 3.58(2H, s), 4.86(2H, s), 7.11-7.63(15H, m), 7.72(1H, dd, J=1.5, 7.5Hz), 7.83(1H, d, J=1.9Hz), 8.66(1H, d, J=8.6Hz), 11.10(1H, br-s)
9-10		1.07(6H, t, J=7.2Hz), 1.36(3H, t, J=7.2Hz), 3.26(4H, dq, J=5.4, 7.2Hz), 3.58(2H, s), 4.26(2H, q, J=7.2Hz), 4.86(2H, s), 7.10(2H, br-t, J=5.4Hz), 7.16-7.37(6H, m), 7.40-7.64(7H, m), 7.77(1H, dd, J=1.9, 7.1Hz), 7.80(1H, d, J=1.9Hz), 8.69(1H, d, J=8.7Hz), 11.22(1H, br-s)

Table 61

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9-11		1.19(6H, t, J=7.2Hz), 4.17(4H, q, J=7.2Hz), 4.79(2H, s), 4.90(2H, s), 6.94(1H, d, J=8.0Hz), 7.15-7.63(13H, m), 7.82(1H, d, J=7.5Hz), 8.25(1H, d, J=8.0Hz), 8.47(1H, br.s)
9-12	 m.p 139.4-141.0	1.15(6H, t, J=7.2Hz), 2.64-2.73(2H, m), 3.32(4H, dq, J=5.3, 7.2Hz), 4.31-4.44(2H, m), 4.41(2H, d, J=6.0Hz), 5.62(1H, br-t, J=6.0Hz), 7.10-7.16(1H, m), 7.24-7.39(7H, m), 7.42-7.58(6H, m), 7.62-7.72(3H, m), 7.74-7.78(1H, m), 7.85-7.92(1H, m)
9-13		1.07(6H, t, J=7.1Hz), 3.26(4H, dq, J=5.7, 7.1Hz), 3.57(2H, s), 3.81(3H, s), 4.86(2H, s), 7.10(6H, br-t, J=5.7Hz), 7.16-7.23(2H, m), 7.25-7.37(4H, m), 7.41-7.63(7H, m), 7.77(1H, dd, J=1.5, 7.5Hz), 7.80(1H, d, J=2.2Hz), 8.68(1H, d, J=8.3Hz), 11.15(1H, br-s)
9-14		1.19(6H, t, J=7.0Hz), 3.52(2H, s), 4.19(4H, q, J=7.0Hz), 4.82(2H, s), 5.23(2H, s), 7.24-7.29(5H, m), 7.32-7.46(7H, m), 7.49-7.62(6H, m), 7.74-7.79(1H, m), 7.82(1H, d, J=2.2Hz), 8.67(1H, d, J=8.8Hz), 11.17(1H, br-s)
9-15		1.21(6H, t, J=7.1Hz), 3.56(2H, s), 4.21(4H, q, J=7.1Hz), 4.85(2H, s), 7.23-7.32(5H, m), 7.36-7.63(8H, m), 7.77(1H, dd, J=1.5, 7.5Hz), 7.86(1H, d, J=1.9Hz), 8.70(1H, br-d, J=8.3Hz), 10.89(1H, br-s)

Table 62

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9-16		1.22(6H, t, J=7.1Hz), 3.57(2H, s), 4.23(4H, q, J=7.1Hz), 4.85(2H, s), 6.92(1H, s), 7.03(1H, d, J=8.3Hz), 7.30-7.69(13H, m), 7.77(1H, d, J=8.3Hz)
9-17		1.23(6H, t, J=7.1Hz), 3.67(2H, s), 4.23(4H, q, J=7.1Hz), 4.85(2H, s), 7.23-7.34(6H, m), 7.42-7.49(3H, m), 7.52-7.67(5H, m), 7.95(1H, d, J=1.9Hz), 8.05(1H, dd, J=1.5, 7.5Hz)
9-18		1.21(6H, t, J=7.2Hz), 1.31(6H, d, J=6.4Hz), 3.55(2H, s), 4.21(4H, q, J=7.2Hz), 4.83(2H, s), 5.09(1H, sept, J=6.4Hz), 7.24-7.38(6H, m), 7.41-7.47(1H, m), 7.48-7.62(6H, m), 7.73-7.81(2H, m), 8.68(1H, d, J=8.6Hz), 11.33(1H, br-s)
9-19		1.21(6H, t, J=7.1Hz), 3.54(2H, s), 3.80(3H, s), 4.21(4H, q, J=7.1Hz), 4.83(2H, s), 7.24-7.38(6H, m), 7.44(1H, dd, J=1.6, 7.1Hz), 7.50-7.62(6H, m), 7.77(1H, dd, J=1.5, 7.1Hz), 7.81(1H, d, J=2.3Hz), 8.67(1H, d, J=8.7Hz), 11.15(1H, br-s)
9-20		1.21(6H, t, J=7.1Hz), 1.85-2.03(2H, m), 2.05-2.27(2H, m), 2.50-2.67(1H, m), 2.81(3H, brs), 2.88(3H, brs), 3.02-3.16(1H, m), 3.51(2H, s), 3.71-3.86(1H, m), 4.20(4H, q, J=7.1Hz), 4.82(2H, s), 6.99(1H, d, J=9.0Hz), 7.05(1H, d, J=1.8 Hz), 7.18(1H, dd, J=1.9Hz, J=8.3Hz), 7.22-7.37(5H, m), 7.56(1H, dd, J=1.8H, J=9.0Hz), 8.01(1H, brs), 8.08(1H, d, J=8.3Hz), 9.29(1H, brs).

Table 63

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9-21		1.18(6H, t, J=7.1Hz), 2.03(3H, s), 3.53(2H, s), 4.14(4H, q, J=7.1Hz), 4.86(2H, s), 6.97-7.05(2H, m), 7.24-7.81(15H, m), 8.35(1H, brs).
9-22	 mp 146.4-148.6	1.20(6H, t, J=7.2Hz), 3.52(2H, s), 3.72(3H, s), 4.18(4H, q, J=7.2Hz), 4.83(2H, s), 6.83(1H, brs), 4.95(1H, dd, J=1.8Hz, J=8.3Hz), 7.14(1H, d, J=8.3Hz), 7.18-7.80(15H, m).
9-23		1.20(6H, t, J=7.1Hz), 2.36(3H, s), 3.57(2H, s), 4.20(4H, q, J=7.1Hz), 4.85(2H, s), 6.85(1H, s), 7.18-7.59(14H, m), 8.67 (1H, d, J=8.6Hz), 12.71(1H, brs)
9-24		1.19(6H, t, J=7.2Hz), 3.53(2H, s), 4.17(4H, q, J=7.2Hz), 4.82(2H, s), 6.89-6.96(3H, m), 7.17-7.55(17H, m), 7.67 (1H, dd, J=1.5, 7.5Hz), 8.45(1H, d, J=8.7Hz)
9-25		1.21(6H, t, J=7.1Hz), 3.59(2H, s), 4.21(4H, q, J=7.1Hz), 4.87(2H, s), 7.27-7.78(15H, m), 8.67(1H, d, J=8.3Hz), 9.61(1H, brs), 11.1(1H, brs)

Table 64

Example	Structure	NMR (δ,300MHz,$CDCl_3$)
9-26		1.20(6H, t, J=7.0Hz), 1.94(6H, s), 3.14(2H, s), 3.48(2H, s), 4.19(4H, q, J=7.0Hz), 4.81(2H, s), 6.83(1H, d, J=2.0Hz), 7.08(1H, dd, J=2.0, 8.0Hz), 7.27-7.59(12H, m), 7.68(1H, dd, J=1.2, 7.6Hz), 8.22(1H, d, J=8.5Hz), 10.7(1H, brs)
9-27		1.21(6H, t, J=7.1Hz), 3.20(3H, s), 3.36(3H, s), 3.52(2H, s), 4.21(4H, q, J=7.1Hz), 4.82(2H, s), 7.23-7.61(14H, m), 7.71(1H, d, J=7.3Hz), 8.31(1H, d, J=8.4Hz), 9.49(1H, brs)
9-28		1.06(6H, d, J=6.9Hz), 1.20(6H, t, J=7.2Hz), 3.42-3.51(1H, m), 3.56(2H, s), 4.20(4H, q, J=7.2Hz), 4.85(2H, s), 7.28-7.77(15H, m), 8.72(1H, d, J=8.7Hz), 11.81(1H, brs)
9-29		0.49(3H, d, J=6.6Hz), 0.90(3H, d, J=6.6Hz), 1.14-1.25(6H, m), 1.40-1.58(1H, m), 2.41(1H, d, J=3.6Hz), 3.51(2H, d, J=3.6Hz), 3.81-3.88(1H, m), 4.02-4.18(4H, m), 4.83(2H, s), 6.79(1H, s), 7.05-7.69(14H, m), 8.19(1H, d, J=8.1Hz), 9.01(1H, brs)

Table 65

Compound	structure	NMR(δ, 300MHz, $CDCl_3$)
2 e)		2.86(3H, brs), 2.93(3H, brs), 3.56(2H, s), 7.09(1H, d, J=2.0Hz), 7.23-7.71(9H, m), 8.29(1H, d, J=8.7Hz), 9.06(1H, brs).
2-17 e)		1.75-1.99(4H, m), 3.32-3.52(4H, m),3.53(2H, s), 7.20-7.69(10H, m), 8.22(1H, d, J=4.4Hz), 9.74(1H, brs).

Formulation

Hereinafter, the present invention will be illustrated specifically by references of formulations.

Formulation 1

A film with a controlled thickness was prepared by use of a gelatin shell composition (a) in accordance with the conventional method. Two sheets of the film were inserted into a rotating left-right symmetric metallic die rolls and molded into outer shells of soft capsules, while a filling solution (b) was injected into the outer shells of the soft capsules, and simultaneously the outer shells of the softcapsules were

melted and sealed by the rotation of the die rolls, then the capsules were cut from the film. The capsules were dried in a rotary dryer, and allowed to dry for 4 days to give soft capsules. Hereinafter, specific examples of formulations were given.

Formulation 1-1

(a) film composition

gelatin	100 parts
sugar alcohol solution derived from corn starch	30 parts
purified water	100 parts

(b) filling solution (per capsule)

propylene glycol fatty acid ester	295 mg
ethanol	105 mg

Formulation 1-2

(a) film composition

gelatin	100 parts
sugar alcohol solution derived from corn starch	30 parts
purified water	100 parts

(b) filling solution (per capsule)

compound of Example 2-5	5 mg
propylene glycol fatty acid ester	291 mg
ethanol	104 mg

Formulation 1-3

(a) film composition

gelatin	100 parts
sugar alcohol solution derived from corn starch	30 parts

purified water	100 parts

(b) filling solution (per capsule)

compound of Example 2-5	5 mg
propylene glycol fatty acid ester	277 mg
ethanol	148 mg

Formulation 2

The compound of Example 2-22, an excipient and a binder were mixed in a usual method to prepare granulated powder. The powder obtained was blended with a disintegrator and a lubricant to prepare a powder for tablets in a usual method. The powder was compressed to give tablets in a usual method. Specific examples of formulations were hereinafter given.

Formulation 2-1

compound of Example 2-22	5 mg
lactose	133.06 mg
crystalline cellulose	18 mg
hydroxypropyl methylcellulose 2910	5.4 mg
crospovidone	18 mg
magnesium stearate	0.54 mg

Formulation 2-2

compound of Example 2-22	5 mg
lactose	92.44 mg
corn starch	15 mg
hydroxypropyl methylcellulose 2910	3.6 mg
carboxymethyl starch	3.6 mg
magnesium stearate	0.36 mg

Formulation 2-3

compound of Example 2-22	5 mg
D-mannitol	158.4 mg

hydroxypropyl methylcellulose 2910	6 mg
calcium silicate	20 mg
crospovidone	10 mg
magnesium stearate	0.6 mg

Pharmacological test

Test Example 1

Inhibition of interliposomal triglyceride (TG) transfer activity by MTP

Microsomal triglyceride transfer protein (MTP) from bovine liver was partially purified in such a way described below. A buffer (50 mM Tris, 250 mM sucrose, 1 mM EDTA, 0.02% NaN_3 (pH 7.4)) for making a homogenate preparation was added to bovine liver, and the mixture was homogenated under ice-cooling, then centrifuged at 10,000 × g (4°C, 30 minutes). The supernatant was adjusted to pH 5.1 with hydrochloric acid, and stirred for 30 minutes. The solution was further centrifuged at 10,000 × g (4°C, 30 minutes), and 1 mM Tris buffer was added to the precipitated residue, and the mixture was adjusted to pH 8.6 with sodium hydroxide. After addition of 2.7M ammonium sulfate solution, the mixture was stirred for 30 minutes, then centrifuged at 10,000 × g (4°C, 40 minutes). The resulting supernatant was served as a crude extraction fraction of MTP and stored at -80°C under freezing. In its practical use, the crude extraction fraction of MTP was purified by column chromatography on diethylaminoethyl (DEAE) Sepharose using FPLC (Fast Performance Liquid Chromatography) system, and the purified MTP was used for the test.

Small unilamellar-vesicle (SUV) liposome (donor, 0.25

mol% triolein, 5 mol% cardiolipin) labeled with ^{14}C-triolein and non-labeled SUV liposome (acceptor, 0.25 mol% triolein) were prepared. A fixed amount of donor and acceptor, and MTP were mixed with a sample dissolved in DMSO or with DMSO. The mixture was incubated in a 15 mM Tris hydrochloride buffer (pH 7.4) containing 40 mM sodium chloride, 1 mM EDTA (ethylenediaminetetraacetic acid), 0.02% NaN_3 and 0.5% bovine serum albumin at 37°C for one hour. After completion of the incubation, a suspension of DEAE cellulose (50% v/v) in 15 mM Tris hydrochloride buffer (pH 7.4) was added to the above solution, and the mixture was centrifuged to separate the donor and the acceptor. The radioactivity in the acceptor was measured by liquid scintillation counter. The value obtained by subtracting the radioactivity in the blank from the amount of radioactivity in the acceptor of a DMSO group was determined as MTP-mediated TG transfer activity, and it was compared with the value obtained by subtracting the radioactivity in the blank from the radioactivity in a sample group. The blank was prepared by adding 15 mM Tris-HCl buffer (pH 7.4) in place of MTP. Inhibition rate (%) was calculated from the values obtained according to the following equation.

Inhibition rate (%) = 100 × (1 minus ((radioactivity of sample group minus radioactivity of blank group)/ (radioactivity of DMSO group minus radioactivity of blank group))).

50% Inhibition rate (IC_{50}) was determined on the basis of the above equation. The results were shown in Table 66 to 70.

Test Example 2

Inhibition of apolipoprotein B secretion from HepG2 cells

HepG2 cells were suspended in Dulbecco's Modified Eagle's Medium (DMEM)(containing 10% fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin), and placed on a 96-well plate (4×10^4 cells/well), then incubated for 24 hours. After removal of the medium, DMEM was replaced by a medium containing a sample dissolved in DMSO or a medium containing DMSO (concentration of DMSO: 0.5%) and incubation was further performed for 24 hours, after which the supernatant was recovered, and concentration of apo B in the supernatant was assayed by Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA was carried out as follows. Anti-human apo B monoclonal antibody (0.5 μg/well) diluted with a solution of sodium carbonate in sodium bicarbonate buffer (50 mL, pH 9.6) was placed in a 96-well plate for ELISA, and allowed to stand at room temperature for 15 hours. After washing the plate, a blocking solution (250 μL/well) was placed in the well, and allowed to stand at room temperature for 1.5 hours. After washing the plate, a standard and a sample (100 μL/well) were placed in the well and allowed to stand at room temperature for one hour. The standard was prepared by adjusting the concentration of the purified human apo B with the DMEM to 0 to 1000ng/mL. After washing the plate, an anti-human apo B polyclonal antibody labeled with a horse radish peroxidase which was diluted in 1:1000 with DEME (100 μL/well), and allowed to stand at room temperature for one hour. After washing the plate, 2,2-azinobis(3- ethylbenzothiazoline-6-sulfonic acid) solution (100 μL/well) was placed in the well, and allowed to

stand at room temperature for one hour. The reaction was stopped by addition of 2% oxalic acid (100 μL/well), and absorbency at 405 nm was measured. Concentration of apo B in the sample was calculated on the basis of a standard curve of the standard. Inhibition rate (%) was calculated from the assayed values in accordance with the following equation.

Inhibition rate (%) = 100 × (1 minus (concentration of apo B in sample group/concentration of apo B in DMSO group).

Based on the above equation, 50% inhibition concentration (IC_{50}) was determined.

The results were shown in Tables 66 to 70.

Table 66

Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)	Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example Inhibition o apo B secreti IC_{50}(nM)
1	0.6	5.8	1-2	42	850
1-3	4.7	5.75	1-4	3.4	190
1-5	0.66	0.65	1-6	1.2	5.5
1-7	7.55	330	1-8	37.5	720
1-9	5.95	3.2	1-11	32	22
1-12	7.6	63	1-13	5.8	170
1-14	82	55	1-22	66.5	179.5
1-23	54	63	1-25	5	8.4
1-26	630	620	1-27	7	26
1-28	35	640	1-31	84.5	61
1-32	8.6	720	1-34	23	100
1-35	1.0	6.9	1-36	2.0	150
1-37	3.5	47	1-38	6.0	320
1-39	0.66	160	1-40	6.9	2.1
1-42	4.4	35	1-45	0.39	0.46
1-47	4.5	750	1-48	3.2	9.7
1-49	20	5.3	1-51	0.96	530
1-52	10	690	1-53	0.43	860
1-62	5.0	46	1-63	16	90
1-66	16	9.3	1-67	27	28
1-69	9.1	90	1-70	1.6	270
1-71	1.8	120	1-72	0.44	2.7
1-73	-	39	1-74	-	680

Table 67

Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)	Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Examp Inhibition apo B secr IC_{50}(nM
1-75	-	97	1-76	-	120
1-77	-	360	1-78	-	11
1-79	-	0.59	1-80	-	8.2
1-81	-	0.49	1-82	-	0.53
1-83	-	0.23	1-84	-	4.4
1-85	-	3.2	-	-	-
2	0.62	1.5	2-2	1.4	1.3
2-3	2.1	2.0	2-4	0.94	0.2
2-5	1.4	0.55	2-7	1.1	0.5
2-8	-	0.99	2-10	-	1.4
2-12	-	7.0	2-13	-	0.7
2-14	-	1.2	2-15	-	0.5
2-16	-	2.7	2-18	-	0.6
2-19	-	26	2-20	-	0.6
2-21	1.8	8.9	2-22	1.4	0.4
2-23	2.7	0.61	2-24	-	28
2-25	-	6.3	2-26	-	8.2
2-29	-	91	2-30	-	27
2-31	-	43	2-32	-	1.7
2-33	-	13	2-34	-	2.0
2-35	-	38	2-36	-	7.4
2-39	0.74	0.76	2-40	-	0.9
2-41	-	1.2	2-42	-	1.8

Table 68

Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)	Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)
2-43	-	9.0	2-44	-	33
2-45	-	39	2-46	-	2.9
2-47	-	1.2	2-48	-	0.36
2-49	-	49	2-50	-	21
2-51	-	47	2-53	-	4.6
2-54	-	8.5	2-55	-	4.2
2-56	-	0.93	2-57	-	0.56
2-58	-	1.9	2-59	-	0.99
2-60	-	1.3	2-61	-	0.38
2-62	-	0.37	2-66	-	57
2-67	-	43	2-68	-	2.25
2-69	-	0.91	2-70	-	2.34
2-71	-	0.54	2-72	-	0.95
2-73	-	2.93	2-74	-	0.84
2-75	-	12.54	2-76	-	0.85
2-77	-	2.74	2-78	-	0.14
2-79	-	1.3	2-80	-	0.79
2-81	-	0.96	2-82	-	4.41
2-83	-	8.87	2-84	-	2.01
2-85	-	0.49	2-86	-	0.42
2-88	-	1.92	2-90	-	1.74
2-91	-	0.54	2-92	-	1.47
2-93	-	45.8	2-95	-	18

Table 69

Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)	Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example Inhibition of apo B secreti IC_{50}(nM)
2-96	-	81	2-97	-	22
2-98	-	0.97	2-99	-	19
2-102	-	14.63	2-103	-	42.6
2-104	-	3.58	2-105	-	0.2
2-106	-	0.44	2-107	-	50
2-108	-	0.82	2-109	-	0.93
2-110	-	0.65	2-114	-	3.1
2-115	-	44	2-117	-	38
2-118	-	49	-	-	-
3	-	1.9	3-2	-	4.2
3-3	0.40	1.0	3-4	2.1	13
3-5	-	2.2	3-6	5.0	0.63
3-7	-	0.35	3-8	3.7	0.38
3-9	-	1.6	3-10	2.7	0.31
3-11	-	0.36	3-12	-	0.72
3-13	-	1.9	3-14	13	64
3-15	-	49.9	-	-	-
4	-	0.33	4-2	-	16
4-3	-	7.9	4-5	-	5.2
4-6	-	7.5	4-7	-	15
4-8	-	10	-	-	-
5	3.1	19	5-2	66.5	875
5-3	6.2	86.5	5-4	2.4	57

Table 70

Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)	Example	Test Example 1 MTP inhibition IC_{50}(nM)	Test Example 2 Inhibition of apo B secretion IC_{50}(nM)
5-5	4.5	5.0	5-6	3.9	260
5-8	14	340	5-9	4.0	28
5-10	6.2	300	5-11	1.3	5.1
5-12	-	1.3	5-13	-	2.4
5-14	-	0.34	5-15	-	6.4
5-16	-	3.0	5-17	-	5.2
6	3.47	58.3	6-3	5.2	510
6-8	50	630	6-10	22	870
6-14	6.3	87	6-15	2.0	57
6-16	2.9	170	6-17	2.3	420
6-19	3.2	35	6-21	9.8	920
7	4.97	60.0	7-2	2.46	26
7-5	16.2	237	-	-	-
8	33	595	-	-	-
9	11	260	9-2	4.2	450
9-3	-	59	9-4	-	9.9
9-5	-	3.1	9-6	-	59
9-8	-	6.9	9-10	-	2.3
9-11	20	210	9-13	-	0.53
9-14	-	41	9-17	-	23
9-21	-	20	9-22	-	0.96
9-23	-	8.77	9-24	-	7.86
9-27	-	0.82	-	-	-

Test Example 3

Olive oil-loading test

Syrian hamsters (9-11 weeks of age) under non-fast conditions were used in the test. Blood was collect previously from orbital venous plexus, and a sample w suspended in 0.5% methyl cellulose (vehicle) and the suspensi was forced to be administered orally to the hamsters at a do of 0.3, 1, 3 or 10 mg/2 mL/kg. Only vehicle in the same volu was administered to the control group. Olive oil (2 mL/kg) w forced to be administered orally 30 minutes after t administration of the sample, and blood was collected fr orbital venous plexus 4 hours later. Plasma was recovered fr the blood, and the amount of triglyceride (TG) in the plas was determined by automatic analyzer (Hitachi Co.). The da was expressed in terms of ΔTG(mg/dL)=the value at 4th hr min the value before administration. Inhibition rate (%) w calculated from the data obtained on the basis of the followi equation.

Inhibition rate (%)=100 × (1 minus ΔTG of sample group/Δ of control group). The results were shown in Table 71.

Table 71

Example	Test Example 3 Inhibition of fat absorption after olive oil-loading in Hamster (()mg/kg.p.o) Inhibition rate (%)	Example	Test Example 3 Inhibition of fat absorption after olive oil-loading in Hamster (()mg/kg.p.o Inhibition rate (%)
1	57(100)	1-3	65(100)
1-5	59(3)	1-6	54(10)
1-35	59(100)	1-45	71(100)
1-66	52(100)	1-72	54(100)
2	95(10)	2-2	96(10)
2-3	68(3)	2-4	78(3)
2-5	70(3)	2-7	58(3)
2-8	89(3)	2-13	70(3)
2-14	80(3)	2-15	81(3)
2-18	58(3)	2-22	61(3)
2-25	55(3)	2-39	68(3)
2-48	87(3)	-	-
3-3	78(10)	3-5	80(10)
3-6	52(3)	3-7	74(3)
3-8	60(3)	3-10	85(3)
3-11	75(3)	-	-
5-9	78(100)	5-11	64(100)
9-10	54(3)	9-13	70(3)

Test Example 4

Liver TG release inhibition test

Syrian hamsters (9 to 11 weeks of age) which were fast for one day were used in the test. Blood was collected previously from orbital venous plexus, a a sample was forced to be administered orally to the hamste at a dose of 30, 100 or 300 mg/2 mL/kg, and the same amount vehicle was administered to the control group. Triton WR 13 (2 mL/kg) was intravenously administered to the hamsters minutes after the above administration. Two hours later, blc was collected from orbital venous plexus, and plasma w separated from the blood. The amount of TG in the plasma w determined by automatic analyzer (Hitachi Co.). The data w expressed in terms of TG release velocity (mg/dL/min)=(val at 2nd hour minus value before administration)/120. Inhibiti rate (%) was calculated from the data obtained on the basis the following equation.

Inhibition rate (%)= 100 × (1 minus TG release velocity sample/TG release velocity of control group). The results we shown in Table 72.

Table 72

Example No.	Test Example 4 Inhibition of liver TG release in Hamster (()mg/kg.p.o) Inhibition rate(%)	Example No.	Test Example 4 Inhibition of liver T release in Hamster (()mg/kg.p.o) Inhibition rate(%)
1	19(300)	1-6	0(100)
1-35	9(300)	2-5	0(100)
2-22	0(30)	2-39	6(100)
3-3	18(100)	-	-

Test Example 5

Combination use test

Japanese white rabbits (male, 19 weeks of age, J purchased from Kitayama Labes Co., Ltd.) were fed previous in such a way that they were fed a high cholesterol diet (0.: cholesterol + 3 % peanut oil-added RC-4, Product of Orient Yeast Co., Ltd.) of 70 g/day under limited feeding for one da The rabbits thus fed were used as a cholesterol-loaded rabb model, and the grouping of such model was carried out in su a way that there might be no variation in the amount of plas cholesterol among each group (five rabbits/group). Aft collection of blood from auricular artery, compounds Examples 2 to 5, simvastatin, and compounds of Examples 2 5 plus simvastatin were added to a high cholesterol diet in t dose as shown in Table below, and the rabbits were fed such die

was collected from auricular artery 6 hours after the feedi on the 4th day of the administration, and cholesterol level plasma was assayed. In the table, increased amount of plas cholesterol during from the time of grouping to the 4th day w shown.

Table 73

	Increased amount of total cholesterol (mg/dl)
Control	80.0
Simvastatin (1 mg/kg)	48.6
Example 2-5 (10 mg/kg)	8.6
Example 2-5 (10 mg/kg) + Simvastatin (1 mg/kg)	2.1

Test Example 6

Determination of the concentration in plasma

Syrian hamsters (9-15 weeks of age) under non-fast conditions were used in the test. A sample was suspended 0.5% methyl cellulose (vehicle), and the suspension was forc to be administered orally to the hamsters at a dose of 30 100 mg/2 mL/kg. After a fixed period of time, blood was part collected from orbital venous plexus, and the hamsters we subjected to laparotomy under ether anesthesia, and then blc was collected from portal vein. The blood was immediate cooled with ice to separate plasma. A portion of the plas was extracted with an organic solvent and the supernatant w

that of the metabolite in the supernatant were determin quantitatively by high performance liquid chromatography/ma spectrometry (LC/MS) comparing with chromatogram of synthet standard.

Table 74

Compound	Dose (mg/kg)	Component	Blood of portal vein (μM)			Peripheral bloo (μM)		
			1h	2h	4h	1h	2h	4h
1-2	30	Unaltered form	<0.2	<0.2	<0.2	<0.2	<0.2	<0.
		Metabolite	1.6	2.2	6.7	0.9	1.3	2.9
1-12	30	Unaltered form	<0.2	<0.2	<0.2	<0.2	<0.2	<0.
		Metabolite	11.8	18.2	24.4	7.3	12.1	15.
1-13	30	Unaltered form	<0.2	<0.2	<0.2	<0.2	<0.2	<0.
		Metabolite	11.8	20.6	27.3	10.9	16.9	18.
2-5	30	Unaltered form	0.01	0.03	0.01	<0.02	<0.02	<0.0
		Metabolite	0.33	0.73	0.38	0.01	0.01	0.0

Test Example 7

Metabolic stability test in liver S9 and small intestine

Human and hamster liver S9 (final concentration: 2 protein/mL), and human and hamster small intestine S9 (fin concentration: 2 mg protein/mL) were each suspended in 100 potassium phosphate buffer (pH 7.4, containing β-nicotinami adenine dinucleotide phosphate: 1.3 mM, D-glucose-phosphate: 3.3 mM, magnesium chloride: 3.3 m glucose-6-phosphate dehydrogenase: 0.4 U/mL). The suspensio

The solutions were incubated at 37°C for 0, 10 and 60 minute and an organic solvent was added thereto. The solutions we centrifuged, and the concentration of the sample (unchang form) in the supernatant was determined by high performan liquid chromatography/mass spectrometry (LC/MS). Based on t data obtained, remaining rate (%) was calculated according the following equation.

Remaining rate(%)=amount of sample 10 or 60 minutes afi incubation/amount of sample at zero time after incubation × 100

Table 75

	human		hamster	
	Remaining rate (%) after 10 min.	Remaining rate (%) after 60 min.	Remaining rate (%) after 10 min.	Remaining rate (%) after 60 min.
Small intestine S9	97.6	91.5	29.0	14.1
Liver S9	7.9	4.3	2.4	0

Test Example 8

Inhibitory activity on MTP and apo B secretion inhibition metabolites

In a similar manner to Test Examples 1 and 2, the activi

below.

Table 76

Compound	Main metabolite	MTP inhibition IC_{50}(nM)	Inhibition of apo B secretion IC_{50} (nM)
1		>1000	>10000
		>1000	>10000
1-35		>1000	>10000
		>1000	>10000

Table 77

Compound	Main metabolite	MTP inhibition IC_{50}(nM)	Inhibition of apo B secretion IC_{50}(nM)
2-5		>10000	>10000
		>1000	>10000
2-17		-	>10000
		>1000	>10000

Table 78

Compound	Main metabolite	MTP inhibition IC_{50}(nM)	Inhibition of apo B secretio IC_{50}(nM)
3-4		>1000	>10000
		>1000	>10000

Industrial Applicability

It is apparent from the above Test Examples 1 to 3 th novel compounds and their pharmaceutically acceptable sal of the present invention possess excellent MTP inhibiti activity and also strongly inhibit absorption of triglycerid In addition, as is apparent from Test Example 4, even wh compounds of the present invention are administered at hi dose, inhibition rate of liver TG release is 18-19 % or lowe more effectively 9 % or lower, especially effectively 0 % lower, and thus the compounds of the present invention inhib little of liver TG release. Further, Test Example 6 revea

are present in portal vein in a very small amount, and sir most (8-fold to 80-fold amount) of such active compounds a metabolites, they do not reach the liver. Furthermore, it deduced from Test Example 7 that a small amount of acti compound which has reached the liver is metabolized rapic to a metabolite. In addition, Test Example 8 proves that est moiety of these metabolites is cleaved by hydrolysis and th they have little or no MTP inhibitory activity. Further, Te Example 5 reveals that combination use of the compounds of t present invention with other agents for treati hyperlipidemia (statin type agents) can remarkably inhibit t increase of cholesterol and exhibit extremely excelle synergistic effect. These facts elucidate that the compour of the present invention can be used in combination with oth agents, particularly other agents for treating hyperlipidem arteriosclerosis, coronary artery diseases, obesity, diabet or hypertension.

From the fact as mentioned above, it is understood th novel compounds of the present invention and the pharmaceutically acceptable salts can inhibit lip absorption in the small intestine and further do not inhit TG release in the liver. This means that the compounds of th invention do not inhibit MTP in the liver, but selective inhibit MTP in the small intestine.

Therefore, selective inhibition of MTP activity in t small intestine by the compounds of the present invention shou lower lipid absorption, which makes it possible to contr lipoproteins such as triglyceride, cholesterol and LDL, et

compounds of the present invention do not affect liver MT
accumulation of triglyceride does not occur in the live
Consequently, inhibition of fatty liver generation as
adverse effect might be expected. Therefore, the compounds
the present invention can be said novel MTP inhibitors havi
no side effects such as a fatty liver, etc. or, in other word
they are novel agents for the treatment or prophylaxis
hyperlipidemia, arteriosclerosis, coronary artery disease
obesity, diabetes or hypertension, and further for t
treatment or prophylaxis of pancreatiti
hypercholesterolemia, hypertriglyceridemia, etc., whi
rarely act on MTP in the liver and do substantially inhibit or
MTP in the small intestine.

Claims

1. An ester compound represented by the formula (1)



(1)

wherein

R^1 and R^2 are each hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalky C_1-C_6 alkoxy, halo C_1-C_6 alkyl, halo C_1-C_6 alkyloxy, optional substituted C_6-C_{14} aryl, optionally substituted C_7-C_{16} aralky optionally substituted C_6-C_{14} aryloxy, optionally substitut C_7-C_{16} aralkyloxy, optionally substituted C_7-C_{15} arylcarbony optionally substituted heterocycle, C_2-C_7 alkoxycarbony halogen, C_2-C_6 alkenyl, -N(R^{40})(R^{41}) wherein R^{40} and R^{41} are ea independently hydrogen or optionally substituted C_6-C_{14} ary

ring A is C_6-C_{14} aryl, heterocycle, or



or



;

X is -COO-$(CH_2)_n$-, -CON(R^{10})-$(CH_2)_n$- or -N(R^{10})-CO-(CH_2) wherein R^{10} is hydrogen, C_1-C_6 alkyl or C_3-C_7 cycloalkyl and is an integer of 0 to 3;

R^3 and R^4 are each independently hydrogen, hydrox halogen, optionally substituted C_1-C_6 alkyl, C_1-C_6 alkoxy, ha

substituted heterocycle, -CON(R^{11})(R^{12})(wherein R^{11} and R^{12} a each independently hydrogen, C_1-C_6 alkyl, optional substituted C_6-C_{14} aryl, optionally substituted C_7-C_{16} aralky C_1-C_6 alkoxy, or R^{11} and R^{12} may be taken together with the nitroc to which they are attached to form

or

, wherein p is an integer of 0 to 2), -$(CH_2)_q$-N(R^{13})(R^{14})(where R^{13} and R^{14} are each independently hydrogen, C_1-C_6 alkyl, C_2- alkoxycarbonyl, C_1-C_6 acyl, or R^{13} and R^{14} may be taken togeth with the nitrogen to which they are attached to form



or

, wherein p has the same meaning as defined above and q is integer of 0 to 3), or -CO(R^{15})(wherein R^{15} is hydroxy, C_1- alkoxy, optionally substituted C_6-C_{14} aryloxy, optional substituted C_7-C_{16} aralkyloxy or C_1-C_6 alkyl);

ring B is



, wherein K is an integer of 0 to 2, or ring B may be taken togeth with R^3, R^{10} and the nitrogen bound to R^{10} to form



or

;

$Alk1^1$ is alkanediyl or alkenediyl;

$Alk1^2$ is alkanediyl or alkenediyl;

l is an integer of 0 to 3;

m is an integer of 0 to 3;

-N(R^{42})-CO(R^{43})(wherein R^{42} is hydrogen or C_1-C_6 alkyl and R^{43} C_6-C_{14} aryl or C_7-C_{16} aralkyl), or the group represented by t following formula



(wherein R^5, R^6 and R^7 are each independently hydrogen, C_1 alkyl, C_1-C_6 alkoxy, C_2-C_7 alkoxycarbonyl, carboxyl, haloge cyano, nitro, halo C_1-C_6 alkyl, C_1-C_6 acyl, hydroxy, amir optionally substituted C_6-C_{14} aryl, -(CH_2)$_r$-CON(R^{16})(R^{17})(wherein R^{16} and R^{17} are each independent hydrogen, C_1-C_6 alkyl or halo C_1-C_6 alkyl and r is an integer 0 to 3);

ring C is C_6-C_{14} aryl, C_7-C_{15} arylcarbonylamino, C_8-aralkylcarbonylamino, heterocycle residue, C_3-C_7 cycloalkyl C_7-C_{16} aralkyl, or ring C may be taken together with R^7 and to form



); and

R^8 and R^9 are each independently hydrogen, C_1-C_6 alky optionally substituted C_6-C_{14} aryl, hydroxy C_1-C_6 alky -CON(R^{18})(R^{19})(wherein R^{18} and R^{19} are each independent hydrogen, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, halo C_1-C_6 alkyl, C_2-

-$(CH_2)_s$-$OCO(R^{20})$(wherein R^{20} is hydrogen, C_1-C_6 alkyl or C_3-
cycloalkyl; s is an integer of 0 to 3), -$N(R^{21})(R^{22})$(wherein
and R^{22} are each independently hydrogen, C_1-C_6 alkyl, C_1-C_6 acy
C_1-C_6 alkylsulfonyl, or R^{21} and R^{22} may be taken together wi
the nitrogen to which they are attached to form



), or

R^8 and R^9 may be taken together to form C_3-C_7 cycloalky
or a prodrug thereof, or a pharmaceutically acceptable salt
either.

2. The ester compound or a prodrug thereof, or
pharmaceutically acceptable salt of either according to cla
1, wherein D is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_7 alkoxycarbor
or -$N(R^{42})$-$CO(R^{43})$ in which R^{42} and R^{43} each has the same meani
as defined above.

3. The ester compound or a prodrug thereof, or
pharmaceutically acceptable salt of either according to cla
1, wherein D is the group represented by the formula



in which R^5, R^6 and R^7 each has the same meaning as defined abov

4. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 3, wherein the ring C is





or

,in which q is an integer of 0 to 3.

5. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 2 or claim 4, wherein ring B is



or

.

6. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according according to claim 5, wherein ring A is



or

.

7. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla

same meaning as defined above.

8. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 6, wherein X is $-COO-(CH_2)_n-$ in which n has the same meani as defined above;

9. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 7 or claim 8, wherein n is 0.

10. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 1, which is represented by the formula (1')



(1')

wherein

$R^{2'}$ and $R^{2''}$ are each independently hydrogen, C_1-C_6 alky C_3-C_7 cycloalkyl, C_1-C_6 alkoxy, halogen, halo C_1-C_6 alkyl, C_1· acyl, C_2-C_6 alkenyl or cyano;

X_1 is -O- or $-NR^{10}-$ wherein R^{10} is hydrogen, C_1-C_6 alk or C_3-C_7 cycloalkyl; and

R^1, R^3, R^4, R^5, R^6, R^7, R^8, R^9, ring C, l and m each h

or a prodrug thereof, or a pharmaceutically acceptable salt either.

11. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 10, wherein the ring C is





or

, in which q is an integer of 0 to 3.

12. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 11, wherein X_1 is $-NR^{10}-$ in which R^{10} has the same meaning defined above.

13. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 11, wherein X_1 is -O-.

14. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 10 to 13, wherein the group $-(CH_2)_1-$ is located at the h-positi of the benzene ring in the formula (1').

15. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 10 to 13, wherein the group $-(CH_2)_1-$ is located at the i-positi of the benzene ring in the formula (1').

16. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 10 to 15, wherein R^8 and R^9 are each independently $-CON(R^{18})(R^{1}$ in which R^{18} and R^{19} each has the same meaning as defined abov

17. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 10 to 15, wherein R^8 and R^9 are each independently $-COO(R^{2}$ in which R^{20} has the same meaning as defined above.

18. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 12 to 17, wherein the ring C is C_6-C_{14} aryl.

19. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 18, wherein C_6-C_{14} aryl is phenyl.

20. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to clai 12 to 17, wherein the ring C is C_3-C_7 cycloalkyl.

21. The ester compound or a prodrug thereof, or

12 to 17, wherein the ring C is

 ,  or  .

22. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 1, which is selected from the group consisting of

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth ester,

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid dieth ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl) amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 9-(2,2,2-trifluoro-ethylcarbamoyl)-9H fluoren-9-ylmethyl ester,

2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid 9-(2,2,2-trifluoro-

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-(2,2,2-trifluoro-ethylcarbamoyl)-cyclopentylmethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diisopropyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac dimethyl ester,

2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-(2,2,2-trifluoro-ethylcarbamoyl)-cyclohexylmethyl ester,

2-phenyl-2-{2-[4-(2-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-{2-[4-(2-phenoxy-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-{2-[4-(2-trifluoromethyl-benzoyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-{2-[4-(2-benzoyl-benzoyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2-benzoyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac
dicyclohexyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-eth
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-phenyl-ethyl ester,

2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth
ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

2-butoxy-benzoic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

[4-(2-phenoxy-benzoylamino)-phenyl]-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-eth ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-eth ester,

2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diethyl ester,

2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,
bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl
ester,

2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-
trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-
acetoxymethyl)-malonic acid diethyl ester,

[4-(2-butoxy-benzoylamino)-phenyl]-acetic ac
2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-
phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-eth
ester,

2-(2-{4-[(9-oxo-9h-fluorene-1-carbonyl)-amino]-
phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

2-(2-{4-[(9h-fluorene-1-carbonyl)-amino]-phenyl}-
acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy
2-phenyl-ethyl ester,

2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-
phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-
phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-
phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-prop
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-
phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-prop

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

[4-(2-phenoxy-benzoylamino)-phenyl]-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

[4-(2-butoxy-benzoylamino)-phenyl]-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-(2-{4-[2-(4-fluoro-benzoyl)-benzoylamino]-phenyl}acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chlor phenyl ester,

2-phenyl-2-{2-[4-(2-thiophen-3-yl-benzoylamino)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-(2-{4-[(biphenyl-3-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2-isopropyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2-benzyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac
dipropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac
diisobutyl ester,

2-phenyl-2-{2-[4-(2-trifluoromethoxy-benzoylamino)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-{2-[4-(2-butoxycarbonyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl-eth
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]
phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-
phenyl-ethyl ester,

2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic
acid diethyl ester,

[4-(2-cyclohexyl-benzoylamino)-phenyl]-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth
ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-
propylcarbamoyl-ethyl ester,

phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester,

2-[2-(4-{[2-methyl-4-(4-trifluoromethyl-phenyl)-thiazole-5-carbonyl]-amino}-phenyl)-acetoxymethyl]-2-phenyl-malonic acid diethyl ester,

(4-{[2-methyl-4-(4-trifluoromethyl-phenyl)-thiazole 5-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

(4-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

(3-methyl-4-{[2-(4-trifluoromethyl-phenyl)-pyridine 3-carbonyl]-amino}-phenyl)-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy

2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenv

ethylcarbamoyl-4-phenyl-butyl ester,

{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl malonic acid diethyl ester,

{3-(isopropyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-aceti acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-(ethyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-(ethyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-

{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propyl-carbamoyl)-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propyl-carbamoyl)-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-propionylamino-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2-propionylamino-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny

pyrrolidin-1-yl)-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-ethylcarbamoylmethyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-isopropylamino-2 phenyl-ethyl ester hydrochloride,

[3-dimethylcarbamoyl-4-(2-trifluoromethyl-benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-phenyl-ethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(2-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic ac diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-acetylamino-2-phenyl-ethyl ester,

2-carbonyl)-amino]-phenyl}-acetic acid 2-butyrylamino-2-phenyl-ethyl ester,

[4-(2-benzoyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth ester,

2-{2-[4-(2-benzoyl-benzoylamino)-3-dimethylcarbamoy phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl este

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester,

2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acet methyl)-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acet methyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

[3-dimethylcarbamoyl-4-(2-phenoxy-benzoylamino)-phenyl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth ester,

2-{2-[3-dimethylcarbamoyl-4-(2-phenoxy-benzoylaminc phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl este

2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-

acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-methanesulfonylamino-2-phenyl-ethyl ester,

3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-propionic acid ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-(methyl-propiony amino)-2-phenyl-ethyl ester,

2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester) .

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester,

2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-

2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester,

2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4 trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(2-isopropenyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(2-isopropyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

phenylamino)-benzoylamino]-phenyl}-acetoxymethyl)-2-pheny malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[2-(3-trifluoromethyl-phenoxy)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl-2-phenyl-butyl ester,

2-(2-{3-dimethylcarbamoyl-4-[2-(4-trifluoromethyl-phenoxy)-benzoylamino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopropylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-diphenyl-eth ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopentylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 3-hydroxy-2-hydroxymethyl-2-phenyl-propyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 3-acetoxy-2-

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl-malonic acid diethyl ester,

2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isopropyl-malonic acid diethyl ester,

2-sec-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isobutyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

propyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-ethy malonic acid diethyl ester,

2-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-allyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2,2-bis-ethoxycarbonyl-propionic acid ethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(1-methyl-butyl)-malonic acid diethyl ester,

2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester,

2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester,

{3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic

2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic ac diethyl ester,

{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphe l-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl

acid diethyl ester,

2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic ac diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-prop ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-prop ester,

2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester.

carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoy 4-phenyl-butyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester,

2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoy 3-phenyl-propyl ester,

2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(9h-fluoren-9-yl)-ethyl ester,

n-biphenyl-2-yl-terephthalamic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-naphthalen-1-yl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-1-yl]-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-phenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[8-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-1-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2,6-dichloro-phenyl)-3-(2,2,2-trifluoro-

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid dieth ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic ac diethyl ester,

2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic ac diethyl ester,

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl este

2-{2-[4-(2-benzoyl-benzoyloxy)-benzoyloxy]-ethyl}-2 phenyl-malonic acid diethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester

4'-trifluoromethyl-biphenyl-2-carboxylic ac 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic ac 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-pheny ester,

4'-trifluoromethyl-biphenyl-2-carboxylic ac 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester,

4-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl

ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarboxylic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarboxylic acid 3-phenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

2-phenyl-2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarbonyloxymethyl}-malonic ac diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-cyclohexanecarbonyloxy}-ethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-piperidin-1-yl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-indol-1-yl}-acetoxymethyl)-malonic ac diethyl ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoimidazol-1-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

[2-oxo-3-(4'-trifluoromethyl-biphenyl-2-carbonyl)-2,3-dihydro-benzooxazol-6-yl]-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester.

biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2 phenyl-malonic acid diethyl ester,

4-{[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth ester,

3-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl-meth ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino benzoic acid benzyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino benzoic acid,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino benzoic acid ethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoimidazol-1-yl}-acetoxymethyl)-malon acid diethyl ester,

3-{[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-methyl}-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-prop ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino benzoic acid methyl ester,

2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-

2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[2-oxo-3-(4'-trifluoromethyl-biphenyl-2-carbonyl)-2,3-dihydro-benzooxazol-6-yl]-acetoxymethyl}-phenyl-malonic acid diethyl ester,

2-{2-[8-oxo-7-(4'-trifluoromethyl-biphenyl-2-carbonyl)-7-aza-bicyclo[4.2.0]octa-1(6),2,4-trien-3-yl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(3-dimethylcarbamoyl-4-{[1-(2-nitrol-4-trifluor methyl-phenyl)-pyrrolidine-2-carbonyl]-amino}-phenyl)-acetoxymethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni acid diethyl ester,

2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pheny malonic acid diethyl ester,

2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-

diethyl ester,

2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(methoxy-methyl-carbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and

2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxethyl)-2-phenyl-malonic acid diethyl ester.

23. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 1, which is selected from the group consisting of

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid dieth ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni

2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-pheny ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 9-(2,2,2-trifluor ethylcarbamoyl)-9h-fluoren-9-ylmethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid 9-(2,2,2-trifluor ethylcarbamoyl)-9h-fluoren-9-ylmethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{4-[4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diisopropyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluor ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac dimethyl ester,

2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl

diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac dicyclohexyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-pheny ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-pheny ethyl ester,

2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl-malonic ac diethyl ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl-2-phenyl-malonic acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bi(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diethyl ester,

2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester,

2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl-malonic acid diethyl ester,

2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2, bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester,

2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}- acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-eth ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy 2-phenyl-ethyl ester,

2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

phenyl}- acetoxymethyl)-2-phenyl-malonic acid diethyl este

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]
phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-prop
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]
phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-prop
ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth
ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,
bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-
chloro-phenyl ester,

2-(2-{4-[isopropyl-(4'-trifluoromethyl-
biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-
phenyl-malonic acid diethyl ester,

2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic
acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid
dipropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid
diisobutyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]

ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino] phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(ethylcarbamoyl-2-phenyl-eth ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2,2-bis-(2-methox ethylcarbamoyl)-2-phenyl-ethyl ester,

2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-

ethylcarbamoyl-3-phenyl-propyl ester,

{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-pheny 2,2-bis-propylcarbamoyl-ethyl ester,

{3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-ethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-bipheny 2-carbonyl)-amino]-phenyl}-acetic acid 4,4'-bi ethylcarbamoyl-4-phenyl-butyl ester,

{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl -carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2, bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl) 2-phenyl-malonic acid diethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi

{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-ethyl ester,

{3-(dimethylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethy carbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-propionylamino-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-propionylamino-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

dioxo-pyrrolidin-1-yl)-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid ethylcarbamoyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl}-amino]-phenyl}-acetic acid ethylcarbamoylmethyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-isopropylamino-2-phenyl-ethyl ester hydrochloride,

2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl}-amino]-phenyl}-acetoxymethyl)-2-phenyl- malor acid diethyl ester,

2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid acetylamino-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid butyrylamino-2-phenyl-ethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester,

trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid methanesulfonylamino-2-phenyl-ethyl ester,

3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-propionic acid ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(methy

2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-

acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester,

2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester.

[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)- amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl}-malonic acid diethyl ester,

2-(2-{4-(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-

2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{4-[(5,4'-bis-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-

acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl-phenyl-butyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl cyclopropylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-diphenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl cyclopentylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-hydroxy 2-hydroxymethyl-2-phenyl-propyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-acetoxy 2-acetoxymethyl-2-phenyl-propyl ester,

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl-malonic acid diethyl ester,

2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester,

2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl- 2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl- 2-phenyl-ethyl ester,

2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bi propylcarbamoyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni acid diethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

{3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl- 2-phenyl-ethyl ester,

{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2

acid diethyl ester,

2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic ac diethyl ester,

{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-piperidin-1-yl-4-[(4'-trifluoromethyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl- 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic ac diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-eth ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis- propylcarbamoyl-propyl ester,

2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy-ethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bi ethylcarbamoyl-4-phenyl-butyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bi propylcarbamoyl-propyl ester,

{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-

phenyl-malonic acid diethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[9-(2,2,2-trifluoro-ethylcarbamoyl)-9 fluoren-9-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[9h-fluoren-9-yl]-ethyl ester,

n-biphenyl-2-yl-terephthalamic acid 2-[9-(2,2, trifluoro-ethylcarbamoyl)-9h-fluoren-9-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-naphthalen-1-yl-3-(2,2,2-trifluor ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl naphthalen-1-yl]-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluor ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-phenyl-3-(2,2,2-trifluor ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-

ethylcarbamoyl)-naphthalen-1-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[(2,6-dichloro-phenyl)-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid diethyl ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic ac diethyl ester,

2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl este

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,bis-ethylcarbamoyl-3-phenyl-propoxycarbony)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro phenyl ester.

biphenyl-2-carbonyl)-amino]-phenyl-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl-methyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester,

2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-

2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-maloni acid diethyl ester,

2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic ac diethyl ester,

2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxy-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-3-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and

2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-

acetoxymethyl)-2-phenyl-malonic acid diethyl ester.

24. The ester compound or a prodrug thereof, or pharmaceutically acceptable salt of either according to cla 1, which is selected from the group consisting of

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-ethylcarbamoyl)-2-phenyl-ethyl ester,

2-phenyl-2-{2-[4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid dieth ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[methyl-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-2-phenyl]-acetic acid 2,2-bi ethylcarbamoyl-phenyl-ethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diisopropyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac dimethyl ester,

2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-maloni acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac dicyclohexyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-eth ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-pheny ethyl ester,

2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bi

phenyl ester,

2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic ac diethyl ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester,

2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-maloni acid diethyl ester,

2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-maloni acid diethyl ester,

4'-trifluoromethyl-biphenyl-2-carbxylic ac 4-(2,2-bis-ethylcarbamoyl)-2-phenyl-ethoxycarbonylmethyl) phenyl ester,

2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-eth ester,

carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoy
2-phenyl-ethyl ester,

2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-
phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-
phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl este

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]
phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-prop
ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]
phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-prop
ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dieth
ester,

4'-trifluoromethyl-biphenyl-2-carboxylic ac
4-(2,2-bis-ethylcarbamoyl)-2-phenyl-ethoxycarbonylmethyl)
2-chloro-phenyl ester,

2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic
acid diethyl ester,

2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic
acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-
carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methy butylcarbamoyl)-2-phenyl-ethyl ester,

2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-pheny ethyl ester,

{4-[(3'4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-pheny ethyl ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bi propylcarbamoyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino] phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-phenyl-ethyl ester,

2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-

ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2 carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-pheny 2,2-bis-propylcarbamoyl-ethyl ester,

{3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bi ethylcarbamoyl-4-phenyl-butyl ester,

{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl 2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluorometh -biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bi ethylcarbamoyl-3-phenyl-propyl ester,

{3-(piperidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bi ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac 2-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-piperidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

propionylamino-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(2,5-dioxo-pyrrolidin-1-yl)-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2-ethylcarbamoyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2-ethylcarbamoylmethyl-benzyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2-isopropylamino-2-phenyl-ethyl ester hydrochloride,

2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2-acethylamino-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic ac
2-butyrylamino-2-phenyl-ethyl ester,

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester,

2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-methanesulfonylamino-2-phenyl-ethyl ester,

3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2-phenyl-propionic acid ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-(methyl-propionyl-amino)-2-phenyl-ethyl ester,

2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluromethyl--biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl--biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-

acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester,

2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester,

2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-(6-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-[(2-ethyl-4-trifluoromethyl-benzoylamino)-phenyl]-acetoxymethyl}-2-

phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-ethyl-2-phenyl-butyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopropylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-diphenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 1-phenyl-cyclopentylmethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-hydroxy-2-hydroxymethyl-2-phenyl-propyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-acetoxymethyl-2-phenyl-propyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-thiophen-2-yl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-thiophen-3-yl-malonic acid diethyl ester,

2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl]-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester,

2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester

2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)- amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-

ethylcarbamoyl-2-phenyl-ethyl ester,

2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-

phenyl-malonic acid diethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[(biphenyl-2-carbonyl)-amino]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-(2-biphenyl-2-yl-acetylamino)-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-naphthalen-1-yl-3-(2,2,2-trifluoroethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-1-yl]-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-diphenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-biphenyl-2-yl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-phenyl-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 2-[8-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-1-yl]-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2,6-dichloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-(2-chloro-phenyl)-3-(2,2,2-trifluoro-ethylcarbamoyl)-propyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-malonic acid diethyl ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester,

2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester,

3-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-

amino]-phenyl}-propionic acid ethylcarbamoyl-phenyl-methyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester,

2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester,

2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester,

2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- 2-phenyl-malonic acid diethyl ester,

2-phenyl-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)- malonic acid diethyl ester,

2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and

2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester.

25. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-

phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcaramoyl-2-phenyl-ethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- butylcarbamoyl-2-phenyl-ethyl-ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-phenyl ethyl ester,

{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl ethyl ester,

{4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl)-2-phenyl-ethyl ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl)-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester,

{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-phenyl-ethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester,

{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(isopropyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis- ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-(piperidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidin-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-

ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-

carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-isopropylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester,

{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3-phenyl-3,3-bis-propylcarbamoyl-propyl ester,

{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]- phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester, and

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-

methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester.

26. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester,

2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid

dicyclohexyl ester,

2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2- carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester,

2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic

acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-(pyrroldine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-(pyrroldine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]-3-

dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid di-2,2,2-trifluoroethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-

acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester,

2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-pyridin-2-yl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-o-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-m-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-p-tolyl-malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-

[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-succinic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(2-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(4-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl)-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl)-malonic acid diethyl ester,

2-[2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-[(2-ethyl-4-trifluoro-methyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-

phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-[(4'-trifluoromethyl--biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl- malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl- malonic acid diethyl ester,

2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2-phenyl- malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiazol-2-yl-malonic acid diethyl ester,

2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-

carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-[2-(2-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-malonic acid diethyl ester,

2-[2-(2-{4-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-ethoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-isopropoxy-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-methoxycarbonyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-[2-(2-{2-ethoxy-5-methyl-3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-

phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl]-malonic acid diethyl ester,

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-benzoyloxy]-ethyl}-malonic acid diethyl ester,

2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-benzyloxycarbony-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-

phenyl-malonic acid diethyl ester,

2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-formyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester, and

2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester.

27. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-cyclohexylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-phenylcarbamoyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isopropylcarbamoyl-2-phenyl-ethyl ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-methylcarbamoyl-2-phenyl-ethyl

ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-butylcarbamoyl-2-phenyl-ethyl ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethyl-carbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl-ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3-phenyl-3,3-bis-propyl- carbamoyl-propyl ester,

{4-[(biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-isobutylcarbamoyl-2-phenyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(3-methyl-butylcarbamoyl)-2-phenyl-ethyl ester,

{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{4-[(3',4'-dichloro-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-(2-methoxy-ethylcarbamoyl)-2-phenyl-ethyl ester,

{3-isopropyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-isobutyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-benzylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 4,4-bis-ethylcarbamoyl-4-phenyl-butyl ester,

{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-

ethylcarbamoyl-2-phenyl-ethyl ester,

{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(isopropyl-methylcarbamoyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(ethyl-methylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(methyl-propylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2-phenyl-2,2-bis-propylcarbamoyl-ethyl ester,

{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

{3-propoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-piperidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-

ethylcarbamoyl-2-phenyl-ethyl ester,

{3-pyrrolidin-1-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3,3-bis-ethylcarbamoyl-3-phenyl-propyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid benzyl ester,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid,

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid ethyl ester, and

5-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonyl-methyl)-2-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid methyl ester.

28. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

2-(2-{3-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[methyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-

2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisopropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dimethyl ester,

2-cyclopentyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dicyclohexyl ester,

2-benzyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{2-methyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{2-trifluoromethyl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-pyridin-2-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-pyridin-3-yl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-phenyl-2-(2-{3-trifluoromethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(3'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[isopropyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[cyclohexyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid dipropyl ester,

2-phenyl-2-(2-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diisobutyl ester,

2-(2-{4-[ethyl-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-ethyl-4-(4'-trifluoromethyl-biphenyl-2-

carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-4-(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-diisopropylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

{3-(ethyl-methylcarbamoyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetic acid 2,2-bis-ethylcarbamoyl-2-phenyl-ethyl ester,

2-phenyl-2-(2-{3-(pyrrolidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-phenyl-2-(2-{3-(piperidine-1-carbonyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-fluoro-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-bromo-biphenyl-2-carbonyl)-amino]}-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid dimethyl ester,

2-cyclopentyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-cyclohexyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}--acetoxymethyl)-malonic acid diethyl ester,

2-(2-{4-[(4'-chloro-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic

acid diethyl ester,

2-(2-{4-[(4'-acetyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(4'-cyano-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-[3-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-propyl]-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-methoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(5-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid 2,2,2-trifluoroethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(2'-fluoro-4'-

trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-4-[(2'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(3'-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(3'-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(5-nitro-pyridin-2-yl)-malonic acid diethyl ester,

2-(5-amino-pyridin-2-yl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-pyridin-2-yl-malonic acid diethyl ester,

2-(2-{3-chloro-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-bromo-5-dimethylcarbamoyl-2-fluoro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-o-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-m-tolyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-p-tolyl-malonic acid diethyl ester,

2-(2-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—malonic acid diethyl ester,

2-(3-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—malonic acid diethyl ester,

2-(4-chloro-phenyl)-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-succinic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(2-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(3-

methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(4-methoxy-phenyl)-malonic acid diethyl ester,

2-(2-{4-[(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{4-[(6-chloro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(6-fluoro-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-[2-(2-{3-dimethylcarbamoyl-4-[(5-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-ethyl]—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-ethoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(5-isopropoxy-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-[2-(2-{4-(5,4'-bis-trifluoromethyl-biphenyl-2-carbonyl)-amino]-3-dimethylcarbamoyl-phenyl}-acetoxy)-ethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-(6-methoxy-4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-(3-methyl-4'-trifluoro-

methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-{4-(2,4-bis-trifluoromethyl-benzoylamino)-3-dimethylcarbamoyl-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(2-ethyl-4-trifluoro-methyl-benzoylamino)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-ethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropenyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-isopropyl- biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-2-yl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-thiophen-3-yl-malonic acid diethyl ester,

2-(2-{4-dimethylcarbamoyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-pyridin-2-yl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(3-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-(5-methyl-thiophen-2-yl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-thiazol-2-yl-malonic acid diethyl ester,

2-(2-{3-ethoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-benzyloxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-hydroxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{3-piperidin-1-yl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—malonic acid diethyl ester,

2-phenyl-2-(2-{3-pyrrolidin-1-yl-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—

malonic acid diethyl ester,

2-(2-{3-dimethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-morpholin-4-yl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{3-diethylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)—2-phenyl-malonic acid diethyl ester,

2-(2-{2-chloro-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoyloxy}-ethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-ethoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(3-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-propionyloxymethyl)--2-phenyl-malonic acid diethyl ester,

2-(2-{3-benzyloxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-carboxy-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isopropoxycarbonyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonyl-4-[(4'-trifluoromethyl-

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-acetylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-methoxycarbonylamino-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(4-methyl-thiazol-2-yl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)--2-phenyl-malonic acid diethyl ester,

2-phenyl-2-(2-{6-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-biphenyl-3-yl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-formyl-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-dimethylaminomethyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-(methoxy-methylcarbamoyl)-4-[(4'-trifluoro-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester,

2-(2-{3-isobutyryl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2- phenyl-malonic acid diethyl ester, and

2-(2-{3-(1-hydroxy-2-methyl-propyl)-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-phenyl-malonic acid diethyl ester.

29. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

biphenyl-2-carboxylic acid 4-[2-phenyl-2,2-bis-(2,2,2-trifluoro-ethylcarbamoyl)-ethoxycarbonylmethyl]-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(2,2-bis-ethylcarbamoyl-2-phenyl-ethoxycarbonylmethyl)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonylmethyl)-2-chloro-phenyl ester,

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-phenyl ester, and

4'-trifluoromethyl-biphenyl-2-carboxylic acid 4-(3,3-bis-ethylcarbamoyl-3-phenyl-propoxycarbonyl)-2,6-dichloro-phenyl ester.

30. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

2-phenyl-2-{2-[4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-malonic acid diethyl ester,

2-{2-[3-dimethylcarbamoyl-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl-malonic acid diethyl ester,

2-{2-[3-methoxy-4-(4'-trifluoromethyl-biphenyl-2-carbonyloxy)-phenyl]-acetoxymethyl}-2-phenyl malonic acid diethyl ester, and

4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-benzoic acid 3-[2-(2,2,2-trifluoro-ethylcarbamoyl)-naphthalen-1-yl]-propyl ester.

31. The ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to claim 1, which is selected from the group consisting of

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isopropyl-malonic acid diethyl ester,

2-sec-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-isobutyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-propyl-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-

biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-ethyl-malonic acid diethyl ester,

2-butyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)- malonic acid diethyl ester,

2-allyl-2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-malonic acid diethyl ester,

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxy)-2,2-bis-ethoxycarbonyl-propionic acid ethyl ester, and

2-(2-{3-dimethylcarbamoyl-4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-acetoxymethyl)-2-(1-methyl-butyl)-malonic acid diethyl ester.

32. A pharmaceutical composition, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of the claims 1 to 31 and a pharmaceutically acceptable carrier.

33. An MTP (microsomal triglyceride transfer protein) inhibitor, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

34. An agent for the treatment or prophylaxis of hyperlipidemia, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

35. An agent for the treatment or prophylaxis of arteriosclerosis, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

36. An agent for the treatment or prophylaxis of coronary artery diseases, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

37. An agent for the treatment or prophylaxis of obesity, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

38. An agent for the treatment or prophylaxis of diabetes, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

39. An agent for the treatment or prophylaxis of hypertension, which comprises the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31 as an active ingredient.

40. An agent for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, which comprises MTP inhibitor selectively

inhibiting MTP (microsomal triglyceride transfer protein) in the small intestine and a pharmaceutically acceptable carrier.

41. The agent for the treatment or prophylaxis according to claim 40, wherein the MTP inhibitor does not substantially inhibit MTP in the liver but substantially inhibits only MTP in the small intestine.

42. The agent for the treatment or prophylaxis according to claim 41, wherein after the administered MTP inhibitor inhibits MTP in the small intestine, it is metabolized in the small intestine, blood and liver to the amount at which the remaining MTP inhibitor in the liver does not substantially inhibit the MTP in the liver.

43. The agent for the treatment or prophylaxis a according to claim 42, wherein the remaining MTP inhibitor in the liver is metabolized to the state where TG-releasing activity of the liver is kept at the level of about 80% or more of the normal level.

44. The agent for the treatment or prophylaxis according to claims 40 to 43, wherein the MTP inhibitor is a compound having at least one ester bond.

45. The agent for the treatment or prophylaxis according to claim 44, wherein after the compound having at least one ester bond exerts MTP inhibitory activity, the ester moiety of the compound is metabolized in blood to become an inactive

substance.

46. The agent for the treatment or prophylaxis according to claims 40 to 45, wherein the MTP inhibitor is the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either mentioned in any of claims 1 to 31.

47. A method for the treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes or hypertension, which comprises administering a compound selectively inhibiting MTP (microsomal triglyceride transfer protein) in the small intestine.

48. The method according to claim47, wherein after the compound inhibits MTP in the small intestine, it is metabolized in the small intestine, blood and liver to the amount at which remaining said compound in the liver does not substantially inhibit MTP in the liver.

47. The method according to claim 47, wherein the remaining compound in the liver is metabolized to the state where TG-releasing activity of the liver is kept at the level of about 80% or more of the normal level.

50. The method according to claims 47 to 49, wherein the compound has at least one ester bond.

51. The method according to claim 50, wherein after the compound having at least ester bond exerts MTP inhibitory activity, the

ester moiety of the compound is metabolized in blood to become an inactive substance.

52. The method according to claims 47 to 52, wherein the compound is the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either mentioned in any of claims 1 to 31.

53. The agent for the treatment or prophylaxis according to claims 40 to 46, wherein the agent is an agent for the treatment or prophylaxis of hyperlipidemia which is used in combination with other antihyperlipidemic drug(s).

54. The agent for the treatment or prophylaxis according to claim 53, wherein other antihyperlipidemic drug is a statin-type drug.

55. The agent for the treatment or prophylaxis according to claim 54, wherein the statin-type drug is one or more drug(s) selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and cerivastatin.

56. The agent for the treatment or prophylaxis according to claims 40 to 46, wherein the agent is an agent for the treatment or prophylaxis of obesity which is used in combination with other anti-obesity drug(s).

57. The agent for the treatment or prophylaxis according to claim 56, wherein other anti-obesity drug is mazindol or/and

orlistat.

58. The agent for the treatment or prophylaxis according to claims 40 to 46, wherein the agent is an agent for the treatment or prophylaxis of diabetes which is used in combination with other anti-diabetic drug(s).

59. The agent for the treatment or prophylaxis according to claim 58, wherein other anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin preparations, sulfonylurea drugs, insulin secretagogues, sulfonamide drugs, biguanide drugs, α-glucosidase inhibitors and insulin resistance-improving drugs.

60. The agent for the treatment or prophylaxis according to claim 59, wherein other anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformin hydrochloride, boglibose, acarbose and pioglitazone hydrochloride.

61. The agent for the treatment or prophylaxis according to claims 40 to 46, wherein the agent is an agent for the treatment or prophylaxis of hypertension which is used in combination with other anti-hypertension drug(s).

62. The agent for the treatment or prophylaxis according to claim 61, wherein other anti-hypertension drug is one or more

drug(s) selected from the group consisting of loop diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, calcium antagonists, β-blockers, α,β-blockers and α-blockers.

63. The agent for the treatment or prophylaxis according to claim 62, wherein other anti-hypertension drug is one or more drug(s) selected from the group consisting of furosemide delayed release, captopril, captopril delayed release, enalapril maleate, alacepril, delapril hydrochloride, silazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, losartan potassium, candesartan cilexetil, nicardipine hydrochloride, nicardipine hydrochloride delayed release, nilvadipine, nifedipine, nifedipine delayed release, benidipine hydrochloride, diltiazem hydrochloride, diltiazem hydrochloride delayed release, nisoldipine, nitrendipine, manidipine hydrochloride, barnidipine hydrochloride, efonidipine hydrochloride, amlodipine besylate, felodipine, cilnidipine, aranidipine, propranolol hydrochloride, propranolol hydrochloride delayed release, pindolol, pindolol delayed release, indenolol hydrochloride, carteolol hydrochloride, carteolol hydrochloride delayed release, bunitrolol hydrochloride, bunitrolol hydrochloride delayed release, atenolol, asebutolol hydrochloride, metoprolol tartrate, metoprolol tartrate delayed release, nipradilol, penbutolol sulfate, tilisolol hydrochloride, carvedilol, bisoprolol fumarate, betaxolol hydrochloride, celiprolol

hydrochloride, bopindolol malonate, bevantolol hydrochloride, labetalol hydrochloride, arotinolol hydrochloride, amosulalol hydrochloride, prazosin hydrochloride, terazosin hydrochloride, doxazosin mesylate, bunazocin hydrochloride, bunazocin hydrochloride delayed release, urapidil and phentolamine mesylate.

64. Use of the agent for the treatment or prophylaxis according to claims 34 to 46 and other antihyperlipidemic drug(s) for the treatment or prophylaxis of hyperlipidemia.

65. The use according to claim 64, wherein other antihyperlipidemic drug is a statin-type drug.

66. The use according to claim 64, wherein the statin-type drug is one or more drug(s) selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin and cerivastatin.

67. Use of the agent for the treatment or prophylaxis according to claims 34 to 46 and other anti-obesity drug(s) for the treatment or prophylaxis of obesity.

68. The use according to claim 67, wherein other anti-obesity drug is mazindol or/and orlistat.

69. Use of the agent for the treatment or prophylaxis according to claims 34 to 46 and other anti-diabetic drug(s) for the treatment or prophylaxis of diabetes.

70. The use according to claim 69, wherein other anti-diabetic drugs are one or more drug(s) selected from the group consisting of insulin preparations, sulfonylurea drugs, insulin secretagogues, sulfonamide drugs, biguanide drugs, α-glucosidase inhibitors and insulin resistance improving drugs.

71. The use according to claim 70, wherein other anti-diabetic drug is one or more drug(s) selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformin hydrochloride, boglibose, acarbose and pioglitazone hydrochloride.

72. Use of the agent for the treatment or prophylaxis according to claims 34 to 46 and other anti-hypertension drug(s) for the treatment or prophylaxis of hypertension.

73. The use according to claim 72, wherein other anti-hypertension drug is one or more drug(s) selected from the group consisting of loop diuretics, angiotension converting enzyme inhibitors, angiotension II receptor antagonists, calcium antagonists, beta-blockers, alpha/beta blockers and alpha blockers.

74. The use according to claim 73, wherein other anti-hypertension drug is one or more drug(s) selected from the

group consisting of furosemide delayed release, captopril, captopril delayed release, enalapril maleate, alacepril, delapril hydrochloride, silazapril, lisinopril, benazepril hydrochloride, imidapril hydrochloride, temocapril hydrochloride, quinapril hydrochloride, trandolapril, perindopril erbumine, losartan potassium, candesartan cilexetil, nicardipine hydrochloride, nicardipine hydrochloride delayed release, nilvadipine, nifedipine, nifedipine delayed release, benidipine hydrochloride, diltiazem hydrochloride, diltiazem hydrochloride delayed release, nisoldipine, nitrendipine, manidipine hydrochloride, barnidipine hydrochloride, efonidipine hydrochloride, amlodipine besylate, felodipine, cilnidipine, aranidipine, propranolol hydrochloride, propranolol hydrochloride delayed release, pindolol, pindolol delayed release, indenolol hydrochloride, carteolol hydrochloride, carteolol hydrochloride delayed release, bunitrolol hydrochloride, bunitrolol hydrochloride delayed release, atenolol, asebutolol hydrochloride, metoprolol tartrate, metoprolol tartrate delayed release, nipradilol, penbutolol sulfate, tilisolol hydrochloride, carvedilol, bisoprolol fumarate, betaxolol hydrochloride, celiprolol hydrochloride, bopindolol malonate, bevantolol hydrochloride, labetalol hydrochloride, arotinolol hydrochloride, amosulalol hydrochloride, prazosin hydrochloride, terazosin hydrochloride, doxazosin mesylate, bunazocin hydrochloride, bunazocin hydrochloride delayed release, urapidil and phentolamine mesylate.

75. A pharmaceutical composition comprising an effective amount

of the ester compound or a prodrug thereof, or a pharmaceutically acceptable salt of either according to any of claims 1 to 31, a pharmaceutically acceptable, appropriate amount of ethanol and propylene glycol fatty acid ester.

76. The pharmaceutical composition according to claim 75, which comprises 25 to 35% by weight of ethanol and 65 to 75% by weight of propylene glycol fatty acid ester.

77. A capsule formulation comprising the pharmaceutical composition according to claim 75 or claim 76.

78. The capsule formulation according to claim 77, wherein the capsule formulation is a hard capsule or soft capsule.

79. A biphenyl compound represented by the formula (100)



(100)

wherein

$R^{1'}$ is hydrogen, C_1-C_6 alkyl, halogen, halo C_1-C_6 alkyl or C_1-C_6 alkoxy;

$R^{2'''}$ is hydrogen, C_1-C_6 alkyl, halogen, halo C_1-C_6 alkyl or C_2-C_6 alkenyl;

$R^{3''}$ is $-CON(R^{11a})(R^{12a})$ wherein R^{11a} and R^{12a} are each

independently hydrogen, C_1-C_6 alkyl, optionally substituted C_6-C_{14} aryl, optionally substituted C_7-C_{16} aralkyl, C_1-C_6 alkoxy, or R^{11a} and R^{12a} may be taken together with the nitrogen to which they are attached to form



(in which p is an integer of 0 to 2);

$R^{4'}$ is hydrogen, halogen, C_1-C_6 alkyl or halo C_1-C_6 alkyl;

R^{50} is hydrogen, C_1-C_6 alkyl, optionally substituted C_6-C_{14} aryl or optionally substituted C_7-C_{16} aralkyl; and

la is an integer of 1 to 3,

or a prodrug thereof, or a pharmaceutically acceptable salt of either.

80. The biphenyl compound according to claim 79, wherein

$R^{1'}$ is hydrogen,

$R^{2'''}$ is halo C_1-C_6 alkyl,

$R^{3''}$ is $-CON(R^{11b})(R^{12b})$ wherein R^{11b} and R^{12b} are each independently hydrogen or C_1-C_6 alkyl, or R^{11b} and R^{12b} may be taken together with the nitrogen to which they are attached to form



(in which p is an integer of 0 to 2),

$R^{4'}$ is hydrogen, and

R^{50} is hydrogen or C_1-C_6 alkyl,

or a prodrug thereof, or a pharmaceutically acceptable salt of

either.